var title_f38_12_39104="PIP flexion";
var content_f38_12_39104=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71895&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger PIP joint flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39104=[""].join("\n");
var outline_f38_12_39104=null;
var title_f38_12_39105="Influenza prevention";
var content_f38_12_39105=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Influenza prevention (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/12/39105/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39105/contributors\" id=\"au364\">",
"       Patricia L Hibberd, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/12/39105/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39105/contributors\" id=\"se636\">",
"       Martin S Hirsch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/12/39105/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39105/contributors\" id=\"de1919\">",
"       Anna R Thorner, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/12/39105?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The most effective way to prevent influenza is by getting the influenza vaccine (the flu shot) and using simple infection control measures such as hand washing. Antiviral medicines can also help prevent infection if you are exposed to the flu.",
"    </p>",
"    <p>",
"     This article will discuss ways to prevent infection with influenza. The symptoms and treatment of influenza are discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      INFLUENZA VACCINE",
"     </span>",
"    </p>",
"    <p>",
"     Getting the influenza vaccine is the most effective way to reduce the chance of becoming infected with the flu. People who get the influenza vaccine have a lower chance of illness and death from influenza compared to people who are not vaccinated. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"      \"Seasonal influenza vaccination in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"      \"Seasonal influenza vaccination in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Timing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because the influenza virus changes (or \"mutates\") slightly from year to year, you need a new influenza vaccine before each flu season. People should get the flu vaccine as soon as it is available to get the most benefit.",
"    </p>",
"    <p>",
"     In the northern hemisphere, the flu season usually occurs between November and April. In the southern hemisphere, the flu season usually occurs between May and October. Flu can occur at any time of year in the tropics.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Effectiveness",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who are vaccinated form antibodies (proteins), which destroy the influenza virus after the person is exposed. It generally takes about two weeks to make these antibodies. The vaccine usually protects 50 to 80 percent of those who are vaccinated from getting the flu.",
"    </p>",
"    <p>",
"     If you get the flu after being vaccinated, your symptoms are likely to be milder and last for a shorter time compared to people who were not vaccinated.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Injection versus nasal spray",
"     </span>",
"     &nbsp;&mdash;&nbsp;The flu vaccine is available in three forms in the United States, as an injection into the muscle, as an injection into the skin, and as a nasal spray.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The injection of the flu vaccine into the muscle (regular flu shot) is approved for adults and children 6 months and older.",
"      </li>",
"      <li>",
"       Starting with the 2011 flu season, the flu vaccine can also be injected into the skin (intradermal). The intradermal injection uses a smaller needle and less vaccine but works as well as the regular flu shot. It is approved for adults aged 18 to 64 years.",
"      </li>",
"      <li>",
"       The nasal spray is approved only for healthy children age 2 years and older and healthy adults up to 49 years.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Pregnant women and people who have a weakened immune system or who have chronic medical problems should",
"     <strong>",
"      not",
"     </strong>",
"     get the nasal spray since it contains live virus. If you live with a person with a severely weakened immune system, you should",
"     <strong>",
"      not",
"     </strong>",
"     get the nasal spray.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Vaccine side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;The most common side effect of the flu shot is soreness at the injection site.",
"    </p>",
"    <p>",
"     People with a serious allergy to egg products should not receive the nasal spray because it is grown in eggs and its safety has not been studied in people with egg allergy. The flu vaccine that comes in a shot has been studied and shown to be safe even in people with egg allergy, so most people with an egg allergy can get the shot. There is now also a flu shot that is not made in eggs (Flucelvax). People with egg allergy can receive this vaccine, but if it is not available, the egg-based flu shot is safe for most people. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"      \"Patient information: Food allergy treatment and avoidance (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other possible side effects of these vaccines include body aches, headache, and a low-grade fever (usually less than 100.4&ordm;F or 38&ordm;C). These problems are usually mild and go away within a day or two.",
"    </p>",
"    <p>",
"     Many people are concerned about the safety of vaccines. But for most people the risk of complications from the vaccine is much smaller than the risk of complications from being infected with the flu. While no vaccine is 100 percent safe for everyone, the flu vaccine appears to be low-risk. For example:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The flu vaccine is less likely than the flu itself to increase the risk of a nervous system disorder called Guillain-Barr&eacute; syndrome.",
"      </li>",
"      <li>",
"       There is no evidence that the flu vaccine increases the risk of birth defects or miscarriage.",
"      </li>",
"      <li>",
"       Some formulations of the flu vaccine contain a preservative called thimerosal, which is derived from mercury. However, there is no convincing evidence that the small amount of thimerosal in this vaccine will be harmful to children, pregnant women, or adults. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"        \"Patient information: Why does my child need vaccines? (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Several groups, including the Vaccine Adverse Event Report System (VAERS,",
"       <a class=\"external\" href=\"file://vaers.hhs.gov/\">",
"        file://vaers.hhs.gov",
"       </a>",
"       ), monitor the reports of vaccine side effects closely.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      WHO SHOULD BE VACCINATED?",
"     </span>",
"    </p>",
"    <p>",
"     The flu vaccine is recommended for nearly all people 6 months of age and older. The vaccine is especially important for:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Adults age 50 or older.",
"      </li>",
"      <li>",
"       People who live in nursing homes and other long-term care facilities.",
"      </li>",
"      <li>",
"       Adults and children who have chronic lung or heart conditions. This includes children with asthma.",
"      </li>",
"      <li>",
"       Adults and children with chronic diseases such as diabetes or kidney disease.",
"      </li>",
"      <li>",
"       Adults and children with HIV infection, or who have received organ or stem cell transplants.",
"      </li>",
"      <li>",
"       Children and teenagers age 6 months to 18 years who are taking long-term aspirin therapy and might be at risk for Reye syndrome.",
"      </li>",
"      <li>",
"       Women who will be pregnant during the influenza season.",
"      </li>",
"      <li>",
"       Adults and children who might transmit influenza to high-risk individuals (including people listed above). This includes healthcare workers, workers in nursing homes, home health workers, and people who live with a high-risk individual.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ANTIVIRAL MEDICINES",
"     </span>",
"    </p>",
"    <p>",
"     Antiviral medicines can help to reduce the chances of developing the flu after being exposed to someone who is infected. These medicines can also be used in certain people who are at risk for developing complications from the flu and who cannot receive the flu vaccine.",
"    </p>",
"    <p>",
"     The \"best\" medicine depends on the strain of influenza circulating in the community. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"      \"Prevention of seasonal influenza in adults\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"      \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      INFECTION CONTROL",
"     </span>",
"    </p>",
"    <p>",
"     Infection control measures, like handwashing and covering your mouth when you cough, can help to prevent the spread of influenza [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/12/39105/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Frequent handwashing with soap and water can help limit the spread of influenza. You can use alcohol-based hand sanitizers when soap and water are not available. Whether you are infected with the flu or are caring for someone with the flu, you should wash your hands frequently.",
"      </li>",
"      <li>",
"       Cover your mouth and nose while coughing or sneezing, and throw away dirty tissues immediately.",
"       <span class=\"nowrap\">",
"        Sneezing/coughing",
"       </span>",
"       into the sleeve of your clothing (at the inner elbow) is another means of containing sprays of saliva and secretions and will not contaminate your hands.",
"      </li>",
"      <li>",
"       Avoid touching your eyes, nose, and mouth since germs spread this way.",
"      </li>",
"      <li>",
"       Avoid close contact with sick people.",
"      </li>",
"      <li>",
"       If you are sick with a flu&ndash;like illness, you should stay home for at least 24 hours after your fever is gone except to get medical care or for other necessities. Your fever should be gone without the use of a fever-reducing medicine.",
"      </li>",
"      <li>",
"       While sick, limit contact with others as much as possible to keep from infecting them.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     More information about preventing the spread of flu is available from the United States Center for Disease Control and Prevention",
"     <span class=\"nowrap\">",
"      (file://www.cdc.gov/flu/protect/preventing.htm).",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784863472\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2875750\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/47/33522?source=see_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/4/23619?source=see_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=see_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?14/48/15107?source=see_link\">",
"      Patient information: Chronic bronchitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/58/6050?source=see_link\">",
"      Patient information: Bird flu (avian influenza) (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2875758\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/12/35013?source=see_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/35/35379?source=see_link\">",
"      Patient information: Food allergy treatment and avoidance (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/42/18084?source=see_link\">",
"      Patient information: Why does my child need vaccines? (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/31/35320?source=see_link\">",
"      Avian influenza vaccines",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/1/18456?source=see_link\">",
"      Clinical manifestations of seasonal influenza in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/58/15272?source=see_link\">",
"      Epidemiology of influenza",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19640?source=see_link\">",
"      Pharmacology of antiviral drugs for influenza",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/13/44249?source=see_link\">",
"      Prevention of seasonal influenza in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/37002?source=see_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22250?source=see_link\">",
"      Treatment of seasonal influenza in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/18/27946?source=see_link\">",
"      Seasonal influenza vaccination in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/7/26746?source=see_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/25/5528?source=see_link\">",
"      Diagnosis of seasonal influenza in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/flu.html\">",
"        www.nlm.nih.gov/medlineplus/flu.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Allergy and Infectious Diseases (",
"       <a class=\"external\" href=\"file://www3.niaid.nih.gov/topics/Flu/\">",
"        www3.niaid.nih.gov/topics/Flu/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Centers for Disease Control and Prevention (CDC) (",
"       <a class=\"external\" href=\"file://www.cdc.gov/flu/\">",
"        file://www.cdc.gov/flu/",
"       </a>",
"       ) [",
"       <a class=\"abstract\" href=\"mobipreview.htm?38/12/39105/abstract/1,2\">",
"        1,2",
"       </a>",
"       ]",
"      </li>",
"     </ul>",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 11, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/12/39105?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     file://www.cdc.gov/flu/protect/preventing.htm (Accessed on February 16, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39105/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_12_39105=[""].join("\n");
var outline_f38_12_39105=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           INFLUENZA VACCINE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           WHO SHOULD BE VACCINATED?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ANTIVIRAL MEDICINES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           INFECTION CONTROL",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_12_39106="Tongue cancer PI";
var content_f38_12_39106=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tongue cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is an example of tongue cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39106=[""].join("\n");
var outline_f38_12_39106=null;
var title_f38_12_39107="Nonoxynol 9: Patient drug information";
var content_f38_12_39107=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nonoxynol 9: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37139?source=see_link\">",
"     see \"Nonoxynol 9: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Conceptrol&reg; [OTC];",
"     </li>",
"     <li>",
"      Delfen&reg; [OTC];",
"     </li>",
"     <li>",
"      Encare&reg; [OTC];",
"     </li>",
"     <li>",
"      Gynol II&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Gynol II&reg; [OTC];",
"     </li>",
"     <li>",
"      Today&reg; [OTC];",
"     </li>",
"     <li>",
"      VCF&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug does not protect you from diseases caused by having sex.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop pregnancy.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nonoxynol 9 or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703874",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you or your partner has HIV infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705176",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Today&reg; Sponge: If you have any of these health problems: Given birth or had an abortion less than 6 weeks ago, have your period, a sulfite allergy, or toxic shock syndrome.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To protect from diseases caused by having sex, use a latex condom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694870",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use as you have been told by your doctor or read the package insert.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11853 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-7CA0D077E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39107=[""].join("\n");
var outline_f38_12_39107=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202259\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013459\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013461\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013460\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013465\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013466\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013468\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013463\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013464\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013469\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013470\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/17/37139?source=related_link\">",
"      Nonoxynol 9: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_12_39108="Nursemaids elbow PI";
var content_f38_12_39108=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F86688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F86688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Nursemaid&rsquo;s elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 685px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Nursemaid's elbow usually happens when someone pulls hard on a child's arm by the hand, wrist, or forearm when the child isn't expecting it. This might happen, for instance, when a child is about to fall (as shown in A). When the arm is pulled in this way, tissue moves between 2 of the bones of the elbow joint, called the radius and the humerus (as shown in B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39108=[""].join("\n");
var outline_f38_12_39108=null;
var title_f38_12_39109="Skin biopsy MCTD I";
var content_f38_12_39109=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F73386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F73386&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Skin lesion in mixed connective tissue disease (MCTD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 234px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADqAWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3eLxfpt4dl7ZSpHx8zKswGfUKSR+VWI73wu7pCqWBABxm3+VR7nbgfjXmEFwsh/1dmXQYL2zqj/kDkfnVo6qsZ8pXuZN3XCliv4jA/Gvalg0vhbOuWE19253d0vg+Td5hsgTxiFmU/gEqlLq/gu2hMMFnHM7DGEtW3H/gbAH9a46fUlaEf8hJ8HiNU6+9VzPIyO07Xloh5CzsqAke4zRHCvrJ/eJYd9WdsmvrD5B03Q5IYkXjDsoC/wDATg/jUw8YX8pKrb2sR9FfeR/n6VwJkhl3b7qDaoHP2klvXtziqVzrem2q+aoEqqQu63TgfUk5z+BrVYOE3tf72arDRfQ9Il1q/kbe7Sgd18zGPwA5qO2nvFnMqXDQyDtMzHP4MBXm0ni7TTBI8VxcrsBZszhMKOpGRkj6c+1Fh4j0STfPbRl5lOGeJXaQ8dSRjP4j8a0+pSS+F/cP2FlsesS32uEqy39pGN2QJWiAb26k/wAqsJb61dL+61eyjznIiYMf/Qf5Yry1PEejS24M19HZTk8JqVlcID77wrAD3zTZDbazbSBNT8K34iO2a0guBHLj/pmZSFb2JKj3FZPBPtb5GTpx6u3yPTP+ER1K5k36hq6TLnOySJph/wCPNgflVe40CxgZrjVPFR+xpklJDBGi/jtwP5+9eSyaX4elWS3ttTt8octZXaSRhfx4Un6OPYnNXNEu7CyAay8F2kjA48yKVZlwO/8AqmIHf7zH3q/qlS2kv/JUvxf6XNfZ30UvwS/U77+0PD8sn2ZNeub9gQPsWhOQAM9HliwxPuXXPp2p7af4Nifz7/w9qFlj788tvcBAfUuP/QjWdp/xMigAgttFtY3PynypGyox1KCPJ/MZ9qtt8VILC2Ml8EuZd3MCQPbSqvqFYsrj33KfaspYeutFF/J2/JW+8wcKkdk/v/yOrn1my0y1t7TQ44p02fItuGlCr64QEn19TWBPBNcN9ri1TUbqzL/6R/Zt7Kr2pPPzRNuYr7DDD+6RkiTTfiZol1ZPJpOmazdMsmHgs7EyMM8ljtJUD8c+xqrfeMfDl3eJcaro2v2N3s8tHubd7Zyuc7R8wJGecVjTpVINpwd+vf8AT8/vIUZp6IivdFtLCBJ9Q1vUWeVyLaN9UmnZyemEJQfhtbrVnTr2KzuLj7NZ3minA83y9EYRMT/dl2Ln/gWMZ5qrH4o8LxxyTW2h6nEoGTPa2xMkg95FOcfVqoweKxLI48NW3jHUUZsCFvL8lCexd1Z1Hoc/TpW6hOaaafztb9f67FOMn0Or0vW9PF7vm1y6uGA+WCS4t+T/ALkfzfga17G60fT43uJJYLOSZsNJdTr5knplix454GeOwFeYXuqeNHcudEvbSyz+8DyTTNtI9/MDD1/dis0XVxDKGvdOsp7iVtsMssNwNwHUbRHGP/Hj9KTwSqbOy8mv00G6De/6HZ+JJrBNZlvdFntbiWcAXESsWDP0BwoPJHpzkVUv9T1PUrS1g1iB9I0yCRJfLkO55th3K0pc70QMAdgUsxA+ZaxIp9encLamytD/ABW1naSK+OwwFAYcd2zxVWSHQUvJJtcn1+bUwxcwRBLZQ+Md2Lg+5bP8q6IUEkk9Wvm/0XzNGk0l2NW/16G81u6LJq0moXDhobCwt9+oJFjbvbOEtgQVG5iHC5IKl+NTSbCeLVoTrPhPxHHYxHzIZrjXHvxEyAsCYRI2CcY43c8d6peH/FS6fbfZtB8PWemRrnzbi5uCwfGTl3C5Y8/7Tc4A5yObm8carqU0M1863kAY+VbIfs7Tn+EhOWYcfdXDY5yKpUKsm4xjZW76/Kzt8m2YOLu7G/qPjO7fU5Z9P1plnffHHYXunxqI88KY3Xc6uoHIfIYk8AYAZcabI6rd3V/qGqq6fM1xpE4eMg5JSSBkdFJ9mI7g1ydx418d3l9c22pPaWeSA9pdwxJEiHsWfI54xuz+Nctd6rcy3jQK8NnMjBv+JYqxqxHTPldT6EH6cV10sDKytaPpZ/8AtqLUGtFoeuR67eWf7qdb6Bl/5aavpxmmjwOMSx/M6ehKbh3PYaOk+MriRlaHVoL+NRli8LxRgejOyKVPXH3uhzjGa8ii8QeIXeSzv9Y1JwG2vHcPKCnpznGPcnPPpW9H4jSwmNmbW3klxgy2OqPEAP7+4LJgf7YIHOB0rOpgE1rG7+X6/wCZfslbuz12PxpCqobu2lEcgGCksUqtn+6yNg/iB/SifV9LuUVJ7CfWET7hWweSVB2DBl4PvkHpXmS6pqDR2hTRb+aC8DCJTqiX32gAclT5TFSOuTj3wa09Oi0C5ZLbXbo28yDix1jU3tHjz/dXy13fUMa4XgYQ1s/k0/1/Uj2cY6v8DvY5NMWSI3WlatGudyrMXmC/9s1diB7baupLHdhpNK0qxu7WNtrFm8p946gKUxkZ7kV5bqWkeG7SY/YdX8N2yJ8xim19iPqQFB/U1Vmm0S2immh8TaKsLgEwwa3JNg+yMCxHtnI7Uvqal1d/NP8Az3+YlCEtIv8Ar7z2iDUsYW4sZrLPG92iKqf+Asf5VjahLDNctNax3N7fRnYjW0MMqq3oZMDb15BYda8jk8UeRdCGw1jQ5uFA2LJID/s/NEVyPTr61m3Hiaye9f8AtGwtGcDBmSKGJl+mMHHvkYq6WVtO/wCj/X/MpYaT1uev2tx4zs2JbT2vcnDxyPCFHujhwSP94cVBqPiLxagUW/h+5iuAR+7YLJGRkZyykknGTgHkjtzjz2fxfYQMyJa3pO1dqPM3yHsVk+0EkfQfSnr448uK6gvY5bRJcbTbq0dxvBUq3mzBug3HvnPXrVvASbvyL7rf+3P+upSpSlrynplr45uS2y/8PalbMOCxjcIT7FlFaTeM9KhtoZrx5LXzP4ZkKnHqP734ZrxG68d+MLYs2h6nM1gAPm1NUnIPf95HHjFYdp8TvF1rqNw2pa5Dbo4DZ0+wicO3cNuj3dO/T3qP7Gctkvvf/wAixvCSey/P/I+jrDxbp19IFgjv9rIXWRrOVUYAZ4bbirmn+INMv1Uw3SqW6CQbM/TPB/DNeI6N8U/Ec8NxP9rha0jwpubrTyURj0BMR2gnoAT19Kl/4Tt5mSS++zxzNxI0UbwgE8ncN+1j7nn6VjLKJq6t+N/0RH1aTdkj3xWDAFSCD3HNLzXkGl+NIwwDXD7gCVkFxHJF7jzH3fiBJ26Cuqi8SQyWSgXiWModY910Q0XPGAyORnPHzGuKpgKlN6mEqU49Ds2YKpZjgDqTVSPUrWWYxRyb5AcFQOfrjrj36Vz+qDV2tI4Le1jZnHyPDcszEDqcFdqj6sfaqFnoZ1ILm1vtNubW4LG4lumnLyrjBJLbmQ56Bhz16YqY0IcvNOX5f53+4hQ0u2XdQOt69Y29vp962lGSWUXVzDGrNCI227F3ZUlmxz/dBoq5p1paafcJZ32pW01+250j+WJ5FJJ3FAeT6kYBOTiilUrum7Qtb/Cu/mrgpcuiPlu98R3gn22t0beNQFWILvO71GAuPyql/wAJDqV0WiXV72cbdxUMQQO5OOgFelaDot3pd4ktppXhy5kAAlnv7+SaUg9emFQ4/hrobPTL4QXcdr4O8H263KMlzDHNmS4U9g642A++a+oli6MdIxVvkei66hsvxPDpfEItyq2U94BtGQtx95h1OeMD0FObXTIAsE8jsSoLyXTooY9iBgnHTIyPSvXF0jULWAxQfC7wyEYY/dTebkjHBcL19s1Dd6NdfYgLDwBZxXIwPNTdG8HPc4DE9sg49auONpv7P4x/zNFX5l/wUeUarM9rJi/u9NmmjbmGGSQuvsQynP40W939svIRby2qyMQFXcBsJ7EkqBj34+lep23hH7PaXE2s24ttVIDfZvs9ztC5GCXQvu4yDg5+mK1IfBPhvWIGOpaHZWUuNrNbXbKzL0zhjkn/AHjV/wBoUorZ/h/T+RDrR9Tx3UboCWNYdXE11zkNZMqwnuqtz+LKQD71RZYpYUjWytbm5fJlkKsw68bSMnPtxXrV78LvCkI3Q6tqCwjAVRCrHP1OAfr0pp8EaNp6xy6dFLEwXaJbmUK5Y/xALt/IZq44+g1o393/AAEKM0/hPMY9JLxu+lanb38ax77qF7aWLyR7+aQuAR1zUdpoes31r9rsbDxDdWLHKyW1pviIHXDfdP0FewzabZpHA9wscUicJLaWkYKtjk7nUjJx1Az6mraambci4gOpPHEjIxF5IABxyAuAo+grKeOlb3Ff1/pFxjUex4zBZ+VHII7nWxdAqBHdWojcE/woobJrrvD/AISuz5VxJL4wttRKZd7SyCJC3XDStMCQP9oj8K62TVDqEpjeXfHj712JLoL6lSxJAx/+qs28u7eCFG8y2AQqQgjjhCntucrjH1NRLE1JqyVn95p7CpLRu39ehBHoer7pxcnWrzeP+Qtb6tZxvJ/svHLK+QPUSflUNhqHibQhIun+H7wWqEs0ul6qHllI6O6KZ0B9fl2/SrVuhub0xw2vnO7ZcRIhbj04OfwFT7bhma4NqpVCVWRmT5GHHDEDDcEdf61jzSfuzs18/wDMUsH0lJMw5fGFy129xL4ZuC2APMm1KWwmdu+7yfLjZvcIDjHWp7T4g6nZTk2mlXzKw3SRam32sxenlSqqvjH98knsRzWnfy3RTzXtbqdNufMwH2exx+h/lWXHYWF6rifT5kizhiqSIr4/jCg4x7mtEqTVpw09b/hcI4SL1X6/19xq2fj5NUT7Pey3ekBAGfU5UnJgbIA2xQtsXPoQFOPm3HrrT6tb3EWLLxVD4tvJnURWMltNhx3ChX8sNjJBZD+VclH4Z0yZZFsZ3SNsb0ExcMvckcHr7mpX8AXRxL4enhlumYHyRceTJ2IdXdlII9ADg96l08O3fmcfLS35XXya+RhUoQp+X9d+h062c8c0Uep+E9Q0oyMFjuZJVuEJJG0HbJHDHzgAEcnpkmty08LXmiedeapYavqcEmQ0Wn3KrJGg/vKGVnH+yjH/AHWNcJqWtfEHQLWWz8UnWJtLdTA4kt4XjZCMENOiluQcZ3Zpsmqa1HbW1vYRSXNm6hI4hPNctCvQByJAo9gV/Go9jWnH4lZ9m2vvvdfezBwb0VrHV+I9NsII7WfSLDxLYz3RxbxJdszSZ5JaEyGUAAHOOncVlX1vq9hpgn1l9WtbFzsAkiWOKUngGRi7OpJ4wyj69qw7R7C0v3/sjUYNCmkAFxPfXK2lyf72woQGH+zng9c1HqOoR6bi91DXI/EE0THybO9mubhADwSzNhV+gJJ46it4Upxaje/qm3993b1bBQa0Q7R5Xaa4hn8TeGPsK8utzqHlRSkHdtKDImx3wMDsc9Havq01xFLqTsbm1tzhbqMOoYtknyYGX7gxyV6cc1xd5rLanehb15BbySbni023kMcRPTYrMoOBjALdc5Pate18L+Ovs1xJp/hp7ZoSvl3VyZVbaM4PlglWGMEg5ArqcIwfNUdn52X+QTglqy7b6hbXM0N3YanqVjeYac6rceY6yYHKRDbye33gOO3FZtzf2LWMN1FHrX/CQA77iWeQPB5e7GeDvy3YcdTycV0d94b8Z+IsN4g8TwQTIkQh05rNkNwyDoq7F2jPTCnryeKdP8PfFcUKvq01tZ2aqSZ7gxrHCP8AbYYwv1B+lKNakrc8kn6/lor/AJExt10OWt9S0r+3o9l4JHmk2rBa3BHkkgAEyyg4Xd/eJ64yOtb2jeM9c+HjXlkYY1umuP8ASY76PzSWwPmUoQcYOR8zKAePWr6eCoNSFvHf/EPw2hiQrGllbwEsh/vYwc/72ce1auk/CnwPZ3TG88SafdSyIREoCxqoPfAfBP8AnFZVsThmuWpqu1pP8bJf1uW0uv6mh4V8SeH/ABTHNca74xg0q4kcS3WnQY0wO2MfM7fPIMAcq2R69h0sN14LjcQeGxHqc5GWe1upZwAP9pCzOfULkjvjIzzVx4C8DXqxyx+LkjEEgY7p4CokUg52uCO3IIINd3p9hC9jtg8c3bxxjbutjZIifQLDgfjmvHxLpXvCUrdtUl90dfz9TGSs/dMy20C61OcvNHqy22/dte2tLdCfVFCiVe2CWz6irJ+GHhXUij6po11JNGeZLm6JaQe+x8Y9uPer8/iDR9OVEm8UzzyJhSqmF2kJ4GdqY/LAp0ev2d+f+Jd4gJbbzCBD5invndjH8q43UxH2HyryugTqLUW4+G3gyeJIz4Z0lNn3WjtUUj8QOfocg96qSeAdJ0smbRdE0u4h5aTT7i3Qq5PUxMR+7b/Z+4cdFyWrXhtL+6jZotXvwjLwd9twfbbEf51nXfhPXLpm3+N9bjj6qkcVsuPqyxKTWcKlSLtKrp83+n+RPNLqzlvE/gnwJq6BYJoPCutSfNGFYWr7unzQEhXGeMgc44bvXn/i/wAHa94bhgvNV1aG/wBPQiC3uYwduCflVoyGAOemOO2a9N1r4aX99p7wLqejTSHc3m3uhpPIzkY3bzJnd/tHJ6elc/ZeFtf07SrZbW8v/E8ABiuI42t7aRDjlTvUSbe25ZlYZ6GvWwmKUFdVeZLo/wBG1p5JuxrCtKK3ueO3usLFJ5bafb3t0QScq0PTsFRlZuOeuQRjFMvbu4gghhvmu7bzk3RRlXKBT1IBc4+nX1zXS+LLvwhNcBNU0PxVoWqLgT6fLeYSYg8OzOHYdjvA5/WuT8Sy+Hv7PL6JPc2d4HDfYJLpbyN0I+8soC7cEHKsCTkEGvcp1eezUWr/ANdG/wANPM7adS9rp6mYr2a3irI4nmzvy1ukkfAOMh8cYz3B9Kt6dq8U8c/2zT1kt3Pl2qWMUkbowHBB3EMBnlWzkdwcVHqOtCPRBpkuhW8eQZHkv7NYn4wR5Um8HnP3fToe1Ytve2s8RxILZG+aSEyMWPOMJ94/mc+xrZWnuDnzu7ujsdN1VINGSC9vNY03UNxaGVPLltgRxiSP/WRAnuSwPUCtPRfE87JDY68bO4tMBYbyJCJoCOAPMQhivPIcMPwridO1OK1hu2lMclszIDKbdfPjw3WF2Knceh+VuOoq1qurQTrFOmnXItowAsjtht3qXCdT6ZxWcqSk2mv68ioJSbTXzPZdE8Ua9YXUDDWbG1sSMLIgW8t3IIBV1iZ2RsEH7w47+nZ6V8R7tPOj1KCwuHDFYprMukDsDgqXYHa3I4OK+dk16PQ5HbT9Sb7RLGn7yC9kt5InA5DKyjzOuPT0NdlY/FKztGuLm0fxBb30mwvFLfrdwSkAAku6iVTtA+4ew4NeViMCqj0p3+5flr/XQwq4dy+Ffoew6n470C+s7iDUdLkO1wrreRqYt64yC6b8EZGOMnPHGSCvnfWvG15dXUtzFHpyWzSNKYXR/LVmOWIVmUHLHcQUIBJPXmilTytRXupr/t6xzPDyW52rafdW8X+jXbKV4BlTzFxnpg9PyqK0k1uB9sk1k0obcJEfyEOe3yhjn1+X8q6LyWDKpmSRE5CEY/Dg80yWBjhlWMQlcksnB54wDyfrWjcX8STOxVehlReJL6zv5Ejk1yzuC21jaXP2i3fHOQWAzx2xmuu07xlqep29xFFqUkpEYV4wojkj7HnbuB+mfwrmr3TbW9t44ZEeWFHLiNz8qtjrx9e9OvLKJDaSosbQq2dqt5e18cDr9aynh6U7XWv3jbpz6HU2uuS/u3ubmRto3RbWkLIe2VJOPwovby0hElxceYvmNtbbCH37jgE4BO388etczc6rq1pJBc6XdLOQdh8+Rg5XOdmcEMRzw3v0qWHxPpmqExTtbw6juPyRoU2nPIIJwee2ayeGaadtBRoX1S+43J0hha3UMYmTsqjb9QePwrHvJ2jGZMsCSCCQSffaD0/OnXdwkcMriKPytvSWP5H684ORnj0/Cs4Skx70aSJnOGG3BAx0+n404xOunS7hFc7l3pKQVOVdAvyAds54P0zVqd3nmkmkAlVcEZXdkY4BzxyfQfnWZFYzyP5UEsiyE7BIVBAc/dG4gndz04NWm0W/+SJrQ3k6N8yxFIwWOMkNuyD3PH51bgr3ubN0ovWRZOIUIzOWYgqfMG4e3f8AoOtVtVs4dVsZoHWa4BG58DDqc/l+X6VatvDeutK0O22giZDhnnHT36/n/KoJbHWbYRJcabcT+WrFrm3MciZ9QFYtjgdM49qSaTumr+oKdO9lJXLHhazcSqlou2PhWxuKqORkEcgkZ65BxyMZzralaQ2zXFloSzfYZEZRY2tqJcr/ABKAwIBOT0A61yk17cyWjjbrFvmPg2hWNiuQTk7hsz0+atU6laWkrxaXb30WoSW5jEjxuYlJIwWKncwxnJHQ+uTVSi73v/XmY1qbcuZK/wArlq/8O3t9OYEkhiuSQ2yW4YyOey4yR+ApkVqdGtY51dYZWma4chNzpIvDgqR5m5gpIUZGQDjnlj27m02QRRt5IQnadpiViSOCe/XP5Vq3c0L2BMMV4JzGZEnuf3Tq5HLeUxBOOMjdzjtUtvZ6r+v6/wAzCc5WUX+RT1rTZb28jksYiLoFp7ozoFYRtyrb0xzjJPHU1DJY6hDZlkQSj73lTurJIO2Tgkf98g8VowTaSs8ektI73d1tbItAUcopOeSxRQeCSau2V7dXZmLfYlvioPmR/PCGIGcA8HDDGeOOvWpcmla2nn/X/DERxE0rdjDguZtPgaSxjvYIiNz/ANn3Lsn0CISCfquao3MFleNBd38V5sKkRPLO6Mwx/Flhz9cV2l/FC94v2gWfmybVkeCBSYwTnJIGN3fIJ4qpFYW08sBa2JlAO6G4VXGcnBO3JOQAeD357ilGovi2YKtB62OUh07ThFKlpcGKOUASI0cMivgdXVtwc9eTzVuzs7cXNvc28qM9qWMCNbwrFExxudYwNoY4HznnjgVtX+nWZuHZ7Gzu7IKQv2bcs6txgu/8A68Ffx45q3Fvoz+XHLZywSAjie62k9xsccHntn/CqU3Lv+BopQlrb8jQfxFrjBozqcqjZzsjjBY+x2gk+uD+NYs8lwzHdqerEAZZDqU0in/yJ+gqrqQFtDcXFvJCjQpv8m6jaZGXJ4+Tnd/ujNRqjWVqHkuACZFCoFykYboPmyw9s8+9EaKjrBJfKxrGFNbInFjamJ2nguLuGRuWdnJAx/Flicd++fSnx2NlDhEtoUXO1UVQoJPbaTgjjoMH8aSO1u7lTcBLllmk8tdyqTuxkgKBn35BNUdVA0eyC3st9Zl3wLgWIaOI5+85kKqoPYgHjrir96T5eYr3UbM8hhCK2FgD4Y2+doOOmHGQ3tUTtGEXbJ5cJO3Bc7CfcjOTx14qhCJp9QmtrO/myioxUx+WRk8Hdkqfz/AdabqFldWMDPcXsZjiJkmmLFyig852L3J7dfzqVDW1y/cW7L8k/mxht8ckZ/jaMEA5xjfhiB75H4VUv5LG3geacXa3HRWh8po1OeBgjJHfJJHHaoYtHE10IoNWjLNGy7YJQgBA35KN1YjIBzjJ5q3bpdzWD3ErDTkeHy7i5BWAgZGEO8H7xxk85O0Ac8NwWhE5Qj/VitpeoeJ0gnutO12KGz2bl8qJF8vC5YFWUICcMc9unvWnp2r3Os2at4gvpbiXyd0aCztZircZPMZ98Ac+tYr2tpfTW0MMNtqPnh5ZFWZkRdh+ZVZlG+TdhtuPu4PQg1f1Lwxt1ezuLOS4vPtMTx/ZgDD5nGSGII3A89DnpUzp0+qSfoun9eQnGi/K/kPt47lvLS1/snT7cqZbW4luEt5WyScvtbluRgLxxk9TS+H9e8Slmtv7avdTMT4aWxHnj8TtbPcHnjFK0ktnPi08PR2mmxkrcMNiphRgKD/Fhsjqc479KFlWw0QW1leRwJFvb7PbYmZmb+KaQfLGOBwMk89KiVNS0aX9feSopJ3Sd9v61N628V67I7ol5dGSM/Mn2ZW59DhOPxI+tXtO8WXsBa4JtSs0h3lrVk3MB03BsZ9sGuQf4i6zYwndrVmsSqNiC2Tpjom0H24wfrWtp3iuxivZNV8d2k8sgiW3juSVe0iXJziM4COxPJO5iOMgDFc88O4r4E/T/gpGVWhKKu6a+W51dz4l0jWIlg1jRI7xAflEiRzR5/4HjH5VnalD4L1UQ/bPDaxtA2UeO3iGD0/hOCPr/OtWxtvA+oMq2P2GOaQ5HlP5Tlj1B6c+3WtmPwloigFLTqME+a5LfU55rj9tSpOyUo/16nE5U46ao8r1Xwz4OldQ0PiG8jLcRSXAMIz6o2cD321XXQPDcqJFBoltM0WNsbzXFxj04V1UY9hXstv4d0e3ULFptrtHZkDfzzWiYlDJtOzb2XgEelX/AGk1s2/mP6wltf7zxXTvB0T3Uj6do08fnsWYwwiFVPsWAIHfGfzroE8F62YwAmnFS+4i6neUn1Jyp5+lelTzRQIXnljjQdWdgB+tVYNU065OIL+0lPXCTKf5Gsp46tU1S0+bIliZy2RyEPgGN5V/tC30S5i4yrWCkqB/tEEt+YrYXwP4cFwk/wDZNqkygqDCGjAB64UHH+Fa66nZyRStbXdtM0f3gkynB9+eKwrjxS0UoEH2C85+ZEuREyLg5PzZDY9AQayU8RUvZtfgZc05bGsfD+jEDOkaecdzbIT/ACorltT8ctBbfaLSK3KlvmDyFx0x94cCihYfES1/U0jQrSV0jiEYK4kEbFgBjOP5U4srsqyHMaoQq9Mc+3UUl0QRGgAC7t2MdT6NjniiC12CE73C5HLnOcdMnrX0Ttuath5SbImQyMy5LKgyO/P5U2+t4pbVI5o1mWLBBAyVHr7jH5VIULeer7kBwj7JMeYmQSMjpyAfyqU26SJmWNccgbzu2n3Pv61KlrcOaxRS0sDLO8EXlMUXMpXAkGTwffngnkfSmtpVvMmzyF2k7w6qN2T3x2PHSrk0bPFtgSIgH54ZiyDB+8FdeUOM464PtRYJEm2OxeaNodyjzGySqnlSTweOoPB6iq53YtVHF3TM9dKklm8xrl1ZtpS2uRsRgDyQeofNas1hbPC8UrlbkICu/kknnCjOWA9e1WpFF7pUsLxwzKQdySIApHXDbiRx65xxVLSpLTVbQYkRZoV/dzx5CsvVcYxwPpg44yDWbm2n5FOrOWrexmW0+pvfC2nMphtQZIypWNV5ZcSnqcjBzkk4A5raF9bW0chthI095wJ5InMCkKeWI6HgjPTdxzWVeWF7cS3IeeCQWrGQm6k8tiQo5z6EHjn1qv5l7PpbahJKktv5ohE0MyleVJG0DIZcdD+FFk1ubOnCpZ3RrafNZ3AW3voXt5JECDbhsruDYj4BPIGR1+tWXiks5IpdWstSgjlY4t4TvL/PnaZFICKcA44J6E9aoWyQ6Xpket3lzHa2csmLURxCWVpMkbAfX5ec4xg1rReKm1GN3tDM6LwvnBIgJDxng/MRnPJHY1MlJv3P+G/rr+hhWvduK93YwtSee7vbqZprqK4uCxFqZPJM/OQnBHYcA56d8VpRaTC4VZ4zZj5Z2eHaC75y0TZBGCPlJUfTHFYeneFYVtnlvPtNxdLL50bXJ3yRsrcOzhiGOOhGOPeuomimhiaQ7GhY+WXLg+c3cgY6fTj8K0m4xSjFjnUcny03pb0GzWNj5hltrKZVVDlFu2bzNoO0OGblcnuCvJxg1mW88166pe28vlSyIzhhtJKZw2YwNxIwMNwcAc1o6jLbzjTWeOWGY4s4rhJViEUhJOyTJH+sJ2qF5OTnoKpaJb3jeRcWaXtjGWeCd7gNC+1UBX5G+eUFiFBAGOT25zjdJt/n/X+ZMakLPn3+ZYt0uJLGeCIzaZbSS8japOc5UruG4ZPOD9O1TxwavpsM0lw6yzLGUtopGZFlJHBbaMlc9cCszTr/AF/w/pzrf61d3kaZ8pBArOq5ztOc7mHrUNlp1xdXs+sT6jq2+8G9LW9clYMjhQvJVfQHpVez1d7W/P8AL9RSqSaaaVmdUHtRBBcyyJp5mnW2xOh2tIQMeWwySCc8tg1DOJPOeK5228eWVkdgoYjqCc8//XrDlZdItEvtSkYFpBErRE5ZieAuRnB9cDHrWeNVtbiaRr6+vYbwv5VrYPDI6yLuT5t+DlQXAJ7YbrggCovdar+v6v8AkQm1u9Dpbq6eKWK30m+txD5RE8FnKkuDk58wdCeQBjoB09ceWHyo7Oe+lTUDI3kzRzxZjkkcABmjAwo4zkjaDnkVDpemX72sxtbWNdVWd7YxXY8uGCdV/wBV5wIMm4kFSqiuj0bUbWbUbvT4ojdQWMAiN5J5hLzKxWXc7IFJQg5UMc8nHQ0m1Be7r3t/n/XfzJ9qov3df69RbRLO1uYQtoTc25KzpFJhlHI2gMcKMjt121kzTi9v3toLWX7JHEWkmdcBn3H5FXHIGGJJ/DPbXtrdSbibcNgfG88FyQRk59B9aoyaTPpV5dXWjpDbyzL9nE8hZU+bDESoOoxnBGSeM1ClG7vudEZWd76mhZ6i8EFw+nWFvcXSKjgDEUchJwcuBwwHPTtSala3MmkyXN9ei+aFiWeJRbk7z8sRBIBPbcSf5CqUttd2d+iyROWk+8yyBSp6KFzxzzx9OtWis7mBreTyxuzPbujTCUA5wF3lVA5z97H8O3rUtJNSRMo8suaLIptJtbi7tsaYfJgZZZljvcRynGcZXG5eSO4IPIzwKccURQtB5E19FJK8KNCEETsNu1G5Ea7Rt3cnGeR0p81zJPf3dnIbpoUj8zegVYhk4KDByrY547HrnpNbaPbPaW8FpA1vaQkSp5blDgdAuD8ynPIOc56HrVp8q95/18zS6teT1F1aySe1inu0mCHiIqynMuOQAACwz0OB2PJqtB4cur3QGS71rT1mh8uS8gDbQmDnD7RlXUn7nr71bvtEgsdNa5tZYUnR2ny9wfNkV8klW7MCTtHXrnmq3huytY4fKvYIv7MkUl73eqpE+4JHETnlm3cEA49yanm933X+H9f8P5i9tanzJ7PsT6bZXX9n3MNpaG4RXWaAlA0kDbivynoWAJwSTxmrl7bXel6A0E1r58+ozAMm0PHbybuHck53sCowvQnNZt0PsfhDxLbSPJNb/Z4YJ4kaV4MlsMVZV8xQysATyMLnjk1DZwW/heLVLfR76SFJ3MrST5mN0jIAXideOOFCsPlxuz1BTTd/Xtvon+t9v1MuaU5XWut/MzYIEt9QYSTW+k6fBPsxcwzfupBztQkkA9MZGCCevFSXtjZmJY7rVri4FvKHtZfMmnBDn721lEcRwx2sCeDj2q/NYz3cEOi2t3NqNtDbxkQJGFt0fJYGORcliN2CemB65rUj0ib7GLKaC2iPBYLuZs+7HnGecetW6nVv+vuv9/3nQ6ii05Pb+uoukafax2VokVkLETkqGu1+djyAGK56nnr3H0rK8TQQeHbCaKe2thcyXiQ2k927tF57EGMN5eCWAHBxkcZxWtLo6o8LSrNKY8Kvl4C/r0rUZktcER/PyF2EED24rHntJNO5zOrLu9TmtcsrcyXV9Ml/eW1soM6xKsl25bjYmAN5GQxzkAdc9RiXMU63H2dZJbKGJfNk86UzEc8MVTKg+w9etdTbQLbq0tvbmZ2YsY5pDhvqAR+X8+lc5q8N/dXGqX7N9gCqm2OGDamVKjcmXJ5Bxyndjx1ran/K3/X9XN6VWSeuxkw/2p9ttI4rm9eyl3BZJJFjV+RkAnqOo6Aj1JqxDcNvAZfNtVBjmRJ4mkZs4wFyHLHr8g4AqxBqc1wn2a1Jjlbf5gMh2epCKTkdfXA9q0L62i1HR9MS7WVZFDm4uY4i5lO4hVYLy2ABgn8vWnZWvH+tTsnaNuZKz8jnWtmm1WOWHToInjVgly0JKRf3Y1YEYcjnBOT+tFzqQi1CxQ2d4ZZ/3kcpjYqQRwckjjAJ28jnOanl0PS82Vuk+tRiLeYoVsZ1RC2Mnfjb/CvBOOPwNufSrKTXC92stzfSIVknupWMjrt4VTjAwOy4wK1tHt0/r+v+HM1WUX5f13HWGphZGEdvaSSlsAMMuDjP8JGD7DP49abd6nouo2Mja1oLGCOUgmSZo9zA/eVXDcenQ1et7KJf3NukKWqknyjK5KnvjJ7nnnmqw0m0Qym0aKFg5kkVHAJJ67/XNZqnT3e/lp+RLqwk7tWIbrxVZQJDHonhlz8uIp5v3qqnU5Vzs9gffoKKbcWsHlpIJgsGMkYBDZ7980UpQhHTlv8AJv8AzGpUeq+9mrH5UaoigMxO45AB/CnW++J2eUeYzA4G3aMHpgdxRL5DXG0yhcDjeeM88/zFOMWGdEYoxUFsMAcHp16fj/Km2ec3fUdAS8zOzEMD8owOnfIx7VNGEfEsfyIyE4TDAjsQPf0plpE7yHYgYDnHsB29/wCdOSUCKQxrufDMqFwoYhSQuTwNxwB2Gah+QmEQWQ4kbaDwM8D6jPP1Halmg2JI0qB5B95VGSwHQ5HX2z0qMzPLbKg/czFQ2CAxjPdTjgjqCRU6xDy0MR2xt03HJB+vcf54o2He5WkKTqYpVIEkJ3hl4ZDwQTnBP496TT1iS3/0N2T7QoMcoBJHGFPzZJOOnapFuClw1vKs8bEbsbdyt7g9x+FMs3/0iSEsWUHI2RBFx/d6D+f51XQq7tboR6k6Rapocl5LJcW1vu+2RCJZJZ0xhQew+Y9O+T3xSahb6VodpdRapbS2j3hH2fS7NYybe2XaFbaTgHIx9ckc1pWLSxXDTSrbfao8iDYpBTPU/MME8Dk5APPYViazoUt1dm6a8+0XLqSvn253tjuSg+Ygd9uTjpUJ3dm9P6f9P5bFUeXnXO7Ig1K3n8QXMt3ceTY2dnGIYY45x5SW6tkB/wCHzTj+EnB4OAM0+wttN12wNsltbQmG0MssjzLGhkBITcxGCDlVyB+YOaqWiahcPEsgMEbHJWQDyw+PvMAB0PqB9K19AsdOgvZJfEqi/iEe2C1NoWjaUjljtG0jAAG4Z5yeeaufuxt27HVJqnCye21ivEbvTNdisGjb+zBshG8r+5YDDsjBQChJB+bJ64POBt3WnyTLK1tDHNOnyqJJ9sLHI/i5OMegNR6p9o2Jf23h24uFcExWVvcJFDGy4G+aVyMZyAFQE4B61qyXaP5sNpEQq8A4KlvoT29/zrJ1G7NfP/g2f/D9zhlU193R9f6/yMqCO4gtvMuIbZ9QRfu2u7YDngKW549T+lSLfT28P2rWmijRUJY7+nt2H6VXv9QfTbeWZ4Q0EQGPLmUySuTgKqd/97OO3NV5bvU57ZbrT3jjeU+W1vLHuBTGCCcEHPcd/atVBy1diea+hsyyG7ZJhM8aMAVEaKOPrVHVtQt7JbyW6tryfy7ZminhRPmlPyqmd+Q2SGyRj3FRrbaldXcccErRQuhUBduFYDgKMHJ9+1VIdGS11mTY8F3dxv8AaJY71C8MWRjKsFIBPBwMngEdeUoxWl/69egrLqynZX7y/ZdOuryzS8kh2PZx3AuLpuvz7g3TGDnb3/Cm2GlPqE+pvpsk1zFYN9mmgE0pcyY3Dy0PyH5fYE+vatVfD1oZ7q6nWQF42iSeIeS0EZA3Kkgw/JBJY4ODgY70Boq/a7a6sdTWMXME7S3AuGZZN4QoI9xKLGfLXhjg5Jyc1t7WNnyu3y+fr5FOTWqNjW9P+0G1s7Nl0idYvOknkiXy2dsAsyggtIAMkkYwQD7WZPtd5dQJPNqDpABJFcGPzYQisAfMjDKfnXdjsMZI7HO07Trmz0yVNQhtrmMxI0E91LHJcrKeGCoigBByAeWOc54qefSTpssbWM1wlxcXH2q6tZVbiNlw+CThD8qgZwAMnbXK2vhv6df6+egLY1hqV5K0VpFDezvJOyQXDWsRRYVTcJCo+fBwUB9evrWXdSSXeqG10jS7grBF8rTKokuJGbHykNtVFAJOV5DA54qxciZLe7u9Mmls5JWfaDdPMsbkDIMeQNvHyjsMgYzVYy332yVNNWK4hRobqYSQ/Z1CgEFMg4ZiRnaSAd3PSpiktVZf15af1pYdOMo+8c1qVyuttpunwmd7w3wC2sduN1wiDDAMzjhMsSccgDpXVX//ABMLy6tb6MKkoaCeGHOZPlKlVCnB3cKQD+ffm9H1DXbrw9JqOnW8RsLybz4FeYPH8p2+UxRQUHLE4DZA+9iuh8IavZ6PcxWss9xf3d2Lm5jM6AtCEI3eTIQE8oDPGc5z1zW1ZyS91aq+33vXpa3/AAei1nPRyWxh+Hba41LWry9v/skdmql8xAN5e442xgjI2Dg9CBkZ7V1EcLyXWm3M9rDuiO4NNIU3xsjLmLnfuOCPTHPSsA6xY3em6jcaHtuXj8qeVJLlIInSZGcbRx85wX2gjg59BWtdy3SpGJ7iSeNLdTBfMNtrucBgqyn5XVuRnIA45HSpqc1+3T8P+D/kTOoqmiZbvbuC3RrfRDdiS4nM7NdhZljzyVjyDgdvTsOopIJWeVJbprdJLyL7P9gUboSFyT50eflLZOML9cZrOhu7ueyi1HTWSGdLmM3BvAdkUGxy3kqCP3h+7k5xz7VPoscMl7vvbuaK9xvuo7OAtCPMLfOC53jI+9n+VZSilF/8O/62ISSumU9Fj099Cn/s62+yfbrsQXU1ighgEcamLy5EcglQiFQI1IPBGRuNMsZXvdT1S0ni09rLTVjMnzEyMXX5NiYJK/KQd2Dxx7XIY3svDUepvfW+tXmqqVF684a2VxwGTaufmxkD+HkUlzqVzbQQxXaSXd6kQkkSytySUxkKgYjLEZwCea0X2rd/y3/y6dNCYSf2TRkaC/06MWonWKVQQih7Riv91ujDjsabcH+z7eJLa3DRlgqxRvjy19ST0AFUTrVkbiOBt9veGD7VJBIsiEIWwNwZQNwwcgFuhPTmkm1pzqIgsvKlaKMSsuTtcMSB82MNyMEA5Heo5ZdtPMqCcnaxseVEZt8nzlQCp3lQOPyoEX7pQcZzkGI4A54qlc3KPZx+TLZJdXCM8CXkjRxybGVX+YA5ALDnHUgd60bgeXKY4h5u0ZwgHmEeu3qM+hrPb+uwru9mZeqSi3vbOOOYNf3LhI4JJeXjBHmFVAOWA5+vcVe8q3CssKyDL5ypClvc46n8ajmuRA9vM1vdxvJlNwiYGFSMnzO6A4Gfw4qOWeZo4ns445FLASMzldq+owCSfQHj3q9WkNFO/s449UtWkAVzGxIkj3b1TBwWPIPzHb6/MK0PKEKRgESAcBmycH8ulOt44raMpbrHBBnds+6Cx6kn3NTjmbYjRsSdu2NgwB9D6H2ochub2bKjRSOW3eYiMeAshC+/HQ1n3tjbR3Ud/Ijl7eNwr7QZEzjhcc4ODWz8rCR0IkCEgqmC4YdRzxn/ACcVFHNF5dtcPDM6SorGGcKrxkjO1tpIyOnBI96am0xc1tiu5YQgSRmRioIDjDISMjIY59OOtVGgKEuEnXzMeaWYfO2OCf165q/H5yXSLCkZtirbjuIdW42kdQR1yDz0wadLEjXSy/Lv8to0xu2AN1IXOC2R1IPtTUrFKRiXdssyLFLC7qx5YcFcc9cHNFbDggFNzKR/FjbkfjRQ6s18P5stTZhWtuIwxjRAzg73PP8AOldIowwVFMhA5z9457H8elDXLNJLb24jKxNliV5U9Pz5qRW82Ms5WQoQ4fylKhh90gYxkHpWzve7MnfckTMMKx2wUg/MxJzzTEYwqRcYMnUBB1PoKqW3mTL5f2ma6YOd7zEFmJP5Y7ACln1JLHTp5rexOpIsoglKybUiwxDgHaQDkY45yKTTXmK3TqXbO486a5CQyoIMfO8YUN/u8kkfXH0FQXiXN1/qn8uF+WIGGHHp0680wIk6WN08rCWHev2K2mZkTLkh3JA3PtC9gBkjFPAJnxI5ZcdGGCD65oWjuKKurloxgwoskx3AY+bo3v8AWmXUMkkJ+zzMJFxjzAGDH0OT09+fp3pXIYeVIqyo3BySCKUZs8KIkli27R82R06H0qdd0PyJFSMQKZgyk5A2gYP5cUWatHbRx+Y88xADOyqhkI/iKAYB9gapNDc3X2aJYhLASwuA3YYG0r75znI9MHrVmaOZUVrWESKWRZCz7QikjLk4OcDnHfHWhpdxPQNKvotSFws9r9lkgbymF2u8Of8AZBA/Ice9RtfWmnv+/SKAEARyJGkYkJPT+9np2xz60691JIlERfnIVdvU+gAHPpSvNawu7SyGS7gjMhhhy0oQ8AhBySeg9aFHy0Y7ol0rUmujczvbIhiK+VOzMyy5z0yo5GOR2z2oaZlR2T96WPCwLvbPUk84AqnftH9qhBlMN48ZWASSNsiOPvMg4zxjnPtzzVK0mktVntrdbMyoA15eeQLOEIVy8pYABvl5J7D0qlT6r+vmRJ3emxp6ZfveQxGML9lmPzzTRgnA5Bj79c8+wx609YI9Qldr0PeCKTMSMilYQBwsfA9e57VHDZx67C4ubWFbWCT9xmQ7XX+F9qnDFuoVs7QM8HirKXEFlcvIyXIg+yFpJDM/2aFUYHO0/IhwTluuFOeKmTV/dWv9dQbSVySxszHpkbQwR2jykTbJpirJubLtvKfeUZPQZxjiprqNYtWlhtI7UPMC813tG98jCsWPXqOvTsKyksrO90+5WytJzZ6rDMb65Ev7toz99RuOUkcDClcgY7Ve0e60qy0qKG6ld7G3tvLBCZcKyFFznPITAzznBqZp6tXb7f15kJ3Zm+F7221G9vrqGU3Mb3AihncsBJDEQCTnj5m3EYH3So9q1W08fZpbe7MLnLGMeWEKrn5eOgwMDHpWZ4Y8PxWFtPY2sm12K+Rf2rsJmgAz8642q2Txt5q1ooniWW1itljhtpG81nLMGZiWzuI+ZiCCewzjnGaqTu24vax0VGlU9x6dCXTbGeSRxFDKog5hI24duvXsuRx9KTS2trKEJ/a/lPcXDlklbc01wx3+WhLEnj5sDAxgKOuIVijk1bGoXczJqObdNPS7Ecm5M/PHFnawwWyMZPJPQCsSDVIUaW4ttPg1CK+X7RpcFjKjShIlZXXyn2sWXJyxYtubAXAxS5XO/wDX5/P7mROXTqbtpfwajZ3V1aXC3ZnEqoIpVfygByWGQRtAHGM45FXFMX+hMlq91uRJliwD5SGRlM7IcEoANw5yRkc98e80GdbDMNzBYXV2sM9zaMjGSE4ycttAlcng52ADJ57xJ4evtS0/U7VYZxes7JNe3aGRQ3ynchDKw2jABBG0rxnAymoPXmsv6+/5fkynL3bpk9je6lqumWs9q9ubC5FzHbzGBrcsC7FJUt8eY+3ncGZEweM8ZuLFHZaYk2rgS28AEjOkSokk7AIdirkhjgfKBj06k0lz/pDzySRtIEeGKLbdEvHCpDR7jncBwCQfvc5DZqC/eNdahk1C58kWNnJcQ2rhmfg/PN5aqSW5G3GTjPHGQ0rvb7t/w+7a3W3Qz1SvfU29QsbCe5Dz2cR+zurwmWNHdHxw3IOG56dh6Vm64YhDZaNBctBLJamK3jtFkVIZdoaJDGPlOSGxu+TCgY6U22ea+gnk0ot9pOIPJnR1RCDggqeRkZOR1z1PaTX/APRI7jUtLH2bV1jVI5svmYofkjkwR5gPT5yQN2elRGPLJK+v6+fluOze5Dqdj/YaW+t+LYFtNItovLurWxtxcBw3RyQN8apgE7BySewrTgvtb1n7I66TfaFo8ckdzH5NyouJQD9ydBnYu3lsFj90Z64qaN4sfxHODd6bY2moW6Il2yjzzC/XygwHPJPAP5d3LHd2WieXa6rdTTSAbZLyQyPGuMFGkKgsSedxHoO1S4T0jUS5vnZeluvm76W20FJOTu0WNV1C61LxK5jVV0yGHC78FtxPO0dge56nAFV4XFxeSPBdA21urRS24Q/67jBJ69BjpQlzJazqJLOeXEW9powu1iDgIAT9489eKgHnG8gfUtHjhm2F/tAPzRHPCOQQC2CDznHODxmrjFRXKtktNjS2lkGo6jbSaZFdT6be3UJh+1QCK0LEOcLhd2GWU7jgdcA5IFZ9/YXWkWV5peqQ6fqGlXVuZli2C2uA6Ku1SBlZTwd5ABz0BHFa9vqwOpX6Xkot5rUKSzHbhGJ2sT7kN09Ku6kRNMHlaC1OCYLqKFX+zOR99Q2V6dc8GjmcGlbT/hmv6RF29LnM6xeNckvdtMkMKmWS0jHmKojAB+6PlA5CrgZI6g8GTRIUF3NdRMzRSQrKrJCvQ9E3D5guRuOev6VDKZ9Is5SLi5nguWV1t2AKu5bIWPcM+XtHmMS3GPoKv2MN9c295qm6D+zr25/clJlIt40whAKsyyM5BOF4BHck0NqMbdP6/wCD/wAOb89lymtvdtkqlCud2GHr35pd7M7bgSq8+3NUbqOO8mMapcR+QAzP5mxWDZwq8Hdjbg859uRVbVJxb31nJLrFpb6fArteWryE+ZGcZaPaCzSoxHHK8kH1pKN9jFtpXNUtJ5iRRIcMpbzsqFTBGF5OST7DGATntWfHHFp9xeXVxKizTneQEVdiKvJJUZb1yx4HSlmW4Equ8d1+5MkT20EaMznbnJ5424zgkD35zTrnUdNhtJTEsrySoDOPLVVWMj5RI7HIU7uGGe/ynFNaaLX+v68vxByKt3qGmxSWn9r3EX9l61EkUC3EAMErP8yv5mOjDA5OORnOeNa2km+0TxzlIQpPyFBtXn5eg4H0rlrSwFzf3cKf2ZFdTKLgCB3mCBEVQVDkbZg+0qQgBTjCsMjUuorx30WDUdVvUvbEuTIZR5kyMTvjcHhlC4UFstjJyCcipKLsl/Wn/DJ/eD0V1uWbtrm01K+vnuprtJVUx2abVW3AHIUe5y2TjrirCS2n2Sa4fbBGVMskrgIoAHJck4GAOTnt1qBoLW2uU1SS2l8vzfINwCd0KN0kkG7YFXu2MjjOeDUF9rkUFlb3FzZvb31yQj2aRCVgSdpyFBVlxz6bTn1qUuayiv6/rr94tdi6oC2sSQKhjVFEYZyqqmMrgnPy46cYopi3Ju7m1sLO3kMkkZeMW0BECoAMKXACoPQcZ7UVjOrCm7TdmVzGVHZwNFOAPJeRm37OCxJ5JNRzAGznS32b4wfLD5IZgONwB4FJqcwjhZ45RCVJUFu+eMckc9vr69KQ2sdpcXV1FKolhgW8u5XhaaJCo+cbQwzgDO1T6nrXY+7YpNoI7LV20lp9PVdPvYUE8bnaRKwOcFGU4XG3PB4JIxUx+3ax4qktZNJhh+zwvPI8Fx+4mWTl3RGUZYuOWwenJBNVLm3GqMLfTtV1KxS6t0lWe0UPO4jR/N3NJny2kBjOCxwEXkc00azb2GqQXUCTSwadpkYhkyrzQynbmNlBLF9hUuMsoBB/iqbSk3Za6207/Pvpb1MHK7u9y2tts0+7Gn+RAkLKQYCXb5sAFz/CSSfp+dOF3C7W0bgAy5CvuHzFfvADqcHr6ZFVvKWzuJ5jbKEeR5wVtyu87sFWKsfuruZcrySCCCDTUS2gtIZ55FuIreEKj/ZQwYyMCpLHkfdBYD+PHPAq1Z+f/Df5lqTRoly020W+9xjGX8sNyP4sHHGexpITfuJUurCaxuHLmNHjI+XJ2k8nnGO/+FQahbXlrc2FrFGJftlywjadmlJ3FnOSowgHIGeAAB14p5uLQR3FjdLfLJNIk0CxFvnIO4ZmAwqcAHJGc7eeajdJrX+vUrmLul/a4I3eaVvKJ+WREIAXAyGPQnOecDqPrVTXdQSzjSG2hu5ZG5It4mZUBzjOB7H1/WoGXIa5gEy3BDIywO4SUE85QHDEEd+nPvUN1rcVheRx3F032yCAtPpsC+YwLfdZjjC9D1PPWmoXlf8Ar+vP7ylHlka9rJLDpYuHTNwPl2YGfr6c1BeXCWOl3N9emKCIIHmeXCjkhQXYf72Bz37VZsZDdadZXM9u9tc3IZvsrtuZBvKqxPH3hz6fXrWZ5cN7eWd7ILqNmjPlxTZTEe/7xj7M2MgnnGOmaiNm9e/9f8OLd26jpxB9ttjfW8M8+S5kdVRoUUcuDgkYPyqMjrRBc3WojTLSztgkl5ETJDsPkjAJKO45HzEckHJ6Y606W8aW78sgxTzPIYd6ts2x4xuY8Ddxgnr2HFaLaqbbzbedYraaaAMztmSNFA+dFHAYc9ePoelOV7aK7/rp/l2G3bYyNFfWEuJ5Y2tYbORMQSQOdn3vnbZnO/AOdx7rzitC7vYo7mCOC8traxgYieWVgXlkIGEUn5RgnkgHPAA9YUmtJJ7fStP+yNDErS/Z4lA2JGefl4A+YKNxIG7qc5xE3kX0DXWoS+VZSBdtjKsbwEkZ27gCJDvGSfVeMdaUk73t/THUmpyulb+vzNa2WbzWuJYi5iQRgyMCrjuxTgDJHXg8Y4qGPUIIrLULiZ5ruW3k/e7j5kg3OCqDaoOFJCgc4GM+tTSW9zCLS41JZYQyjpmOOZ+DkDnaeOFz/U1IHW3vYVtoXS4uyxZ0ACoFHVm6jsBis7p6/l5ENdRkUsOnObeW433TRyXJ8xhHK+WJKgDhVGQozzjHvSQG8u0sJ7lzayEMXtM7l64U5z7+meBUWkQafDNNq1lbSM04cQpJAYmiJJ3naSfvMS2fQinaVJCstxDI8rTRz7pcXTvMBIucK3VdowVC8YzjFOTSvZa/193+fkJX0ZX/AOEfi1PxhehkvxvtIUur5ZgI0RGbMSBWDRMMsSynPPu1T6LJFe2tzf2Vu9pb6i+fs80OwxrjbghhlScEk9yc89aqW+iRweGr3TZA8tpeXEjTLcTFTcFzkRkBuAFAXauM4OcZNaIjtYbuyJ2nUVgMCQ24Yxqp2k/LnGRtAB7DIz1ob3V7/wDA679dPSw7a3Fv5bm3t7q4jSG4hSNWCu7eZx/rAWPHA5A74qKwluY765C3k81hqOWj8lVjtoQQm4OcbmaQAsrY/ifPQVLql95UtvFH5IaclAht5JWGOpXYCB/wLOfpVO3d2kMOoR3dxBjy0njj3lyc5V1XGwDA5JIOe1Ci3HX+v6t0+Yr33LcT3VxaI1zaCxvEYf6sDdMAc7sEn5OSADzjrUus+WLy21CWJLkygCa5tgfNhC4OCR82045xxkdqbZXUrWTG8sI9N2EkhZPM3ryASQB2J4/WoLaO7hllv7a6eW7KnbOY8bE4BCx5APtnjuOtK1nd6f131/P5dA1L4efzmM6K1oqLtMcjGR2ycjpjA4IIPrkd6oXVwPtMIRUmUq5vJGyqpAQdpB4BJIPr07Zq9tdBGN7tcYwTsAJOPpzzxjiq+sxpcWF3avD9sj2LHJCjCMyBmCyYLZ4AJ7dAcDpSg0n/AF6f1saC6fbTNBcSXDJ5BdRbRgfvMclw56Afd6fmap32qXMd+oa0Z4XYsJSdyhQOcjrnnj1rUVVWyty/3Tu+b07dKg0k3M7WRvLaFLlGZZIEfcvU4DN0Jxjt3pqS1k1f+v8AgFJbjtKtLzWZlmiK26ROrr5i5aaPB5A7DODnv2qGGDVr3UbsPEZLVVBAQDbvDHO3+9gYqaA6i+iWM8lvcaTcvqbxyxfaZLkyHeSWLsCQvB4OAMYHBFdzcXkOm6bJduk0wGSREm+SQdflA5Y45x1rnq15QdopO+i8rPv/AMEw9o07nD6wDDAou96RSusQVUBb1IYH1GRj39ayYbI/YbwWN8q2T5GW3loHwB8pY4VAMfLjjnqTW/f61Zz3Vktndi8jvopJ4GwAQqFA6kE5yN4yCvHIJB659lbWwtjbyPd3kUMzMWupOYypz97A+VT6k/jXRTlKMVfT+vP0KUr3Zn+H72O7ZdMkgkkMfym7CYQvu4BU5O4cev5Vb+zXM+t2NvprWTaTFHJmJiVaFh90xBSI1XIOQeQMY5rOFjIXjuY3MHlyi4S4iwPMhDDG0g4If2rW8P6XFpml281tfTSabPCLZYxl1LeYS8vmZ5LZwR/s9eaus4xvKL1/q433FuTHBDAHkXzLgiMOi7cNgngc44U/41LZvFbSSS4SG6gXgnG5FIxkNyAMHk9hn0qtYams76nboIpkt7z7KrW+WKbFVn8zJGOSOmcYA5yal1R/s8CuLmOKWZ9sbFflAYbV4zzlmAx+fWocfssfM2rGbDJDdXtlfWku+31KzM5YRIWudvPm72+baASqrzndnjrWjNZylre4t0SZWZIpU+Xf5Z9icAc9euMAelZT/a4tUmjmto203TLAKJ1iVBMWJwqY55LHjAAwOTnFM0SOxk0yWzls9TeC+vlsp3vppbhrvcVyF+cnkKDuJAVVbgc5Je8r3/r8Olv+ALWFmXtPtJIo2kuDHPMxk+bCnI3ccgA52+/JxmopoJbPwp+6u5Lq+Lu6ysiRvFEpHy7ucAf3u5zwMUWMQldo3t/mgiZYrlFClFbjCAdMcgnAA46nNTzm1eO60uUXTGPYpEDeWZSTz8x6L1ycYPIU+ul+WXzu/wCvn5eYm9DPnsbttNA0qaaa+1CHf9ledprIM0Y2tJuyduDnC93zj0mn1QXVwbRtICXypuEAvFeaSMHBk6KAucqC2WbjgY4uWktgXu70RQQvC7RyySsUXBAb5XOWIB54IAx68ViQ29lZ2EDWdnKluqhIIbCJWlPzZL8HdLFudWYKccgkjNVH3t1qv67/ANd7grJ3Zqagsr2y28fnASqCSVDBCMcEev8AhRU0lxdy+VPEw8zdtuC6GCRCFI4UcE5IGckYzycUVy1Kk4NJT5fu/WLKV+xX0+4t/Ivbu5s/tQsQyMqEMDIDjfnnIDdMd/pWDd3sl9pWoJY30iy28iFrgT+SrORkxFgGbGCOi4bOBnk1pyWtrNqMhjheIiYzOHUiJmXPzNxjIBJ9elR3AthYrcQyRLaiRJBMIwHcqcoRtGW68A5wK7Ypc17dv6/P+kSkupnTC7lEd1bWceove2+XivJ5Ft33sckov8WOAepAx0PEiT2sdlb3tpqDRW8G1LjTrLy/LSSNNsiOAA24bkBJ5AjUcDitazMFv4gtd99tludsNuGIMQJDPvYDvtBwTjoOtO00y3GVvkuJILN2azmuZlM0zSb0cS8Dg5OMDoMY4FKU7dNP6/r7zKVrjNSMenQHWIpZ5ppEQJaonnNMSMqWU5A4H3jjGc9TzPa6ZP8A2nZxQm4CkSTXAkbzWkSRS6xAkgqokP3lyygbc4yaq6dp0VzH/aEMBafVIUilkDbCsRBUcngkdOBnpSRWa6Za3dnDaRB2ZX3urzea21FLSDK8YXsRgAHk5FJ21inr/S/DoNrQmS4a80vyIIZdMDSARzbQstxtb518thypAPz8cc5PUwaxcrDJLbWsUk7xRxPI8iCNJFboFckAle/f061avNJSC9a4sNGhu/7RkDT3KTCNw6sAWG4/MFVSWII6dCSKfOZbszfZJYxc7AGYoCQmOMAjAJXaeRn+kxkr3W3/AA2+7/rRdnFmJpd1bzalc26akb69QB7pclYoEBYRpEjKDjbgtICQWHbOK1bp5ksnEM1vEqEMrSwLJtbjJHfPbrx1xWXfXDS27WdgNskpV1jUZYRKcLwOpYjJ5xithXlllXcoMRTczK3RvetZx2f9f10NL2RKh2hWKSPJMxJYnJ4HLOT1z/Q1FF5kt7MYoGjyxKhxuG369T0PWqeqzQz2qQS+UYblxC0cjbd6Z+fAPXjPHerOiS6vd3OoTX8UMFqs22xhjYARQbQAGI4HIJ49fesnFqPMKN+Yk1BYpfLtseWVlyxaMMwCj73cKeDg4JGOMcETXjxwwRtJZy3aRFRH5a+YyjsT6cfiaIp7Z7gwNIjTW6q08Kvhk35AOcdPlPb60ahaAsY4zfWF5coFS7towZI0BLA4YEEE56jnt6iNmk/6/pFczGtJJaRJZ29skVlLhREq8lmYk7ic8D37nOfV3iS7k8H2Gl3l/ZytpSXGJIrSNZMEDKqqADkndnOFGOuSBTdTtI7q1jtr66h3XA8uOORSJndVLFsDpwCfrmpYtVnje2vI9Qaez092tZo43HlldvzhlGVYjjqMgjHrlSV0mvPvr219QjJKS0uYelLHcXt6l/eS3mnay0l5BJdrIlx58bF0iwThQkYPIUBuQCeK6EpKyW7CVIBE4eQSY2mI53J78HI9/aufm8MW2jW95r2m3MTarqly9xb+W4Dm3uCB84Ykt9foPWugmh+0FYHnQQQqWubYKjG4RjsXdn5gARnIwDkg56UbpNPT+v8AgI1rSpt/u3dEbXkskFvcWds91FKMo0ZDLtGDlecEHA56dTT7y8lOpWJnykADl/3yqhkOMIE2/MMZwQQB6Gk+zzWbssUanG7IjJxjBCIq9AcAA9BzVLVUigaJY9IuLq6nPnXUqti3tAvQljlmfHRFHJPOOpaUW1/X6mDNCCVpZbiC7QXd1ZsrbRB5JUMeCrHj7rdR9KW2it3vmluLkpHA0ioto/7ydghBiA/jIBycdPr0nkhfVrE2skRjS6twJkuFyVUj+IA9icYB5PAPeq11ZxaAlvcT21uYI0WKwupyXm3sDuO0DChiSTjr34FRzX91bv8Ar+rdBWurGle6m9npq2ekzGKQhlU3rBQCeMnPzO2TjHqQPasfRlmTRmjv9TnmlhLK0oj5Dk5GEPYbhke3bpSW2nrHqFy9/bQC7SYbJid5kiADLnJ4cEFiRgZxgZ5p8Mss11dwyQbYIlTZMzf6xnz8uO2AOvufSiKSTUfW+n9dSlDqPjmunsXFpummhcW2JysRaQkF5A2OSAeFHHHXHFR2rSz2yTafevcNGy27vcqyh1X/AFjIAAfMIPD/AHQR0pSrzeJmuhBMUhto4IZJGDoycs4Vf4SW6nvgdgKbp2lsupx6le3rzagbf7MzKSkPl794Cx8842jJJ+6fXNVolr6/8D+vufQUWiawhSFLUW8d5aWkW5RHL/rW6/eySTknO4nPWrDzhCoCyP5h4K89sbs9gPWm2iCztlWO8mmRMuXnkBYFmJPPpk4HsAKlAbz8hW2nruIHA9azk7u7NYxS0Ir1d1vsIdRsZNyP8xBA6HsevI5FZxsQ1tPZ2k6W1tJDsZsnfuKhQS554A69c96tM1ul/HG6LJdSlhFPsZtigZYcDAGO7HvintatcmdJY4zZBFUMB8wcltwbHT5dmPxqk+UFZLU6S21lLawsEaOSSKQLG9xFGWBbOBweevVj9ah8XXslu0ljb27tcPCZredn+UPnG045HHesDRrC8g0wRyXpeGFbhJrQnH2hZD8uCT90A9ufpVSztjCv2aJSNJtvLeziZmLW+3ACj/ZGOP8AJrKNCCm5J3t/n/XlY5407yJIoZHd7u7uzeSSFXEZUHyGCgERkYIUkbipzk81BrVmtzb/AGmWKb93GQjL8znnkrwQD74JFaEl7HDaSPAn2woVEywkOyg4JBHchWVsDkg8U5rmP7RbwHzDlWcAcfICAQR2yT/Ot4ylF3SNtGrIxJkSfQLOOdGtVh8tDGZRtQqSQS2RkjOAOhJFa1rpl/pctul1b25tLywS3u7JJxHbWPl52LBHtJZiWOTnFT6SgS7j/tFRLC8rLJkAoo7cY9x16UC/vbkKL5IYLgtIkotm81c7jghmGeQAcds9aic5N2W39fPS35fPOavKxQNta2sySxzx2LvdxvNOAoWWTAAEu7swAHHJwPep9Qt3mljt7rPkBjCU2gDcDkkg++DjtxiplsYbgSNcwrLGGVgsi7wcHI68cEAj6VHJdR3MbvBKlwVncO6OGG9Thlznsc1XNroVHWRS1t/PhtIJZWQu8LgS5AJDnKrjgbtqgZPUjPu2NnvBcXJm1PTJJbaC3BkO2OH52JRBn/WkqAW44K9atFhJci3CzLOwWeF0ViAAw3At0yByB3GDVNUt5NSkSTS7RGuJppJt8bN5k6kPHKr7dv8AHu5IIKnbnBxaell/XX9PMJJaFa41Ey3ui21qr2yyXd0sscikb1jjDb8+gYgAk4xnjuNLVLttW1IRafJHcWFkuAkEykGQgEliDwMHd1yQwxx1ztl1/bcqXSQyacYMRuygbWIKyKSeu/Kjb6LWtbx2lvmCzjggiXaNkWI0UgABePQADFOpGKtZdPzd/vtoVdJ3ZmzNcfa5bG+vLcWlrEs8lyilU8wlt6DcpQoFK4ABYnOTkgUh8++i+2WktkliLYm3nM4eQwMFZXVNgkjzjBHGMDOe0uJA19PcGW6kDORbmARrsRd8Ydm3AFHXIkXH3uRkCobePzbqbVYmihF0IJDJFsYSqVJZncjc2eOh6IDkZIpt9f6/rsZxupaGnJFPcxRzwFzYOu5TMoEQJxhi5XdnqOP73I44KY+orqNoBZXn2mMMJoYtuMB1DZw3B4bd7BqK8PH1XTqKLT26OS6vs195tB+djHkgeW+nVhNHdMWgtnfMnmQgA7sHgnOQP61a1GyhiisotUkntbYzrGiiRlWZtpIjbAx0VjzgcfQVJpKW1h/pV9eGd3O1p0k/dwoEYAnGfLwQSSQADiqemwnU1g1K506+s7Msn2ae+dllucDO50LHCdx0yAcjHX6By130X5+X9eehzc3RDrm6nmub6a8NxY2JVlZZo1k83gBSoAPy4GQACT9Kjn0qKVraxjuII7i3RLlWUbtjNwJ1ZgQWxkAj7uT3xiTT5pI9NiaxuY5bGM7pbm9LM9wrHGflxjIOQxyAB0Ipt7efZrqCa1VnvJbRoobQwkLMsTADkEKq73U7jgkE8+gk0+WP9W7/AC8xtaMmsZnh1I38MFzd2riO0a/E/wC4Uoz5BUngrtAJwCzMAO5omNpPYTz6xDc6naCcQS+eBmVt2Q390Rhj6EDHtmrlpFeyWlva6t5bXahpz5KnyYiDknnp94jqT15PNQG/Xy2XTovtZjnW3MGPKEOeXkfcOgByDg5BGOuajVvT+l69Pw9CUgvILtZrl4rmT7VcIHSdoxLa26qwyoUkZbazcEYycnOOZtVllVobK1gKG+J3yTQ5hJ4Z2k24IYqMDkDPU1T0u6t71p1t7lcXSl4YpAY2l2Ag4Y5ypIJzgDvUum6et1p9teveRWGlwATXUpYOj4XLAysflXOctnkfhQ48usunl/Xb0/EbsYnieWFIlFtM8sGoT+aPsbM3nJxtG9ONg5z0ViQD0xW5b+YLtIZTJC1uu2WKSNky5UHOCPmXDL0zz37VT8Sa1ZaMizabfIjXTJJ55R3MKsBu8pc5Y4A2IuBk5zjrkfaFtdJhu7VL2xsyRKG1UtLPIWbJMrKzkFicnkkcDjttGLnFK1v6/pf5Kw02zcNjb3V1Yzm2le5iWeVNygpH8oGWborYyF+prb3NCkId1wUx8oOGyR8p9+h/P0rlY5hfXkNheRzvcx7bkPGWjjwwyOQcFeM457ZxXUyW0rSRJlBFBnMUik/Pjjkn5cdcfyrGtG1k2VG7KguSu1GgK3E4YJFENzFFONzEkbQPU9O3WpbK6/tPUk06QXBvpwEkd1+8NhPyseoAHJGcEjuaWWIS28sf2qSO4m2hbiMKWhYZOUzkE55+YHGOlaWhpaWuoy3dxJ/pccTRQLIjNwxBLAdjwBxjgVhJpRbS16f12CTe6M6WeLTtLi05ZJI7xpxDFgGRgPusSB95QDk8jH3ugpLyFZrpFJujZoW27ZVSFn2HJYcGUsCT3xtB7VVv7W9ldhB9lummZDNa3bSeWihsltqYLAnPGccYIOcizfR3Nla28+pfYvtNtYTSNqVxF5McGQM4iDbtnA3cjhcA5NUkk99Xf+v6+V7mbdmNsI7TRPDUME8itLDJ5dsCg80W4wWXOMkbj+eKhlChrSa3ZLS6vJAjlo/3kyoCVX1BAyewGfU0otLZb2PVrqSBGKoZJJfkUrxhRnkBmYADrzjmpYbhYpb2O5+zebLKWKQkszIAoO4fwkEDIGRwvTmqe7a1e7/r8f8ALc1Q2e+m8sWkpFpfXK+U0w/fCylKbgWUgbwcY5xkkD3pt/Y/6cHgnvJJZT5kgjk8lIokwZCCOQvQEE5PIGMnLTfQWtvOwt5FCgLKhgJLc/LwMk+vT6etXNNFtda5bwX1wk2oTRuwUqR5cJKkhlzzlgvX2FLWHvJd/wCv6f4ilHl3N+yRorYCQESOFdgeqjaNqk9SQOT9ayb5pLu4idVQwwt+6DPnB6lgOx7D0qfWruONLhILgSxxsC8xITdkgbdx6nJ7fSs11lmj8uC68qVZtjOUyUCn7gBGOehPv9Kwpx+0xpaXLM8brPNKXjjQtyH+faxPUH/Oc57YpskqxRMzNmNU3bcbsAHn8f15qvI0wRXtok3o64eZfu88kAdTjp/hVkJ9nu1kndyzJ8tuzfInP3gBySfU+nFXbubWsrFe4vZYLdZTNFbxOREWklxgtgKuO5LEDA71YtprdleJMlkABVuCpx1Pp0NV71oFjaO7WEwh0cBlzhgQVx7g9PQ0szpFLFHJy9wGKnGCdvJGfp61VrrYpR7l2Ry6sJFTCrwoQDB7f0qnO8s9hI8W/T7qSIoHliDtEw4DMvf1xRI5SWKR7kQ2yZZwygiQHpzjgjrxjPerUbRGFnDJtHK9gB657CpXu2f9f5CaV9SOFi9gwKCVwmQRkbiOCB2AJ9en4U62RHWF7zy424MiR5wTnnHr7GqaWrvqZubqSadEdZYFcII4DtI/d7QC2c9WJ9qnLDeZlcxsoJwpPUc8D1pNdExW5r9Cxh3S7fWNPtIYo7kNp01smZGXByrDrnpz3LVXi1Bbu3EtiyOssYeGTy8FMjhipPr2pl55Of7UkEguUiCGRixKoTnlR79gMiq9rJDeQxzx3EE+3cqsu5doPVMMBn15FVGGl2v8v6+ffQzgraDrKWCF5IE8lLsFZrpY02HcQVV8987SAP4QMccVdRkniLZSIY/1wAYBSeW469emRz6VTjtSWkcXU5hZQw85sxqynO8HqDjA6449aLS7kKXbxmWSLLFpCDsmA6OAeCD2bvmm1fYu3S+owXMEt3bSSvHC672EbOAwBKjaecHouT0BPvV7UpJoraSW1t2uDHIPMiVsPtzyVzwSBzg9cVimRLtbgPfOYZIHjmU7VaEHOW3YJDY46kDHrUlq+n22m6ekWqQ2dlLKI7ZBK5NwmS2zLZbIx1Jx0HoKpw28vX/h/wCr3InpqX7qW6GqRqss32cwZVVtx5WUbkvLnOW3DCAfwk57VW10TQyWj28TqG3CdIoECZYqRM3Qn5FK7ueXHHGRbmvrePTRqk1wItOYK4m8vcjKeVYN3BGAMZz+tUU1CzNmby1jnubWV8PIkbybTjl2HZVwPpxjrUwUtHbbTb+tQjbuRG8uzrFvYC3lDQqkj3mMKCVJXyz3OdoPP5c1b1vURbzwkopWeMpKOVG7cwOG6KGIJyfWod9rf3toVl3TNCCEL4bYrbmxGT7LkkE4bHfFUNdkliu75ILe3jV9PWSGVvMlRmjJLK6fdVcP7M3vt40hFSmlbp/X9eQ9nY0tUV7kaTAqRYaZZpWkiDhRHlxjPQ4Xr2PvVW+1KLyLuLSIIYIbW7kkvJo0kDzwFSzyRMFIeXkYwSG6bhU+pRNPfXdmk0lrZw6fbs06hWhdfmaUfMDkbcK2RkAjpT4Z5LOwUWMljaqHjW1V22IpA2YHPzAgrwMcEjPNLSy/rfX8n8rGctVzGdp2q6a+kS3t1eT3Umn/ACrshYSFXC7cpnPKsCf5ZBro5VWFHiOcRlXkBAwDjAPr0Y8Y4x6ZrLgmlj1G4lutQ2i2j8qYhVSBx97ejg5BB3Zzzx05yW2EJNiGuVVoiZLmzIuXuyImwysJGXIyGfABPB4PWlNczv8A1+n5dfLVbOyINQs7iO4e6itbV1WGOJWkdhIcFjsAJ2jG5jnAOOOeMFLp0VzfJZak08kMohKuscakSBjkbyy7gRgHAxg5BzRXjZng516qktbK2jts35nRC8VqZmr2jqLm1+0ynSmmNr9hiVCmG5O4MC3PO5s85wK05rq4e+udUbTYIpEQWlvun3CWBcFNw42AMX4HJHU9KuajLb6ddCTzxcLKRGqxN5jrMTnaUxlQF53d/aqeoQQT2rEyiEMwYyxfeJ+p7c176lzpNr+upzKzCwivCdSnlhV5biLySiMSrpjqisdqk5PGenWrSRQ3d2zxG+83iCYMGjG3rujPRsZC+YpI446VALpksgloqyqFXBc4BI9c9h6Uy9v57+8iujqERjRGds8O69/vYCqD3PQZpOEm77B6E66pbLElib2Oaa0TddtNchpQTypkA4GV5HWrmmWv9pWU8jQ2/wBiLYEouBJ5qcfMTxznK456DHWsKxvYrywkuDaMHRmys6+UHIPrgsF44bBJHQdKtafqcU9i0fljMDYdYAY4wRn5cZ4wD049eM4pzpSSdlqU9rIs2FzFdOwtrZk06GOSHzRFmTcrFDGVODjgnPRh0qC73w2VtaTxJfFztUTxI6glgcFcbcDoODjrniq6Tz3U6rPFbx6fEuUT7OPkcH74c9tpAyPU1bgE93a293YcSMys/nrs3RbsMCD0yCCOlDjyO7/r1f5k2uSJpkM9yLq5iiFyvKPLgsfdc89T1+laDWY2RldrZB3qxzu9cj9MVVO4a9NK9oElaIJ9pcqCAPuIueg6ttHGSTT5rx5oV/s+VSVm272Xevyk7kPp3+btWMnJ21GOuy8NnK1owgEalk3xl0B7lgCCfoKgFxFNDHctM5dMNKgi+YAjptODk5+n5GpdSvltNzSK2EG5mXA2jnqTwDgHk+gqW+Ef2IPO0luIw8kjZCqi4+8fcDnp27mpTaSuivQZqglinsrhZxDaoGOyT7s7H5QWI6bScfn7VGH1S3t1mS4s7a9WFkuJUiLQ7sjJVGOdvBHJ6H8KLlUlhkWZAbOWMrHHjIaM9CW9Ppg9Oal0xI7mCS2tRHNp8R+zxKrtIxVBtK5PLehJJ5FF7Ru+n9f1/wAATXUrres8Eclit7PAJV2XNsd0UzNujdWxydv3ugUcfNkUL9m1FkupSINShjkitria0CyRsyH+BgN4UclTx6kcVEtnqV5ps4uxDpk08iRoNOlAeK3Vt2VyOcDdjPHzHjvURWU2baneQWl5d2cLhpWh2BYC+SicfdHHHJJHPWraXR67ff8Ag/MhK+rKP9oQXP2u+toLy90mZ0E1xJEpMsikDzY0PAiyC+4HHBI5qzHbvPdWl80FrDemJyhhkMsLNn5GY/KW6gnpkelaNnbQymS9tt0FxcutxKzytucYAIBbITgDgYAIzUNrIst/DJb2xS4XMMRI3vFGTnbgcenQE544pufRK3/Df1r+HQ2jDQl1ENcM9lHfNG8USGdYkAZ1bOWB7AkOOM44FVbQSabYXUGnqt1qcduQ0dtGGnkOCyKFyPlAIwNwOMnqc1fuimh30c2qvJc3k7FbLTo0Xcw/h808DC5JGeB1Jasy0sF1TTJNYmsmj826kkuZVkYKZFBXIdSN6YyM8rn3AwlJcn93Ttq/wut/02IXvaIsxo5urYagzfa1gCSW0RxEuCNz+WSQPn4BOccDNaH2O7hjSadPLDDKxxsNpHoCOWJFc3BeXK2ctw0FtHBKEt4redBvVWIXEjkkbWc5yBkAgepN3TNNh0y3tLZoIrV4tkJjh3BXGOMMWJIz9T/RSjbd/wBf16+puk1oi3/alnp9gJ7qfykycsFLhT/ebA4Hvj1qxfmRJysh4O1QyDcCCCRyOue1HzrIiBZIfLYyEJGMOB2OeucgUXbXF28cdxKFiBBG1cHA7n0x6Co0voNJ81ypA0dw80xwURQCEHT6nt07+9WLe5S4u5rAM0k9uELhEYhN3IBYDaTjrycfWoJUMcjlUMkzyeV5kzHupU7mzkgAnr0z+FWNiFQkUxWaFQD5b5498dj/ACpvU0m0Pi8u9YxNGsiKwJiKZXI6deOMVFL5cq3CSxoY3XbIhx8ysMEe+RgZ546VYuZW2+YUcj7u7lgD2BOc8/Sq0gUDhVPGXWQNx7cfz/8A1UkJWfQYLLTf7OS10x1itQhimjMxVxvHbnOOT06YzSwNMGVQUm28CUSbiQPXinM6M3+jbWGOI1Xefwxz/j9esV1HdonmCMRyHADY3Ko9D3z+NVe+kn95cY2LDfPETJKoOMkDByOnvTIgIIcIgKhsYTj6EgdKgt5bnzxJ/oqwFcFs/OWOACOCBnkc8noOtMu7iSHzruC2mkkCFDBuABYdcZHU8cn9KfLrYSbV9C3LHGLb7Myq1uVKeTKNylT2IJwR2PHIqhLYzpJOf7Quo7B8xqFfDI4O4tvP8IBChANgAHFaa+Y1okLxMjBQQxicHqSDg8jgHrx9aq3l1Bc3Utg0p85kzt8tiMkZU5wBnqfxpQlK+hk4xvqg1f7PpemTXLQ3KyRsPNmiXflTwzsi4yB1OOf5UyHWFjifULJLt4mxA8T25Uv8+0sAR908ENnHFVwx865gZLlGm2yvcx5ADLgBQSfQDK4wefeoZ9PkuFgWKSW3kspUmgJTbwGyPkJxjBYD2bvirUYNWl/X9P8A4YUYy1ibl5rF2rTQW9syC3VJvPu22Q84DIpUElgM8AdcDvWZFBb2ls2piS7lv0jNwWYsHuyU2qZUyPMwhUAHkY4wa0tQe0n0eSGaCSRpW2N5bMu+NuCDtwwwf4hyKqRQy2mlxxuwmkVtpLRAEZJCDqSTgbSSecZ46VEbKOit+qMow1sV7W2uoJLK7luFVViYuLckRvLhd3BJOOuMknmk0eygitFisHSKzhL4tFiVVJLblORkggErwcHdkipWEkUjFREsciDYu9mLSDk8dBweo7Zz2plpb3kd3eSxXQuIWx5cAVU8nIHHA5Jw3Oc8gYxzV3bVr/1/TOl236iXCTwWTW1mLmee98/a0iq6WxK42N32ttGOG5b04qtpSXEE8Npq0RkNopa3uJVR2hJUIyYwDubGcgADj6VahvopLjUILgy2ptGYrJIdglUKG3rjPy5OPXAPFVYXmWzs3uSoKqykKdxl+UZXJORjI/Oq1tZ/1/S0/PqZxjrYnNnIL37NHe2gnkjlmTTWsw8ToxHlSOq8nDDGQRuyQMYyKUupRQ2bIpkSHS7sWM4jvxKk4dQHD7lLoUZhtAbOWIzgDFgRWto9rBEzQpNCtpFGtw0REagvtRc/w8txg4B5wBVS6gubi6uLaZtZ05YmjWa5A+yi4kJLeZGqcYYMQzHnheOtONpP3v8AL8t+3W35YODTsy3b288V/wCRaXM18l2XuHnBeVdgwoRSGxGyngjocE9aKu6q9wI7bR3aJpHJmu5rhfmICr5e0r8ufvAg89+p4K+YzijOtWjPma06NK+r11a/4a3odFG/KO1jRrW4WSCMCBBdJc+ZFy5dXBzk5znGDntxxTLvzJre9itRDGyZYFlBWPJxnHTpnA/nV64ia2+3LDaOCLiSdkjUJ5sjHOVLHkMT2OOvoRUclsL+3WCQGJDiRo9ucHrzj0Pvjivo4S0V3p/w3Q527mTcRubaIxvFKSMBTkKWHUtgZxx0HWrCbgsTwxL5pXAO3ooP5Crb23kOQ5k2bNqxKRnP95j/AI/lVLyfssOZpGNkEMlxjLShx0JboRjsBx7VspKSJ32IL1pzLBDp1mk7bh50xkChQertkHHHAAH5datTWUUcsMt1cFYoiCP4UZs4BPfGeg7nsaSO5tDIIrJjBczbZpl2HcqHhdx5+Y4wB2HPpV7y0lwbpVebfvUuOjAYDAZ7ZOPSlKbjZbfmaKN9StcX6wC4FrDeXs0YUssKKpk3NgKpcgevU4wCea0nd4ZDmNvnOSTjCj+p9PzqpPbQSO004/fbdkb7v+PcdMr/ALR6Z61FpbwQWMdrprSFY+WNwWJDkkkszDJAJ4HWsmk1dL+v68v0Hazsyru019TjlD3Kk3DQohLSebIBlmI5C4G5QTj8M5qO8js9TluoNJmtPtfnJNeGJioZwV3M20EE7FwOMZAzgc1oJY3M+liE6hN57k7riBFQzAHlQMEbe2Rz6VHdWjNbXVtsktI7jBd7Y7ZZT3xweTjGfxHrV8yTunqv67fgSoKwuoILvTJ55nuRFC/nbbcBXk/uxFTwytnBU8cZ4xTdMsDHpkSzPeC7mjDXEsrKsnmHAx8nyqQAOFAA/MmTTyUtYUuII45EJ/ceZv2qOBuI6t6jJqK21C2uLm9hS2MTwShZZpgFVmK5OzGcY6Z+uAetTaVnFFNa3aJL29gju4YJriJJHbbFDuJeVgOFAA7A5JPHIzVfTTcz61eI2nS2rF0jFwzgidVHy8AnH8WV4znJ6mrUctm1t9ohVZFjVhvyApwfmVMYIGeDjOc81Wt9NZrVRCZbOZi0hWGQtsYgr+8BGGwCflzjPXNJcqTvo/69P1/IqSvokWLrWYNOjsk1S9t7WK8JUlnwHAyFA6Dl8cnA44zSq90qKNUvWZWUJ5EchMO7oMAcsT6c0RSWGYLC8l2yJHtEYtfNkcDn5jwq5OMdASOB8vCadqFtdQLdLFtQZS3kxvaZCMkoxwWzjBwoz2JXBLtZaL+ultP8zG+pZkmUujxzxtA6sDncVUDgtnhQB0556YqhYN5GtXKW5lguYVUAPlURG6beCNxHOeW7ZFU9at2llvdMa3T7K2y8nhitSzqSQyybyNitlW+UAkfIcr0oRr26a6tZftEPOUK3WX8v+IkkKc54yM+9EUmt/wCv1NqdJzWuxshpUfzo5DG0p+afG529eTz+VV7XxJdfZFVJNTSMvjypiFmAPALKc7Qx6ZP1AqTwQkmp67LY3U3lxWIW5EQckyRksiDJ525Qk92PoK9Gn0yxnieOWytyrnLDywMkDAP1AJx6VzV61OjLknG5nUqJOzRwJYXasbmIhmYDeHVvNGMglQuFAPHU9M1mX8Eqala3UKqltAZTLE55ZzgIwBB988jHbNXzFp9pPPb6RcA2Vo728dvA2VLKASp4zweDzjJP4VHw8TK9yzPJ+9dcZZQOqg/dXnGTnt25FbR0+Hb+v68jWnZ6tjxNbx6tLBIV86NTOVZ1JycYO0HPPbGRmn2dpIjQyXVxG0SP5pXG0u2OnHH8Qz34qoBtllvLeGCABccEtJISfuqcYAzjIA7Z4qKx1a5uWH2vTbq0l3CBvNb5e+CjY56HPT8M1Vna6/T+vuNXFt2LdzFcTi2eGWPyhKXaMJ87Y7bs/TjntTrWKG3mnnZlSRwF3iA73CqSoLdMjpjn2PPFSSxknnadrmWOZCd23+PnuOgHcn2qzcSSuxaXc3ybWEpwuScg8eg9PWh66JluDehVttauNQ+yy2sk9qzQsfN2o4LFD8kkZIbIyD7Y5POKNQvJGNkIbyRLyFS3lhQsF2D05Kkflgjn3qWVluIpY3tVlhMbKPNcfNJn7pyR1HUnjp15xmXmnXCxs3mvDbmUbgw8wE8DhT93PHTvj1q48t9dBRoRbNCxOpSQl7g2vkucsfMDrGf8/StO1lKhIJ43IIO1tg2kjquPXHPv+FVJY1BjYfaYbVoyrpgeVIPU8dasOqStGFMkXl4KSR4Kg8gd8/p39qzlZjnd6MlNoL4JJc20a+TmWFZMA7gMbyCTjH6HpVJYb2d5livBFjgrGWQuD3Vgc5w2MjpU1tp9nD9plgjVp52BkYglm7jJ6e/FTwRs8RaQBTjHyc/N7e1K9tn/AF+JnT0TuVLXSpYrONIJx5IBRH3ee6/7xY5PTv3qGC0hgml8sIHkk82RV+Vnc4yT+AHPbpWjJEgQmVZXYMOgJznqeOfxPSqhjzqjIXvHieLIPkoqpj0bOSTnkEcY7U1Ju92Up2ev4FKK8hudRnhJaK4tiQ6ucDaemPXj+VWjK8hQTSFgDsR93yjPQEHnsfaohO1xq09mllNGkAXZcsAUbjJIb07HPQg1FqjiLT7i8aNpihRD5PzdwCwHTjvitLXaS8vxNE4NJsgn1S8tp4LNGFz9qkeXbcghYYhtG2NVXBxySCd3IPIBrUuAbibzEvbpA0Oz7KCoRHBDByuM7/TPYdKgsZ5TKxhuzKrjqI9u3Gcgt0IIxxjsc9aspPNdKspeSZx1PDMo/I9vpUyfZGUqVpXsVtq+VFO0DqiNgSYG3cy4Kbj0JxnA7DnFTlIpEEM6N9mdJA6Rvs3KQQ2ec49Md+mKZJFKtxEIbjEe7ZMjAgSA52nKnA6jqCOOneo454BLHgyRRwoAJbhSjPk5zggED+Xelr0G2pKxlWa2jaPBFCki2cqxpFHIPJ2RDIdWHUfKCOvGPen2d9cXl3JcbLOTS2eOa1EBJYxtGAXOeoODwQCAo45q5HLbRxwpcywxvfv9mQZ2bmbdkL2J+8cd/aoZ7E3GmPAJJ7GHzmjitxhZECjbuUnIAOFIY8cEda1bTvfr/X6b/wCZMmoySLNsosvssIuPNncPJunUuzMzkkBj14Ixznb9MHNddOsLa9tNSmW0trN0GnXdvhZYVmUvJGhUE4LA/f5JLAdqfp7TPDFDdhZpIt8SuoyGAOcMAfv4PJBxk8datwCG+E73jSJEkb28sO/nDkZYkHO4YGDyRu4PelF8rd/w333X4r5sipT0TLcX2u0Ms1ybaF2ZkhiXPlwxZBUt/ekO05Y4xuYDjFFMkkjggOmwoI0jVQhkztI5Pytnk8c+mRRXgZjQrVKqlTdlbvJd/wCVNfjc0pU4uOpd1qS7ujOiW6v5dynlo0wV7iPgPvPYg5IXJzgZ6mny3NvBqMdjI7CWRDLjYcYBxknpk4OM8cHFO1Kylu7l5LGeGMyOI2kWENuQNnaDn3P0zVT+0HguVR31OQiTylVYgDI+4nbEMcYBG6QnGBxzmvbirpJf1p/X/DbcbTWxaVZWmaSWTy7QNny1jJfAHTk45OOeD2x3qVwWXYAyqedikZ+pP9egqmras+qxiS3s20pELOTISxlJOFVcfMBxlieecAdabJtR5fOuFMefnCKAPoT/AE/Cla/U0jfoLMsDiaH7NFO9wAjjgK6gdCfQAfU89O9lcEo8mIrcKWyBglfXntnv+FU7p7iytJGuLa3nvXm2w2i5VwG+40y5JAC8kcZ74HBSG1trW6mt/tYkZf384mcyM7sDtBPYcfKg4x0UAg1SStdD5lexTXUHtLm4urv7XE0lwba2ijxI0/TDR8AKMZyzEkfU4qxNf3b2IR7OJb0BpEtp7nCxpv2hmIz1xnjJ4PWr8eiNLcPd7p4tNh2yTQxnaZW/vMerdAQCQFwcA5qBLaLT7x3srcQ2rqqwIu6WbI6MQx6AEkknJLHPJquenLZa/wBaf1f1M0/fL4nKTYR41CKFlQZJV8AhcfwjnoRnkdKxpHuoNQvZZ5JBBIV8vfGqrxwFBzuZ+Cc8DHHGKoQC8kgtLLSbq2tYxKZZhbxeY7ruzjABAZuNzE1t3UwRhCYFcxncyoxLdO+37g6jrnmly8j01NlBrdDkmkLvDKyQgAYJIPfLYGe3TnrXNWk8X+kvb2Qgikby5zHvKyHJHyl8A4BBO1QM9zitKXZdPJBImzcPmEMW0E9l28EqBweST69qtuqXMbQPICyRiMMJWQ8jnryCB0JH0oVomijylWKJ9sUl3cRxzRR71ZEPlrn7pAPUBc/MehyQBxiwst1bQbLISllBceWVzIw5ABJxg8cnjr9KV1vFijtXS4W1tQYyhKk4cc4YDp659KrRJGsxZcKrAozYLFu33wMdu1T8Q+XmTTNnWGkuoGu54j/aEDl0AIjJ3DG1d3CkjKk88Z55qDEcwtbi8hj+2QjesQfiM455HbFZUtzpNlbia6kiskU7FdlYrkjHc4J/nVoiCK8ljuLmJoxgASOIdx9sEZ+nWhQaVkv67Iz9nGO7IBvtkSMNNPgDNuk53uTzmRx/F0wADjA6dKW8uILGN706ijxtHvea4j3Opb5mXj+LIwcetOu0SRpHtG3tKxMgJwyjGMFfQ5P4VnaRoEGpgaJpDrYxuB5j2x3PCmcFgegY4+n1qtLc0vmbJRjG+x6b4IsYotIj1BIZopdQjjnZJ49ksSFAVjYdsZPHYk0/W/EFvDPLpthsvdSGFlgSQDyAwyC57cchep47c03W/Eq2129ppscd1cxnbMxb5IDgEBsclsEHHHBBJGRXnUMLzXupTra3jxyzFvtEMm8TsAC7gL9xScjJyTtPYCvOpUHVk6tX5f16fP5HBTpuo7sv61bXkMJgsYo7IwtukkIEgOXBYcYBLAEHryc445qEyoAkkX+iHaUCIP3jH7pXs3b6dhnAJJBab4JoXVhCxZEZy6gkYJIP3jj+8DzzSXbNFYpNZ28crQz8hZHiyhI3beNytnkDGDmu9JpJf1/Xz/zO+MXFWaG2epJqLW9zbRrJb+WrQ7WDBwDt3NnBDZzzt/hPBIyLMMqQTzM4KIZNsatu2hwPl/AkfpVaPyrmNTDHDbthVHUyLJ0x0y+eetaNvI4FxJFI0jFihZUC7Wx1GB1Hf0pNdkVJqPuvchs59ob/AE1YwGLOrRBt3PI/X2NT3F1GEMUcbyTybljKHcWfI4Veu3r19PwqBJVmX7M0TrmUKGjyTtAyR9eec9sVMLiO4hYC3kyMoJY4to2k8qC3Qep6Umuo3ZspXEsx1WGzube7dyu2MwwkKwzksWPIHOMY/KrH2SGyaPMhgb5lcyZZpUOMLtOQQOe3THIxTF/s26tBbLZz3Mb8Pm4Kq4/uqq/MRz1wOtNu459ONvLZxQhAuH2De8UY+6EUnBAwBnrVLXTb+vn+Qm3exJmIyCO3iMLKxCyO7FX9ue1NiV0utzsIJEAGI0+Vx6/73q3U/WrnkxmBbi5MrSEBipiCsQe/Xn86S8eylhkuLcBGi4K7sDPvnGOfWle+iLU4vR6lYXyR3rRx25lj+YmeadUye2A2OB7nP1qxdXot42ZpkhcFV/eR5DFvQgkde/Fc7c6lpiRrE/2+a7dz80aDy2PoMHJ/Kry3EN5pz21zDfJEymJhgtHsbgghsEA55wKpxtbT+vnf8ipYfS6v80bdpeQT+as0pilVgOW2qp9lx1+v5VTkk+xi5+xWSMvmeZI7ttS5JBJbIJMYB4ZmAA469qd7plwqs14QRDHtidZWPlgcLn1UZwQe2CMYqG8M0sVvb6gkaSSH9+ty22MoQcqyn7+enPBHXNKMVfTb+v6/4Nmc1Si7Xiy+lzFbwxJHapDLJESI0mOwSkE4yVGV3EDcAeDmr1vI1tYySaq7MRbeZNbWoLuMDkRjGW56dzWFDDJLcSRW8MNrcSruivImWVERSAuFIwrkcYIIA5BPGNOS5ZdRleWRFVSpSIPuZWBw2CSGGOucHpxTnBbIyaewzU5CxkWO4zu/dLNAF3AY4JH94e+efWszSkuY5YbG/W2vbpwSkyr5Xmbc4KgEAH1PAbBwM1bvn869R7bTWASXy5pJJHTevZ0ABDfQgVWuNkdms32iGziU/LK7LnnHIbOQvB64x2px0Siv6+46o25btDo5bpNQEck+20j+bYFJkduQ5C8gAY9c849Mys8r+d5ULZI81RMvLhjklcD3PU1Bpl9bywo+mzRXkU0mxbiNchCM5bHfnvz19K0jbSPpsWnFHe3EbRSOpeNiNzEsoHzd8fKe3BxzSlo7S/r+u25Dkl7yRFcWdvdWsYSAXEIYM29+VYZxtAH3+vr/ADrChvL271ZLhBJJBZswWUOQLiM8bWGPmYdCjjcpHBwRV29sLm4nvpLWcwlQPLt7i3R4JVYBBGknLqynMnzrkkgZKgmtG0d7bSLiK8Rbm6WUtuibYXJA3c9iTzyeM078q0d76en6eXYUaikndX9TOa8k+3C7QT2ksh/exxuskUqnIyG28NjjG7p+NSQtIL8PpdvZFpELPuH79JOxZACGXseQeKSCG9mvAY/tluzcyw3UnOPcqcOn+0CR6jtVua5e3C27LFcLO/kPCkgDQkKTkbuZFGASgJIDZxgUPTRDqOCSUSqltcW2kSW0rqFnfOCkjKQDnHL8HI7Hp60VJJDMbR5pTG90IVjRJWbyc7wSWUDKnGcEd+OlFc1eU+e6b+Tmv/SU19+okqcdHH8v1NXUpfN1HUbY6tJDJHZksxQItupZwsqk/JuADcf7IJ92XkccmiTSyz3MkXkj95GC0sowB8qrjJPHTufrTLm2+13pkmtNiNNLBcRXn8UeDgoqkrksFxu6Cp4w80K+bFFZxR4jjjLgKiDpz6/n1610KySs/wAvwORRs/ImjnS3h/dgqqDC5OSPr71Wg02O08N3l/DeCC4JIslRRIVkY8nkgGQjgHPy9TkjgdZkmtmSO0/ssK4mjlRmlkyMDYAQAM5JYntjnrWcqagb5YLfKW+0osgbBt0A4SPHTPfAXP5mhRvs7dfu6Glr6LRdR99ff2MLaWOC2iic+Xcb5mlkBxgHc/8ArG4BZ3I4GSDmr83l6fM1y8uE2s8mz5jJISBuY+vYD+grPu7JdPjD2sYlv5cW8ZlhM21C3zFUHC84yxNaF/cPFBBZhBvRsxxsAvP97bjj6mqdtLf8P+YuTmdokviTxQltBbaXp9jNKZim2GLDvK2Mnecj5Acbj14wOtc5NLcLehnjYX0svkmKXn7ICASiFhgJlTtRAx9Tnk2o4DaM731zMZWYKttDGXLZbA3SthfX5QCcdOtX1tjBKlskEVvIyl9xLqxHXcFIziiChTXur/g/1/TK9nTptWd/66GZDZ3sDEXd35Ykc7m2lflzkKFHIwvG48n0FacYiSdYz5xtVyywBmRGz/ETj5uncnrWU08sPnLNp80kSTCJXcKzXGQf3iqp7epxUcdxBaXU8EM0wuZxuFrdTbpABxuAA+Vfqce9W4N/8D/gf16GjfMjf1OUvExV/LbcVcKcKB3y3fr+dZ17JBPbrG8iG3chEV5Y4iCTyCVALcYznkkD3p0Vo0srvdWMDlVwWhZ23HHAJXP6dKj1SMzWaJDDYbs/JA4LeSAOp2KcHk49+uKxikrIaSVktxpso202VftUkcTn9yyZBx6IMgDtyxz15xVrUYh/Y0md9iDGFF1HJ54TAGMvznODuJBye3SspZ7oXCWsk009xID5aywERgdyFGdv/AyPoaffW2n3Bks9XXzLeHeJXvTHBGGjwXO1nUlQHUZXI7lj0rTlfMrvz/r+vkTVlCO7Ldhql5eWKy6jYwwoCQG/1gA/h2scHGcEZAPIHFMnCa8Ar6f5bWkylLi4jQb8dQg/h5xk/wCNLejzNXS1vhbxWUANxHa20pMl5GoXDBFOCEfgjJzlcdCKv28rztc3K+S+5AQoXBCjICj05zk+o9jlO0feitf6/r+tJUlLZWsZU8Nxf6omh6KvmajJC0827CQxrnBd25J5YfL1P6125ax8FWFrplgFm1a9BbeVwX2Ab5X9FXIAHqQPU1r+E9Cg0bT02rG99OqtcXAHMj7QDz6cDiuR1i6trzW7/UWZHhUrawygc7EB3AEnn5y35CuJ1ViJ8i+CP4v+unZGHO60uXoVVWASyqtvGscpZ2JXHmEnczEjuTkkn6VUkdrS8eaF38wPiSSCQZBBBCbQegHOOvpUbSTfaVubdpFjlkMM+8OCoVCAAvQdQCBgHOTV+7SNrMxRCKB9wZguA7Hb1Pfj3rqtY7V7unQq3E8k9w9xcXMyTsejRkhSenUjacen40k4H2ZwlyJGwpDRIMnB4znGME5wP060zT7S5R0zcSSWSxLCPNcbiwGAcnknPJ9c1HFMI5pdyvNgqqgnhvZgATj2B5p2S26GkUnoi39qjs/KM9xGtxIA0hnkYDyz0JPqeuB1HPNTWlzC8DmHUdyKOJRGWDg9OAB1qhIksQheRZLf7UfMZ5UKt1wCVxkZ56gcDip9RgS2nmaO5glAjO14Ml5P9kgcg89/160rJ/1/wAdOK3epDFJPMjrIQAZNhl3bBnuc9zz+H61JHaWy3BSeZ9jfeeWEszAdC0YxkZ6Dnj1qKeJVDT5vYYxgwwsgjkjwMFTyV2k5OeuetNglmyH8y5ifHBN7zjtwFH5ZqtXsXH3leOi/EvNJtCx7bZo0j8thGWQNz3XA4wc4IyenHWn28ccIMttMGKj5wsapgdPUkDnGP5VmJJcLLc77mSCCFTPdu5MhVAMscZOTjsM8kVa0S1kun1KKa3aKNJjHb3DpsaVDk7gnKhACqgjkkMxxkCpceWO/9f12MpuNN8r1f9bixm2S3u5NcvXS3kmVvNkcRRqc7VTOT64H/wCunpbq+oziYeZNA+x0WSN5FwBjcxUt75rRnh8nTmhaGFE++J5FWUR4HDBGBXIwDuOenas67u7FmGo3v2NbhRDFcXsNkVe5LnajeYOM7hnA4HfAoj72tv66bf59jJ1HF+Qmo/u2FwGQgFjPyWIXHy7R25OOmDzVaK++2TlNO86VQoBJGAvrjjv6nP4VW1E3lvP5sF1ckADy5IMldv8AdCL82efQ+vIqWGa8tTJJfteoAm5VKYLAck9ySRxj3/CrUdDqhyqF73/r0Jl4QW4iFuiFmXyYSyYPXd16nNNubdJ7dFWWLdGjRhslQwPODno2eR2+lLa26vDDNbz2yWtxiRiWEgYnkMQTuz26cVJe3f2eZ7ee1htzgHEaebhecZCn5s5J9MEdwRSer0JjO1lFGfCwjgVJ38gox+ZU+dcqeQOhxxwT159hJZ3GyKNXa4eVQFEsiLvPfdjBOfpjPp6Ns4x56TJYvBHj5irLIxb1Oc7R6dP51s3MkGn6dNdyWDytjczPETIFx1TaSd2egGS3vSfbv6CqOMXe39f15mTe3L3sUggDlIzh2lJhTcf72M89eBVaLzROI7tLMzMQUWMFh+eMfiat2ksENgXeWV7snEYLfNKo6HOF2dewJOOtIlzd3a+TNOI0U4WBIdxY9Mb8DHTpVNaW6GkJSV0lZFS6jhjmmcW+2aJgkrzYfn/aAHA/OrNlbS3l2II4x9okH7rbyXAP8Dk9B3AwfWmi0SzS2efSWt7beVXfLtkLDk5BOOPTIPPXtT5tMSO+iu7SRriTO7a6kEKP4SCSc4PUDtzRdJaP9f1/rYr2iel/vLFu50aaYXEZfLiTzN5cxu2dz4z83P1HeprHTxbg28095cR/cnPmbWZhllkHTkA4Ht1rAeGdb15xcMZiBiKRmOzHcRscA/Qe/WtWFbWe2C6tLKiORIriRj5hznJKnJHTofwpSXW5hWpWXNbXy/yJZdPuIohLdRRarKqqFlaERGUjqCASqnoM9BzyaU22nQ3cAgnVrxnaS3hNwscjED59p6AgdenTFZevanFqF5DbW32xZIh5kd1al0ELHIyWb5G4yMNn25xWnJqEtvZRbrQyEgB3Y5DHAG7OOcnnihppK+7+X9fh18mZxp1mrL+vvHRpOILK7sAuoabd5Uzwz+csrAEgrhsFRtYEdj16UUW32OaFryGNYnU/vI4RtXn+IDv7nFFZy5nsv6+8l05p6mtfXETXMzswj2yP8oXLnDHse36VQvlmSzkmtmjW4VQYY5XJLuTkDJ+Vdw4ztJGc9sUy706wknv7e3MiSTu5M6OfMUMck5PqcYHtTZrUSR2rFZZGtG3W4B+eWTGMuem0Dkn+VaJJWdyJRvoiKa4fULS133C2xlw7CFvNAUH5kQkDOem4/Wmwa7D5n2SwsLm4k80JO3MQhj9V3A7j256+wxTFtZLJ5JZ7xpnuVCpESqLwSWYEckdvTAxxUpSQyo0dxbCYqDEbj5IzI3QHHYDn17Vo+X5f18ylTSVpbF+b+0pEAMklvFHkDdL5pXrxkYUtj0AAqPR9KltnknuZ41uGbKfZ0ZiP+BNy7dycAc4wKbAXhjiWGaW53sQ8yISZD1Oxf4U/2jzVyIWd3emLY3lqFdpJfmhVx91VOdpcdSOccZ5rJyaTS2/ruZzbirLRGJerdafFdDQEtrWaKYLLFcITG3m4dpyxBLuq5wEOMsQckVViS60yApZWun6XCXZIEgjKSGPdlQdxLFsck4AJPTHJ6LUiLXTZLxThI2G5pUY5XPJCLUP2Fp1aS6+zyIsZMDxW+6RcjkKCRjPHQj3q41NLvb8/689Qhywd2rv+ugywsriO1DyOgaXlEdck+67c596q/Y4rjWC0kEVxdE7s2aNI6Y6lgAcD35/WrUNtBLpO24tp3uGJANzGbdMdt6JIS474LAHHam3ct7qFtb2VvrckRgKBmhDWkZxz8gjxluB8pJGKm/vf1+H/AAbD9rN3cF+hqadDdakjS/2ddrGgx5t7GbZQM9AHAb/x0VHLbXlk91c2l7pc8nylbZr5I1ix0OdvA+ufpWdJYw6xqMlzqGpDVdOizAlrLKZY/MBxIZAflLAgADAxzmm6rbaL58FjbafYyXjRtOlp9nREmVTgcsuOp/njoalK7svy/wA3/kYvme8v1/VDJBZ2F5cS2jeGF1CRSotrC+BmnlY7mDfKApySc9/rUWpWt2be/CadPcm/urSKBmBeK3Z3UyEFNrRxBYslskFiM56Vor4ea5sb23sZpdNkufmM9qAXiK4JChht2/LyMdKS0vLW+1g3zWt3dWMcTCEtiO3uMgHzMnqMdAOnPHTDUl9np/wGuq6ohr7L/D+mY+l2y6V4blsNTnu9MmjYFCl2biZDJKQjxlFJLbiAZGTHJA6VvT6de2UjEZnaaZ5J/MUDy4myRHGUGDtYnHOTzzXP2WnyLrF1Fd2k40lrcwPqUjCKdlZixhikVt+3kADjaM4zmtrRoLi21W31KbX5Jra4SVVhzElrIu5gmSmfmQYXjHK5PcVVV6uSd769/wDhnprfyGuaDNKDVL1/B+pWEE0ltcLJ9jsLhwGacYXeUB5IXLKW7EH0FZxjxbSWtsPKiV9iIG+ZyARsBPTjnIIyfwqS6ihtJCYGy1umNpiJKrwfvY5J64Ht9RXuNSkhWC3JmSZitxGGkEXlIVxnjJ6knIH8RHGOcIpa8vV3/r+u9tzalG22txjWMFglsoiuDEeDvnd/L6ZA3sGbJI+6x6VFDZkSfPEI2A3ghWQ4zxhW5J/P61MJ7WKzEAb7RsJbfDHhcnr1wR+HB9O9VluIw0bvHc+eXCoM4Yg9CBkn/vnP0rROT6nXBSirv/gF24Yxwb7VA7wjLmNdpLMOFwf4jxx9aqiDVhCN0/2BpolZ1tGCmA9SNwHHGckcnpmr1xqbHTpUjb7FpcbbC0MeJXcjkL0zK3JOfujk46Vn3DQxWL4jW3851Uh3LM7N91f70jdzj8hRG70sKnzbySt5kTEK9v5bzSQSfO087AbxnAYnrgY6En0q2XsrnS4ZZj8ssmYjzmVFJy/TcFzjnueBjBNV4bcXt9PayrGmnWCxrNc3Kuqq4UbPLf7u4HDcbjnGOel1rSTULWy8oW+o21lAYXawnaO7CAgx/u3BBAG4EHnnIPaickrf1+O19v62UqnNJX2RTkDSM4iW3mBGNqxzOAfXbkgfU1cso7aSd5DbxSPbOsbTMq/MCG5jwNyjK4wWPUHjpSp/ZDzuhS+ZYig8nzo1UMRnBwufx61Wma4gmuINgsoCRHFIJUD3EzDiOIOfmbHAHGT68mhXlo9PWwqtWHKXbQrp0Yk1OWyjutrSyLbx7Xn2DJYISSRyuTyMkDvWVbTu99c2ei3MkE12YZ1tVBmlicszzvMGB8vIKgZcjAGADxWhtttOGmyy3VxDK8ccRsZoxNKq7WYxFkyUZmAJZjtLIAMcVknVbu1aNbiTU7KWS6xFbJdmMxN5QkEHlggyyEYGE3Lk8nrWkPeba/4H3dV6ff0ODmTO40q2N6At3q2nxXc5ZoI4gSzKBuB2uQT8pVjx3znBFc9qrmzvbS3u38y3nnCWIt0YF22kscA424ycEEfzqm2jSnV4Nf0kwzag16LqY3KGKVnEbJtZxgqgHBUKc5H1rq5vFJlgKa5oV5bxDYJJLN1uF2n72QMPtHfCk+1c654SvH3l1Wiafl1fy/4bV2jZrVHLaO6zyXMOjQaVbWsLMAsWXZ5C3Vxj5Rjd2OSR6YrXc28zSbBJJ5bbGBUkj6fdH+etZ9za6rp9uL3S0sda0iSNpGubWZUdeSRkfdPHGcjkHNaGma1b/wBmNdX8SPGE8wbVaNguM4G3du/Stprm96Gv5/O+v32GpWV46lSO+hgvLp7i0cJGmwyPErLnJ+VQeScYJYDAyOc5rDmltZZ2uFS7A6tGrrGGOehZt2PwFaTTw6ldvBH5Iguo1uLBX3faNo4fzEI4XdxkcfMM89YrjToJf9KS4lS2Vf3ltMEIUgnnPHfHJz7VSiovVWOvD1Ip8zbuZVndTWd00sN9Ikkh+WKR4+Bn7v3F3j2Oauwwweb54jtI5vN815YyYmYkYyBk7ce3BBI473Yo7O5gJEmmTJ2f7XEDn0wxHSor1EtJ1cWVw0jfdHmDH1xzx78Cm5a2SsdTdOcvMfNPJ5NxJK0hu512+dvBfb/3z1+lVUSe4byr5TdNjKSRRxJLMp7vgKHbHpj6GrayMGw8Q2x/eWdSjDcD93IAH51Bdv5kSwXESuF+ULICHHt1/Tmp9CIwV3bcrJeajY6jK+ngTaUUZDAmYLiAj+8JGKj6jae+PVtrNqspZNTsXeIDzSj3RJBPAkEgRRuwT69uvWtF4YZY4J2do723G0PGGbzFHTez/eYZI6nI4xxVO1Kx3wnthDIMkeSu/YFPYwsSqkHoRTumr21/rz/EiK8r/wBf1/wB6GcqFt5pBIgLFr2Lzox6HKnOfcYz7YrKh+0m2XzLmKOaMszFC6xkZPUFicHj/Gt2TU7ITbrmSeSUMEAtHZZA/cZxtIxxjFY9prWnXBn8i11bTb2KQhoryNbuGTHQsxXap/3T27daEp9F+X/D/gylOz2f9eiLtrFLcIojtVmnZctNNMWSMEYzzgKB23Z/E0ybw7pWqXcMM9+9zqu3CM6E27MOkYcnIPHBAA7VM0qzQj/iWWk8gYMDbloQx9SMlM/QflVEXyt5dmLXaSdqvbIzSqR1+8zA/wA6n3ujt/X5fcVFOWq/R/56fca2mvJazxRf2gzRlDuGTGQc8gEgFsd+aKjivb9rmaWxBVwFR5J7VfMZgOTnjnv1zzRWUotvp+P6IynTnN3si3fxW893LaZbyBM0jnfjzGJ6nnJ/Gq9xdXP2rZDHH9iRNsXmAtGZP4Q3QEDrjBzWwVH2W4OBl5XVjj7wz0PrXP6xczjWbCITS+UI3OzecZAOOPatIy15TKbTewzU03SRzSXXn3ch8su7g7vZQPy2gcdqrK80FxNHPLNNOrsipHCUBjU/LkPn5iBg4AH5ZOZ4xmktY9R+zSPD/wBc2K/xH0rqPhhLJdRwR3LtNHnOyQ7hn1wa0k+SHMbSlyxu1ewk8c32a0e7ikkadAZP4V3A5x5eSc9COR+NJb273motLOyfZomxChBkkJ4yeoAxj3HvU9y7hJnDMHLPls8n5sfyqtZqPtIXA2iNAB2GTzSjezsZ8qfqbjXgJd2ksi0QwGRkZ/TLYJI9+ePWqo1SORVYx75yGQrEoQtg4yWbPX6EdO5qC7+W2s9vHmXDh8fxY6Z9cVVtnb7Yp3NkLIwOe4HB/CslFNXIVKKb8hHikuoFjN07XPzINyKSDg4bPQgHGcAHg9M1JGlxFbJHcXcNyiRjf5BAidmwrthSShzg45Gc8c1Z8xxca04dg4hRtwPOW27j9T39ak8RqqW8ZRQpCr0GO1HNzNLuCtNpFCfTYbi7t7ZL+ee6kQD7O6MsaAYyQSPmbrnP5Cn3cCaRqN0kk0ke+5P2EzS7NsYRQUC4yyZBOfVuKTVpHTULGRHZZDO6lgcEjA4zVa5ke8vNLubt2nuFE6LLKdzBf3XAJ5x7VpG7td6NP8P+GIg3KcYt6Fy6uxcCOJZ0aQq2SQy7SP4SBww6kNjP8qoXyfbGt5YriSG5hAjZPPaKKUA5BI4HPQjnPTvWpoEEMl7rqyRRusUCmMMoITPXHpWPIq/bZkwNgyAuOOlNaPQ6qVKLbjbYV7Ka2+2HUtKUJfAed5ErR+YoGBgktgY/uletMiutL0+KI22lmzsFUo5RmlMa88BFAHYnaoz3qt4knli8PagY5ZEMQ/d7WI2fvYenp1P5mt/V2P8AwklzHk+XCg8teyZ252jt1PSnK9k5a79+lvkQnCUnHls9f6sQ63crcKbE2qTWxA+0yNkbmA25AByQMHnIJP0punyi6tktrO1McSSGS5vJnVQzHuWf72PcsasxqN13wOIocf8AfKH+p/OpL6ytUu3ZLaBWC5BEYB6isk9OUcYRj8K1IrBEaJru7jhmhX5beC3jd3lI6OC2OvHBGB2zxRc6u2m6TNeatbJp3zbFtIHBuLjJwEeVupPUgYHscVc+zwz6hqCzwxyqkJKh1DBcEAYz0rF0sl73a5LL5Dtg8jIJwfwqkk1zSV1p/X/BtfzM5U3JczY3UW1LU5IZZktoraIeXFbqSIoQfvFm6s3TOBzxjNVibHUrm3bU7bUEEUhAMkhgwccN5SHeF4xljyD0q3cO08CrOxkULkBzkAnqearWZLSohJKjkA9AcjmrT5Vpp6aHRGPtaavsi3eCa4XUDbPOE3RlZJY8wSA5x5Tk4JBzlcgg9vW94ZtNVNsqzSWttB5gW4n+0LDMU7kFevHODU2oqscE6RqFXzkfCjAzg8/WrHjP/QvDttJZ/wCjyMyBmi+QkFTnJFZOTdo9zNtqHJ5le/XTbue4l1O6tWW6QpKglEgmx/DtIGRgA5yT9M1Sl8P2N1H9r1KxgWPcywiKVy3klAocqAPLyrFcdvU9auabbw3mnGS7hjnkiQSxtKoYo46MCehHrWlgf2akmB5khO9u7fKx5PejmcF7raMKi5WkP1aytGubezvzbTNLIJIgWbll+46sB8rDgg8EEcVxulxXtxeWkNpLJdpBtt7TVo1UpeWeI/NVyS75Llh5gwCRznqNWBQLS2lAHmxMojfugZPmAPbPf1qTUYYodS0l4okR4Y3jiZVAKIyDKqewOOQKqKcPd30/K/8AX9K2DpNO99i1a6Ro2mvNa+Honh8qNpbi3tx5ZuAiny03t1Y7cZyeCCTSaHKNXWS7zdQXFs4jmgkUxyQllDqHyOQQQcjj3pmpu+2BNzbY7dwgzwo8pOnp1NYms3Ez6dbs8sjMl9KiksTtURQkAegyzH6k+tKClO13q+ppy6LXc6S2jn0e8uZdNaztfNJaZwAFLEdSOmTx9a57VNS1a5tLaaa2t4jE4C3OnEGFxnksnVSf8mu+aCKbUrJJYkdDHuKsoIJyvOPWuE1F3i8ey20bMlusjKIlOEAJJIx05JJqqE03zNJuwQipa9TTsLm9huIrbUfs0eoS5eymjGUuI8gnAIyrcDcmTggHmqetx2sl1G6XMMss4MVnaOwCuxAZxycbsrkZHB6dcVu2EaT6XrMUyLJHDEssSOMhHyfmUHofcVn6LY2kuvWlxLawPPHcmRJGjBZWKPlgeoPvTg1700tr/PS/9fPvpEW73XQyIoUgvbSH+1NLjeWUokMsgMkwVgp2ZyOXIGTjnitf+zDHOy3HlRqyp+7AkikjZc5ySCmOT0Bq/rVpbJsZLeFWSXYpCAEKfmIHtnnHrTdXAEGABhmjU+4PUVnzX2/r8DWU6jalKWpmvsRYkt5bwEklVRo50U9MgHHY56fhUd5HdzNLb36291BMjRs0SCGTDDHVcEMB3BHXrVuzt4YL9kgijjRo2JVFABI6Zx6VD4mmlhulEMjxjH8DEen+NVe0rIu1vi1J7u1jijt7fTQkRCRxoVnB3DOCuOQSOPr3waz5rWW5i8y3RbkPwJ4JVK8cHK59ueO1a2tsX8OBnJZhPgE8kDy6zbon7UDnlh83vnrmohJtJl0ZSiroqW9iLaUGSW3t7jAX5ENxKxx1HIjQfjmum0+7WwsHlS1i1V3xuVim6If7WSdo+mc8VyNyqreXKKoCBVAUDgfu89PrzUcX7u00+6j+W5E7KJV4cAMMDPWnUp83xa/19/4nRUpyqxu5GtfW+maq4ng04WFzkbY7O4WRv95o9uQPpkVmz2Gy6Sa6mWSJl+Z5WEbKfTK7kcZ7cEe1W9UjTfZPsXe075bHJwy4rrfCcUckCiSNGG2ST5lB+fzJRu+uABn2rOdT2Ubrb+uupEpyoJNO6f8AW5yyxFo8WdvJdORhEt33KcHnIXk/hgCiud+JOp39rpOorbXt1CBJGoEcrLgbunB6UVhVxTpuyX5hGo5an//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Biopsy of a skin lesion in mixed connective tissue disease showing an interface dermatitis with prominent dyskeratosis and suprabasilar lymphocytosis similar to the changes seen in subacute cutaneous lupus erythematosus. There&nbsp;are also conspicuous vascular ectasia and areas of vascular dropout, a constellation of findings suggesting that the primary antigenic targets are both the epidermis and the microvasulature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cynthia Magro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39109=[""].join("\n");
var outline_f38_12_39109=null;
var title_f38_12_39110="Loculated pleural effusion";
var content_f38_12_39110=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67846&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1099px;\">",
"  <div class=\"figure\" style=\"width: 529px\">",
"   <div class=\"ttl\">",
"    Loculated pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 509px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiographs show a loculated pleural effusion in the left major fissure. The mass-like appearance on the PA view (left) forms a pseudotumor. The lateral view (right) clearly localizes the mass to the major fissure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39110=[""].join("\n");
var outline_f38_12_39110=null;
var title_f38_12_39111="Protective mechanisms in edema";
var content_f38_12_39111=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73684%7EPULM%2F69933%7EPULM%2F73443%7EPULM%2F61194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73684%7EPULM%2F69933%7EPULM%2F73443%7EPULM%2F61194&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Protective mechanisms against pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 268px; height: 400px; background-image: url(data:image/gif;base64,R0lGODlhDAGQAfcAAP///wAz//8AAJGRkSIiImYzADMzABEREQAAAJmZgICAgEBAQMDAwFAqBH8AAAAZf0AkB4CAYBsVDp8AADAwMDAdCmAwAQAfnwIx8fPz8B8jL+ECAh8PD0BAEM3NwHkJCS4ODqUGBh0kPVlZMAgux/Ly8k8AAGZmQAYv1VBQUAAPT+8AABslS9nZ0AAv7xUodA8AAAADDxEqkBAQEKCgoExMTNbW1gotubu7u9DQ0GBgYHV1dSAgIPDw8Obm4AQw4z4+PgAGHx8AAHBwcFlZWQAjry8AABMpgrCwsODg4AAJLw4rng8TH+Tk5AwsrBkmWaamkAAmvwIu4b8AAM8AAAApz7OzoE1NIA4VLgkfeZCQkI8AAAYmpQAcj8jIyAAs398AAK8AAF8AAG8AAHNzUK2trQAWbwATX4ODgz8AAJ+fnwAMP1YsAyYZDDsiCEYmBo2NcBcnZ1xcXMTExGdnZ5eXl4iIiGtra+Li4gsbWwodagcklggiiAQqwxUVFcDAsAgVSGoKCsMEBAYfhSYGBqECAmYGBgwMDA8PD4gICA4SHg4ODh0gLRsLCwQEBJYHBwYJFikJCQYGBgQXYwIr0QAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAMAZABAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcs2Zg4GcHskpLEgR9u7IBcg2IuABkIFCBjgHcxRL4McCGYAoKFAIGMAgAUrYLyARo4UKeQCQJJigRbHCjinsJtEx4IFQ+ROzqGAtWAGrQl/NQxgLwC9AnFHro2AwgwEPCgg0LEZQYohCIbcBi6cBwAGCxToGF77N4IkxgGkuC7bq14d24nj/14OOXDtBeUFI0C/Xa5v8gCEOza9vjaFgXqxp+juvXd0uePpZl59u9UXIALw4YbcEAzUV59jvSGABH9d0TbQdsf9lt55G9anBQKhZXfgckjQ4CB6AvXwm2IUcmWhQDnwYJx8BaJXo0BD/JZZggjm8Jte6D0o0HTKtWjkRsIlceSSFyGGIpNQRinllFQ2WRkAQ6CXw5VVdpmEAoLh1mBjXd5FQ2epMdCZZwB8iUSWE34ZJoJjLnZaCnGCWSISCijJmGZlYgVYCgrwAJsOCuhFQ4M8KCDcWyCSV+dxhV7X4I8mfjaDc4FmtWmKPfSgRQrCgRkpEiDWKWakXy4gI1zJpf84AwWoftYpVkLGN4MWH5ra2Jiq0gliErPSMB2sZAIwnXCA3lrVdlqoySgDyJmqAwOPBvtcqsZBF1idAjWYnbNX9aDDbzwkYeJ63Mo4g1/a1jndrN9GOpCME5IrFrgZ9QCcvmPxi1GvAKtVghc4DIAGETUQ4DABCDVRsFpNeKHGwxhn/DAQRBAxgBoUULBDGSVM3JUNApWQMBEUaOzyyy7XMIAXJltVwgAwOyzCE0fIsAQJQActNAlLyHDEEyK8TIEaNUdlww4vs/DCzwFUbfXVWGddNdEvsJAxEGigDBMOYhdE9kFnN11QGURoLMILN2Cg9dx0a43BDS8k/XANJJP/lLZBaAxwUOCDC662QDYAkbEIR6BQ9+OQZ43CEXoTQMEAEodE+EE1EMG55wZ1fjgATUD9cBw3RK766lbfEAfGO2TukegGNeFw7bcXZDvETd/cMgEaHPED68Sz/sMRGjh8eckc7X5QGQ7jsHb00xMgvck4KA68DHIX7/3qGMiQPAFAXK8R9NYbZDoaBa3fvsPs61tCCU207fAR3X+vv+oYvPAwEbK7iPsKor0aENBhBiRIAeVXgxr87gmO258EV4eCJyjPfBZZIEFsgDHZcfBhHuygs0rQMIdpYAkTTCHrljC+HVzkgw4L4MUeVoaBzNBhNRTIDQmQw0CR8GEsGJ4K/4cYuR94jQA1YN5EdthDANABdgN54sNcKBApOoyKZfqhw15AxC5GDgNHBELZImJFAmAxPhgDwkB+5zA1CoSN5PNhCQngBC/a8XFgVN4YHwJHNxJkAIYrCCAPMkg5mpAEd0wk3e6WPArs8SGFNEgk/xhIShoSeBFUpCYl18hHNmSSlpRkJQcCSilpUQOZ3KQqrYaCRioRkqMkZSwBUEpazhJKJXhYKlfJSxQgUCK1tCUhZxlMJpmujrxMptWccMWIBLOW0LzlknBwP2Vas2pHoB4sERLNYVapBC1jwTXHmTQKvHIhzySmOqtkul2Oc5XMNOM2vSlKekrpgzJ4Jzkd5v9JewpynfWcUttEkD99JlMGDgMdQ9LpT1lOyQsOQ6ZBlYmBh9FsobfsZkBxqTgRTHSc/pMnRrkJ0H9KCQ0OQ+FHrelLh52zoQ7daCibkoEEXCEDKaGmwwq6Ul5akABMQ2dGSzrTpVihAwYwQAJQksst9vSa8UygQhgq05gqxQpXSGpSr4ASiDosdU+1pt5ealKYCrOqRfFAVrXagQTg9CReJQBPw6rKlmLQrGctq17TegKtGqCtb0UJzgggTrpa02vSFAhV92rVobSgr36NgA9YYrojGNaa/lMoSTeL1rwGxQcR8KsBJOsS++XzsgeN41SHatZi5gS0oj1BC2DyMET/opaXJMhdQhZb1MbypKZI1eoJPBATjNn2tqrMLe92y9rOurYmCQjuVokrE+Mid5UPC8BqOctYxSZ2JhkYgV+vYIWaYMyd1/ViRR2mXeZyt7fe5UkLpNuB8trEuulVpHIJ0N73wtezvrUJFCIbWJsEwGHHza8d48nf7baWqDXJQGiTWt+dHJgACVZwFxHKXgc7F8Iz8YF4tzpbCyfttBr24us67N4H4/Ulf5DuCQqckwBY0LIp9uJPG9ziD7+4JQnw61J9EgCEFjbHRMRYf/Gq0e66JANkYOsfgBKAG+wUyUNkcOo87OQmw6QFazXACEr8kwCsV6JYlmDl5Mbl/3rZ/yVH1WoEaNyTqnmNi2mW4A/0Vtg2BxjA8YUJHPwKhaGwdwlXzvP+1qtSPwe6y98tyYT/Sl2hsJfRit4fouVaNUcD+tPPJcmkR0Dnn7A3AP7zaKa/lzQ8L7mzoAYxSiYdgaOc2sp0XHXx4nlcT7/50SqhNVJOjYHkEVTX4EvaE67ma1mHGiTCHjZ/q4ZrFCP7cRx2HIv9++dfS1rOSjl11UKK3mtXbXgtxfO2mezsSHsk2kkRt5mTd2RzY00EIvCaBrq3blh7+9kcgXe8p926atr7agwmAFgv/Gonx/rH7wY3U+Q97ogevGqtfJirGd5sF5tE4OEm+NWOWG5F32B8hP/FWr8d/m93ZwTkIbdb8lBp7k2bkKcr/+/DYd0RmC+FbhnXAAnmiuWQmtCdOf/zzh3OkSAntdZRqVvGCUt0DefxYTTPWtKB7WZZc6QFEo+61MfHgqqnd88Yy7rWecxtrrv90xwZ8QioAjkU6E0EGVYwBiongpJvHe4tF4nTDUBmsePxiATAX46N6LCy1+3vvO22yycC9qQOeSqrMzreNcxCp6qu4z4GidytwrqTP0zxyK2gCRceOdBDGiSDL7xUiPeDHYtAiGHdqdGfgPvP9/j1PLdI5ZVqFYpH7gZ60wD3eoo3E+qM9atzfdc/Mvriixx84jOh8PSJN5SbcPnek77/5D0S+6sYf3U/MDoBUBeA3muy+y57gfuJJ/63A/whw798Vc5vvOxn7AkyMHR3NHUZo3zzVzz1t3QaUX3md33fgwFOgHgZIzVOUHLFczcawwJOYHb093vTF3wSUX5YwX/fMzmVozEacIBWAzRF8wJPcERbswRdsziNo0KQ11zAlxH5pxUkuD8oIAMS+DA70zM/AzQ5ozMuwwIyYIHec4Nt520UwYAj6IBEdDcy8ATed4Q5owEAGDd35IQex3QRIYJZ0YPFUwVd8ABquIZrOAmAoAgHcAB+wAhHuDMA+DMq2EVgGHpi+BAZEFz6N4UThIYqEAMwYAIOkIiKuIiLaAII/6ACF+ACT7WHOahzY0hhpbZ/VKg6RVCIh7gFVCAAojiKpFiKorgCE+CIkCiJE0WJH9iHDfGHltcVZjg3LqACMACKpriLvDiKqKiKF2BQrjh+INgQTtcBmUh6xIOGMWACK9CL0AiNqCgEaxAF7zSM9ud1fgiIX7E6nWiIJhAG0TiO0ugAMHAGX3BN2KiASvcQx5iMygg5F4AADhCK5HiP0AgGYhADD8CKvLSOgVcRskh83SiPCDAB+JiQ0TgFaRAEwfiPbMduYTgRA/ZX8BiPdDOPCKmQHNmLE2AE/JiOmwSQ7WYRIxaIXPE4GikAG/ABIBCHBwACH7ABHdmRUyAGCP9wBtaoSgkIhQ3hA1o1WWBRNysZAhwgARDQAEoJARLAASFQkx0JBuaoBEWwST2pjQxRkXMXFnRTBAcpACFwABVgAQVQlmVpARVwAE8JlR05ATCgAv5oR1cJcQoxYoUGFufnAkGAkBvAARVgloBZlhXAATTJlhy5AiYQA1V5R3NZjAgBlEkllF9xfg+QBqL4ARJAloFplhYgAR9gmDUZBm8Zl0PUmLCIEFopFsb3BQgABqIIAhCwmYEJASAAmjWJmIrpRaZpiQthl6rpgGvgAKN4AA0gm4DZAAdgm1A5AQjwkKXpgcR4mgYBmQYgmZN5fUUgBM8oigfABsZplsipnMv/2ZxEtJvtqBCp+ZtYowQbyZ3F+Z0FEJ7iWZPM6ZxXIwVZgAUwiQVZIAVzQ5IT+RC+qZ5WUwUwsJ2vGZvwSZvzOZ6LaTVcwARIqZQNwJRMwAVaA6B8+BDUaZ3XeTVnIAaliJmaKZud+ZkNSp9B4I9cIJYlepZpiaEqF5H+VpIRkZ4EGgAuEAP2OIp9+ZfGOZiFmaIdmQYPUDVSwARAKpsVwAT+eTUaWokOMaA5egFGsIthOZaBiZZqSaRQCQYIkI5ZkJnf2ZlZMKMNp3MByaFBSRbipgJbwItGOaFL2ZRr6aU16QBrEABYoKDfCQFYgKbm+XbomVRbORbixqO92JIv/xmHMjmkeNqRKyAERUCc8BmfByCo0JmNdFkQVDoWBQoDkTqqpjgBQdCdl4qcmtp27Eioj9mmZWE1XWACpFqroygElgqfqgqlNMpyNuoQOEoWVvMAwmmrtToBi+CnxgmoqyqRG8oQUWYAdxmrVUOsxmqrkUCmxmmmzVqjAboQWiV7YjGsxXqto1oIiLCkm9mkT2o1UfqKDOEBW4UW5GqutUoILrqlMUo3gwp3BzFoo0Wv1Vqu9oqnEwAJEpqUdXqhddOv9zdi9mUW9VqwkboCCEAJ+bmf/fk4DutyGaBVF8kVp2atFBupJmCf0bepreqvBWEFhooWpzarJRupE6AC4f+nsmu6EBMGBzA7bQY6s3hqsaTZejj7qwuxVpVWFonao0DboCeLgEX7rQcxfGnxpnHatCnqAGYAtayaswlRkWRQtQRHslg7jowKk4+6i1Owp6rzrtGpEE6Hkog6tgRbtnJ6lApboXZqilQQBKvjtpwKrUkVsWYhbmRrt1iar4DJpXc6igjwt72qpkabEJCVtEpLt4jLiz/6nUJaikJQBW0buUrntQhRuWIrqyKauaZIomXqmaWYBjsJOYC7sgYBsqdbNVFwpapbirB5qQxKimNwpJEzuz5JEFqlFvKGALtbirn6nfI5ig4gvLIruoRKugbxsUm1Fus5Bcs7nN6pq8n/SYrRG7ppOrqTexDyagAnoL0gerXd27zG+byiOL7DS72Ad74Gkb7rqxZYY6Xdm6C+W5viK72PQ7xYKRAuawBhy79YEwPc272su62uO8Dk27EMEbfsezUPkLrLu7lBSpilSL/TW77Vi78FMWFyK6xYw5qu2b1Z+qIFwLimKMK+17UmTBCmy8BYcwZ1q7pzmrdM6ZS7GLwdaMNSWxCwmhZaEwWi+r8s6ZJoO5O8CLtF7KxSOp3Hi7xUyJ5OrJCfW8Xe+qz5m1T7e7v9q7tdfI+PC8a+esQD4XRQZ8YN/MBpHI19y7VWDK8HgcJrwX8bXMfjuLZ4HMZXXBA5LMdXw8KA/wyNWjvIbSzGSByZfbyJAcDDi9yLT1vBUQvJA0GdbEGCTHzJvAgDIlm/JHy/bgwA+vvJlBwAXCzKpDgFSsA6BvxjcMzKREmrsDyKY7C1kHvKkRe4CIHBk1w3LoAACArLRhC7pmzBCUHMWvw4KtCeogwGMUA8tRx80IzIWXMBugzLNYvN9hvMtCsQ26zEj3PMybzImfzLzjzMs8gWkTPNu0zK4gzMOKjHBXHOAvs42bnOaSzLxZPNYsjPZ6E6wSnKvTzQ45zPb2sQBi2xkaPIi7zMDI3PT4iVEU2tkVOZi2zN+/POB7HRKhw5eimOdRzO+iPSEB3PGRw53gzI7XyzRv/Myebs0txMN1/QxF0stCG9yYX8xjjds6yjBHT8vyq90kCtzwRB0jkaOWYwBrt4to4qxRQ70zSdxw+9z0N9FrV4Nblrij9MoUHcuMbq0z9d00EtEHxczKwTAy0sii+sr11qrkmt1GrN1ANxyDldN/Qsih7MpCB8rUaAsrTc0Bn9Y3xN1KwT05eprSY6wbZKBTEwtO681FuNw0lluV7dylqz06PYuwsqwLYqBmewPwTNm0nc13Vj1O6ZquFbqysAA6CrP6l9nlns1qwT1dz5vc4b26Q6AbOM2ogtta6V29FMPGEtAPArm/I7qlh90SxNEJ6My8UD1wIg2n9K2qOK1rb/XdyQXEyr3BbfQ88RHNkoGtw2K0G37arjLc/eY62Bva6DTapCYNjSjdnCPMbqexffQ7JzvbhpadYG67cT1N7+esvkHd/lOtZ1KsS1ypAE/N0YbdzS5NSgyuCkSNUxadW1qqfMTOHTLdQECd/Fc7hNS8MpNOI3XeIvzTooDrQqPkEsDgAb3QNwMRB0YRcUgRpF8d89PLMm0AVdVOMbjRwSIhC7QRG5AhRfnTUxPrO0XeT6Xc4bLSPUkR6u8RyxoSaoIRc9kCU6wOP14eVsAhmWkSzm5dlzE+UUS9m6WeU+GdG18huqERj6oR3XgSrHkR2+4SgzoCQEgiiKUh22cRNP/441bl6wW7De5Snn2hjR01EafbEheqEi7AEilYIYylErHCIqpBIpvaETia7BQU6xM07jkP5iBu0v6yEj97EbJjIdfqEXCnDrvrItjVEfvsErov4kiM7mWrPo9prqEmTkXQ0AH4Iom74brj4DcvEhKcAASEAcm6ImCGAXDmIo1cIhOVHqE4u1xt6E4F3IxWTQzIIjybHk00EcSo7l+5EDzeEXHLIutu7tOAHuA2u3457feZ3ZLZ7Cl+s9fy3uE07cFR7eF57shSvsWKPO/H7wIr7qPIfhYaHvjl22d83e5c7U587wA088cIq43s3xCW/uC+/iC7El9F6GDn81ioq40f/9PQj+8SqvEAKDFWfI03ZrqjbY8Zlt8zzrEHXyGIvxK6GBGT2QKPReGgsw5lxe7QuQLxZGPDKruvedQu86B3IAkwcgB3Ngie/NENpCHoBBL7PyG0lALBSgADOgGGevF9xR9axT8Ijr8wcO9I9mBwfQBm+glG/QBgdgB+049gtR9gKiHjYSGMueKIGxG8ghGHSvOhC/u1lv8qBXBwegrGUJAQdQB+5Nxg+B+AhyI5EBGMzeJ7ux5DpBPBmvuhtP7idvSXhwAG5gnG5wAHjgr5XHVUQfKRiSI6U/IIt/GL2BBNTCGubB+jVW9+6ruiWf1hJ5BxIAnxJwByyL3IcfKTH/MiPDr/gbggTC0RtfsvzmMfmRE/PLO/NZ7a08wPmz6RzHnb0Lrjo/i9QGrupG3NyBCRANDgAYMADAQYQJDSxM2NDhQ4gRJU6kWNGiRAIEAmzk2NFjFxMCRI4kWdLkSZQpVZYUcsHjS5gwJRaESPMAmwI5de4USNBgxCsLW1wkWtToUaQIM8aE+cDBSqhRpaqcEITp1Zczfzq02WDn1wI9aUY8sdBDUrRp1RpdipWj06lx5UZt6dat1poGeUAAuxMCD58Syxo4u9bwYcQA2tqFO9fx45ETVNjFivchzTsS+uqUcCcwWbOJRY9mq5GymaeQVctdgcAFZaaWuRrEc8DN/2Y3B/B8hghnYQLSwYVHXIy1CIIwq5VPNeESdselshuOrXOA71cIB+ocHAsxwe/h4cUXv/pgzHL0UCU/h65ResLudg60edOgwZs2B+wg7P7wuwHgxBOQNPKYUmEC9Db4AIQDGgThgw3SE6C119gLILqI+oNvKwDmkKPBBuWYY0OJoFgoggFTTKxAmFxAYIXlQuBAAgjsawACCTgIQUITuoCpjzxAPCCPPtoL4D3+OEzyMiUb8mChE1SUci0WX7ogJOVCOKACC76yoIIDdkQvDASc44iP+eq7Lz8+OMIwLzhnY1KiJw2Icko8karSIxW2UG4DDirYrIAKOIgQvQkQKP+Coz2sAyu7PTZ6c05Kp2uSt4fqHCFPTovas6MYqFDuAwm63MwCCT6QcIvJApDCNtwOkOJC9zK8FNMl5ZRoIQM69dUiu6qAYTkQrhsUAhAkpDAAPTQbVAI9aD3S1jgtrRQiXn/VViK7QFruAK8GDesACQVoLgAmjO0LAiakRZK7SzWEd6Jst7W3IbdciCE55W4Sd9xyw4jhC3DFFchdaq/N1VqJRgjtXojdUgHLfsMdVKByBRhDCX8HZeMAhKtleGQSBXsYYnuNgwFGYtVdN9mMjSj4YpAn1fXmkkl+aLDCUN4Wqz7TI9XUvlBVNWMwOHAZu3Y5ehfXeXF+KIKFoPD/OeWrQk0PUEE3K/TQjANxdjNoO3paXqjTTui/AK/+9Sphy9WSSy/BFDNjATaAta/cZnU6Yamj1tkhtt3+dU9v5Z6xRvtw1BFvkh5xFLsDIjUb8MHTRjshEw0gw3Bf9wwCwYwVZNBBCCEvKZE07cPvgDY9Ojte2ieq807Q86yyCyFU9x0qQRoRkkiZMM/5+IUhuj13Tlm8ALnfo09J4CoqMz557AWHqIWFOmBed9M6Oo506csvyQElKoxpdoW1x5ah76csMAg/zbefJBNa9cjmzDWvnV74xU9F5LlA7+53wAkZ4QEv4R/ysuc/inRAKAIcYPg2MjoEIpAKMFiUkdgX/zi1JYRnFExRcQqYwQxOQAn7q5XIHAjBiYyQhAIqjhLIh0L7rQAG1XNTC9vnPiCGECFkqNoMaRg+YbEMh/cTwxk8eL0gom1zawOPEcOzmDOIYYkajIH6GvhAGPaPigZAkRXDwxF9iWqLBzSCmb4YxDC+0EkL2ZQZh8ORCxhhjQgUWIXeqDYp/k8iGaiXHYPzltSMxHQgehDY9oie/EnKhyCMIxgbIkEDDMWQpEEkSWREIxs57m6PVI4OF/XHzQXyhw4ZjBU2ycmNNEYAcyNaTr4UJlKih1UhW6UqKdmQwr1SNJ3MW6AG9bVcKocKMbicCx/oy4lYAUrCHGYsUzO0Qf8ZrXyLRJ0j07PDvzkzioKUCPcM4D1qIoaYxfoXsqT3ScbdKEejhKSPNvLBzE2xIbzKQDoN05YuaFEAM6NZ9GhZN1xKqCrh7CU5LdkQhxHGn1QyTRT0OFCcGIxcvuPaMQ1VrrpMS5yVhKNDqAagiaplMQgQCUE3gzHfYfNUqSrXQkXa0B/qc4yfSylaFqOEKQiAneJyp++GeiyYSagu+HyhThFSpyv01KfhO4OfZFo0mvrOpX2BqYQcsECmPvNWDiHkQvop1aMsJqDF7FpfkKnVjBa0XA4AWVjHeZGgSBStpeGIRUVy0J3ckp542ypYupoeut6UktCU40OIiNK9esr/giz96+JCOU/pHXUzRfVqXaFIUiECcyE8jexFahhUkXDzAI0s31XBos25enakjH3oHA0Q1dKa1oJV3WNHvfbRcm3hEIrtH21LSlZ+5tYiJrzoGgGrE8HibQqSIK4cjRvahuS1Z8rFiAXT+Eh4XvZxkENAdcF4Xacm5LFt4y63PJJFUqqWtaozQhTsCtqIdA537Y3IS5KYTPuJoQv3vW5EfJBc/vb3JTYEsPm+SmCHUiSvrkwwRGBywgZL78GfRe9Ye3OiClsYJhjM8O82PNsIY9e26Awxvi5swBKr7sQ4BWF6L3myFh+EKSSOMd5mvNgU2zghJ4VDjhPCFAz3OGM//y5ukD0MEWne1sgHEd0NlYweAUN4lYPklQ+mvKcirOzKEqqvln9pMsjm+FMTG3N6ymtmMZZoIbhVswVfoi9+tVk1U1ghnBs7SExSuMWfCkCYlahnx2zBiX6ubUROWsdB2xkmbEb0Y4TgB/PCscNIOTCOE0zoAOjLypWOygQcMckm5/TJEnksaSsM6kIjYNSkVsmlUW1dJyelTgbwcohhHYDnzZrWJtlCEFB5q00nJaJlfLWkkSzrYatkDDGIwrHFWWCLRLkDZ/20s58tbFqDwQhK+AIvgazqtOSVve39NR6hHe2RhAEGZuhhpgGZa7T8Z9shthCw3x1tB8Sgg5K0d/8q8Z2UDGBy3dztt7/BreQVmEAJPKw3o49rEX1zu70NdzipqWAEFaiv4hw+OMIVXmGOd1zPE4DBAmFibXSf+SIZT3DKCx2ENIAhbwtiZOoeOQEhBGHgDLz1eUtu8ipu3OYueAACDGHZxmF2i0APgpmsh+KYq4XmSrd5AAaxpVoWILoZBAPVrX4Xkmc9LQlPunK77iomtBUsbzXfFMZghBio4Ox2sbiKMd49jUe23UzJQqmymVXVrWAKYXCACWCgBDNEgeN9FzJF2J7m0g4+JlhYGnaSWsrFO2AMaTACAhCghDWY4QLltjnlV02UrWfe288p7FcEAgMTOGAKaoSK4hn/P/rSnz71DyhCFET+9oIj++hrP3luNQ+TjtHsCxcwwxqCgAAhpGEMDuB+94FvetSbgfjGRz7asV7j18Me8M6fPWxqzxOQeaQKUXhA/e1f/+Ifv/yUcX1iLr/wnnq+l+C8dsKC/TtAFkq+a0uxtIg9tBJAjyi8sAssCcgCBLxAc0s19BON/5O9rpOCuDsmJvAbDNw/mNtAmUOK/8gkwWs/2OACsEMoLihBBDzBfGJAtYgoSJMqCHwJLmACUIo6JphBGjxAG2wqHEwLc8K8lOrBl5CCLMACEMGCLCDBIiy/IxSrLdM6XtGkAHTBKwxD9sjCu0pBtNDBvRJDNXw7MgSt/8oziiUEQGpaQzrkuDZMtuBYQS/0pxKoQ/aAQilsECq0whosOk1bPtFAw57ywxdkAiEBkSEswTtExMSIw0WUFEZkChh8xEckwkJUQLVrtLXQw5Ryk0yECRDkxEccQRrsP/FQRH86xavIAlXkRAssQVcMD0ucqIwgAVn0iECsxSk8QBnICAKYCIMLReEgRX8CAgKQgV/sCGHkxAOMg4wAAmRUPmUUDlikJiIggCOIRo6Yxkc8wCfICCLIxgXcQtFYQmYTpgEgABYQx40gRyExwox4smREwQFZwXfcJBzICAygx2CcRgMsPycwRhxQx218w7U4KTKiphLICCegR1q0x/9bRD4RMMYSYEh+/LPggMh/tKMaIIAXoMdUnEZWRL4f2EgCqAGK2McbxBORFCY1EEh63ERh9ETkw4CMUIOY1MaPVJGa3KSJJIAloMcA+EFVjMQDXIKM6EiPnEkzDEleGUkj2gECEAGldJUonMIqvMCN3IGKkEkk7JSitKOAJICK7MowTEgC8IKyFEqq5JS0tKISoICtHEi3pEEM2Mh0nMt1rMrhuEsjWkto7MsSLEYCsAGLMEst/BXDnCGtJAAUUMwD/IEAQIGMIMvHpMuz1JbJpKC8lEfM3D8REAEWIAAKkErBbMj0E5DRFKC1DMfT7Dq4zIiFvAjILMNtgcgTCDz/CqrMtrzNhkMBDTBGz+RN0IxMe4HIERBOASpJyzTOfruB5MwImCyK3sQvtOSVDthD0tRLDbhM64QNqDTG1jSK7sS2TlnBDtguCrIB8iQBvjzPq3gBY2RNx2TP5vRNiImyhRA0EqLPjGCB+8RPj8CA1VTP/vTPwYwzX/EATGJCATJQeUxQBQ2AltxPCnhQCIVNw2mBCsXK77EBZ9xKX9zQjfhLYwQCEA3Roby4X8mAiLIT6WSeEqBOcNRQ6/yBBq0B10SK9kzCbcmAwTCA6LSiylRRBV2C7FxOtChSdnxO8BRP2tTLjDgCH3VLFDhH1txNtaBSwvwV+JRPAWqCb8wI/xHQTLcUSP1ExyY4DDKV0ADlFQMgUBLCgRTVABnoUka8gTjNTiAQU8OoU5BEGQrlFTn8nhIYAC3VgCNw00B9gexUzwEY0kP9T+90GxK9SjtqgiYlgDi4AQ5VQ0G91P3cgTkdDUQVRZSxUV7ZLyNqAkjdz4x4AhmwTwxETlzNCAoYgFYljVel0atBUhAzyjLgUVxlgRdwAvN8Owy4gV+tgTLQVFflVPfMnQig1U2yATRI0V8lAA2gVJggARJYAhl4gSdo0I1I1xdo0BdFgxgVjmL1uymTEhsYAGY1RhF4giOQgSVAVxIYV1x1SVytgQGo1/C4V4fM1xQpARwYACLQUrSDvdhfpQAiGAAcwNYBcdjYhNhOaQIvUAOKJQJxNVggIIKNVQMvGNZOAVmRndngkFmavVnEsFmc3dm00Fme/VkZrctEBVqi1UChLVqkTbsZTVqmNbptbFqm9VmohVqpndqo1VYjtVqe3RwvkEuH6NqHAFuthVqxHVuzPVu0TVu1XVu2bVu3fVu4jVu5nVu6rVu7vVu8zVu93Vu+7Vu//VvADVzBHVzCLVzDPVzETVzFXVzECAgAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An osmotic gradient favoring fluid reabsorption from the interstitium is maintained by retention of serum proteins within the intravascular space. Fluid which does leak into the interstitium is transported to lymphatics from which it is returned to the circulation. Finally, tight junctions between alveolar epithelial cells prevent leakage of fluid into the alveolar space. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early development of interstitial pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 479px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breakdown of the capillary endothelial barrier allows leakage of serum proteins into the interstitial space, undoing the osmotic gradient which normally promotes fluid reabsorption. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Late development of interstitial pulmonary edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 322px; height: 504px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The quantity of fluid pouring from the capillaries overwhelms the capacity of the interstitium and the lymphatics, resulting in interstitial edema. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Development of alveolar edema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 506px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breakdown of the alveolar epithelial barrier allows leakage of edema fluid into the alveolar space. Arrows represent lymphatic movement; small circles represent protein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39111=[""].join("\n");
var outline_f38_12_39111=null;
var title_f38_12_39112="Treatment of endogenous endophthalmitis due to Candida species";
var content_f38_12_39112=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of endogenous endophthalmitis due to Candida species",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Carol A Kauffman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Marlene L Durand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39112/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/12/39112/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Candida species are a common cause of fungal endophthalmitis. This infection arises in two distinct ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The endogenous form follows candidemia, with hematogenous seeding of the eye. Fungi usually first seed the highly vascular choroid, then infection typically progresses through the retina into the vitreous. The aqueous is sometimes involved as well.",
"     </li>",
"     <li>",
"      The exogenous form follows trauma, eye surgery, or progression of fungal keratitis (corneal infection). Fungi are directly inoculated into the aqueous",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      vitreous. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36102?source=see_link\">",
"       \"Treatment of exogenous endophthalmitis due to Candida species\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of endogenous endophthalmitis due to Candida species will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of fungal endophthalmitis are discussed separately. The management of exogenous endophthalmitis due to Candida species and endophthalmitis due to molds are also presented elsewhere. Bacterial endophthalmitis, Fusarium keratitis, and candidemia and other types of Candida infection are also discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=see_link\">",
"     \"Bacterial endophthalmitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=see_link&amp;anchor=H346085004#H346085004\">",
"     \"Treatment and prevention of Fusarium infection\", section on 'Keratitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=see_link\">",
"     \"Overview of Candida infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377352637\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terminology of Candida endophthalmitis may be confusing. The term \"endophthalmitis\" means infection within the eye, and in general implies infection of the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ). Endogenous Candida endophthalmitis often presents first as chorioretinitis with minimal vitritis (vitreous inflammation), then later progresses to produce vitreous and sometimes aqueous infection (&ldquo;endophthalmitis&rdquo;). The term \"ocular candidiasis&rdquo; is used to describe this spectrum of infection, and some articles in the literature reserve the term &ldquo;Candida endophthalmitis&rdquo; only for cases in which the vitreous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aqueous are involved. However, the majority of publications include the entire spectrum, including chorioretinitis, in the term &ldquo;Candida endophthalmitis,&rdquo; so we will follow this convention. We will note the distinction between chorioretinitis alone and Candida infection that extends to involve the vitreous throughout this topic because the approach to therapy differs between these two conditions.",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled trials of treatment regimens for endogenous Candida endophthalmitis have been performed. The evidence comes from case reports and small observational studies. In addition, studies of the treatment of candidemia have provided insights regarding the choice of therapy for endogenous Candida endophthalmitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to treatment must take into account the site and stage of infection, the pharmacology of the available antifungal agents, and existing clinical experience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/1\">",
"     1",
"    </a>",
"    ]. Therapeutic approaches include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Systemic antifungal agents",
"     </li>",
"     <li>",
"      Intravitreal antifungal agents",
"     </li>",
"     <li>",
"      Surgical removal of the vitreous (vitrectomy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, patients who have only chorioretinitis can be treated with a systemic antifungal agent alone. For patients whose lesions threaten the macula or exhibit mild to moderate vitritis, many ophthalmologists will use intravitreal injections of antifungal agents in combination with systemic antifungal therapy in order to attain immediate high concentrations of the agent in the posterior compartment of the eye (",
"    <a class=\"graphic graphic_figure graphicRef57690 \" href=\"mobipreview.htm?41/35/42549\">",
"     figure 1",
"    </a>",
"    ). For patients who have moderate to heavy vitritis, vitrectomy and intravitreal injection of antifungal agents along with systemic therapy is almost always necessary.",
"   </p>",
"   <p>",
"    The overall prognosis for Candida endophthalmitis has improved, but only if the infection is diagnosed early and managed appropriately. Close follow-up by an ophthalmologist is required. (See",
"    <a class=\"local\" href=\"#H148501932\">",
"     'Outcomes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278914249\">",
"    <span class=\"h2\">",
"     Systemic antifungal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have only chorioretinitis respond better to systemic antifungal therapy alone than those with vitreal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. At this early stage of the infection, systemic therapy is probably adequate, without intravitreal injection of antifungal agents. In patients who have chorioretinitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endophthalmitis as a manifestation of disseminated candidiasis, it is essential that systemic therapy be given to treat other involved organ systems. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link\">",
"     \"Treatment of candidemia and invasive candidiasis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of early systemic therapy of candidemia in decreasing the frequency of endophthalmitis was illustrated in a retrospective review of the incidence of fungal endophthalmitis in 214 eyes of 107 patients with systemic fungal infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/4\">",
"     4",
"    </a>",
"    ]. One hundred patients (93 percent) were already receiving antifungal therapy at the time of the eye examination. Signs of early endophthalmitis were present in only 3 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501878\">",
"    <span class=\"h3\">",
"     Choice of agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most experience has been accumulated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    . However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    are being used with increasing frequency and are excellent options in terms of efficacy, tolerability, and ease of administration. When choosing an antifungal agent, it is important to determine the risk of fluconazole-resistant Candida isolates, such as Candida glabrata and C. krusei.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501885\">",
"    <span class=\"h4\">",
"     Amphotericin B and flucytosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard systemic therapy has been intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate (0.7 to 1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    orally per day in four divided doses) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Two major drawbacks of amphotericin B deoxycholate are that it achieves poor levels in the vitreous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/2\">",
"     2",
"    </a>",
"    ], and it has known systemic toxicities. Increasingly, physicians are using a lipid formulation of amphotericin B rather than amphotericin B deoxycholate for the treatment of candidemia. There are limited data on the penetration of the lipid formulations into the eye. One study in rabbits that had inflamed eyes noted higher concentrations in both the aqueous and vitreous with infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    when compared with either amphotericin B deoxycholate or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/27/18871?source=see_link\">",
"     amphotericin B lipid complex",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, flucytosine achieves excellent concentrations in the eye. However, it can cause concentration-dependent bone marrow toxicity, which commonly occurs in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=see_link&amp;anchor=H9#H9\">",
"     \"Pharmacology of amphotericin B\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501892\">",
"    <span class=\"h4\">",
"     Fluconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     Fluconazole",
"    </a>",
"    is an easier drug to administer and achieves concentrations in the vitreous in humans that are approximately 70 percent of that in the plasma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Increasing numbers of reports have shown the benefit of fluconazole for the treatment of Candida endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/1,11-15\">",
"     1,11-15",
"    </a>",
"    ]. However, failures have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/16\">",
"     16",
"    </a>",
"    ]. In animal models of Candida endophthalmitis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    was superior to fluconazole in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/17\">",
"     17",
"    </a>",
"    ], but not in another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/18\">",
"     18",
"    </a>",
"    ]. In many of the case reports, the doses of fluconazole (100 to 200 mg orally daily) were likely too low. The Infectious Diseases Society of America guidelines for the management of candidiasis support the use of either amphotericin B with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    or, when the organism has been identified as C. albicans or another fluconazole-susceptible species, fluconazole (400 to 800 mg orally daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501899\">",
"    <span class=\"h4\">",
"     Voriconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     Voriconazole",
"    </a>",
"    is being used with increasing frequency for Candida endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. This agent achieves approximately 40 percent of serum concentrations in the vitreous in non-inflamed eyes, is available for intravenous or oral administration, and is active against many species of Candida, including some strains of C. glabrata and almost all strains of C. krusei, which are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/24\">",
"     24",
"    </a>",
"    ]. Voriconazole has an additional advantage of being active against molds, such as Aspergillus spp, which can also cause endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. Because cross-resistance occurs between fluconazole and voriconazole for C. glabrata isolates, susceptibility testing is recommended to guide therapy. Increasing resistance to voriconazole among strains of C. glabrata is worrisome and may decrease the usefulness of this agent for treating endophthalmitis due to C. glabrata in the future. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29018?source=see_link&amp;anchor=H9#H9\">",
"     \"Antifungal susceptibility testing\", section on 'Indications for testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a treatment trial evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    for candidemia in 370 patients, a post-hoc analysis of outcomes of the subset of patients who had Candida ocular infections noted a favorable response in 29 of 31 evaluable patients (93.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/23\">",
"     23",
"    </a>",
"    ]. The favorable response rate in the voriconazole group was similar to what was observed among patients treated initially with intravenous amphotericin for three to seven days, followed by oral fluconazole. However, 13 of 44 patients (30 percent) in the voriconazole group and 6 of 16 patients (38 percent) in the",
"    <span class=\"nowrap\">",
"     amphotericin/fluconazole",
"    </span>",
"    group were not evaluable because they died or had no follow-up eye examination. Only 4 of the 31 evaluable patients in the voriconazole group had extension of infection into the vitreous, whereas 27 had chorioretinitis, which is typically easier to treat.",
"   </p>",
"   <p>",
"    In a review of several published reports that included seven patients who had Candida endophthalmitis treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    , visual acuities in the six survivors ranged from",
"    <span class=\"nowrap\">",
"     20/20",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     20/100",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/22\">",
"     22",
"    </a>",
"    ]. It is not possible to firmly state that voriconazole was solely responsible for improved visual outcomes, since several of these patients were given other systemic antifungal agents or had intravitreal injection of voriconazole or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501906\">",
"    <span class=\"h4\">",
"     Posaconazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/60/33737?source=see_link\">",
"     Posaconazole",
"    </a>",
"    has been used in very few patients with ocular fungal infections. Concentrations in the vitreous appear to be low; there is no intravenous formulation, and absorption can be problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/22\">",
"     22",
"    </a>",
"    ]. For these reasons, it cannot be recommended as treatment for Candida endophthalmitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501913\">",
"    <span class=\"h4\">",
"     Echinocandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The echinocandins do not achieve adequate concentrations in the vitreous, and their role in treating Candida ocular infections is unclear. It is possible that they could treat chorioretinitis without vitreous extension, but only a few case reports have addressed this, and both failure and success have been noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/22,29,30\">",
"     22,29,30",
"    </a>",
"    ]. Currently, echinocandins cannot be recommended as treatment for Candida endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that one might gain a sense of the success of echinocandin therapy for treating Candida endophthalmitis by assessing the response to therapy of the few patients with ocular involvement who were included in the large randomized treatment trials of echinocandins for candidemia and invasive candidiasis. A total of 1028 patients received echinocandins in five randomized controlled treatment trials, and 21 were stated to have endophthalmitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. Twelve patients (57 percent) were said to have had resolution of the eye infection. Unfortunately, in none of these trials were specific data reported with regards to the extent of ocular involvement (vitritis versus chorioretinitis) or use of intravitreal injections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vitrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H278914238\">",
"    <span class=\"h2\">",
"     Intravitreal antifungal agents and vitrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients who have had vitritis had a successful outcome documented with systemic antifungal therapy alone, but failure rates are high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/1,12,15,20\">",
"     1,12,15,20",
"    </a>",
"    ]. In patients with endogenous Candida endophthalmitis with moderate to heavy vitritis, vitrectomy should be performed, but in those with light to moderate vitritis, vitrectomy may not be required. An ophthalmologist should always make the decision as to whether the degree of vitritis is severe enough to warrant vitrectomy. For severe vitritis, the best therapeutic strategy appears to be vitrectomy, intravitreal injection of amphotericin (5 to 10 mcg in 0.1 mL sterile water), or perhaps",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    (100 mcg in 0.1 mL sterile water), and systemic antifungal therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/1,11,12,15\">",
"     1,11,12,15",
"    </a>",
"    ]. Early vitrectomy may be important for a favorable outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/12\">",
"     12",
"    </a>",
"    ]. In at least one study of 12 patients with Candida endophthalmitis, good outcomes were reported in the seven patients who underwent early vitrectomy (within one week), but poor visual outcomes were noted in four of five patients in whom vitrectomy was delayed or not performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/12\">",
"     12",
"    </a>",
"    ]. The extent of vitreal involvement was not detailed in this report.",
"   </p>",
"   <p>",
"    Vitrectomy entails the use of a vitrector, an instrument inserted into the vitreous that simultaneously cuts and aspirates much of the gel-like vitreous out of the eye. During this process, another cannula infuses a physiologic saline solution into the vitreous cavity (",
"    <a class=\"graphic graphic_figure graphicRef59512 \" href=\"mobipreview.htm?30/11/30899\">",
"     figure 2",
"    </a>",
"    ). Vitreous samples are sent for stains and culture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=see_link&amp;anchor=H27883777#H27883777\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intravitreal injections may be performed with or without vitrectomy, and are given at the end of the procedure when vitrectomy is performed. High doses of intravitreal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    deoxycholate are toxic to the retina, but an intravitreal injection of 5 to 10 mcg (in 0.1 mL sterile water) appears to be safe and may be repeated several days later if evidence of intraocular infection persists on serial examinations. Patients have received cumulative intravitreal doses of 30 mcg amphotericin B deoxycholate without apparent retinal toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/36\">",
"     36",
"    </a>",
"    ]. Increasingly,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    is used for intravitreal injection. The usual dosage of voriconazole for intravitreal injection is 100 mcg in 0.1 mL sterile water, giving a final concentration in the vitreous of about 25",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    More than one intravitreal injection may be necessary. The second injection is usually given at least 48 hours later, with repeat sampling for staining and culture.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Approach to treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of endogenous Candida endophthalmitis varies depending on whether only chorioretinitis is present, whether the macula is threatened, and the degree of vitreous extension that has occurred. Patients with this condition should be evaluated and treated by both an ophthalmologist who has been trained to manage this condition and an infectious diseases specialist. The antifungal doses recommended below are intended for patients with normal renal function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Endogenous endophthalmitis without vitritis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with extramacular endogenous chorioretinitis without vitritis, we recommend the following treatment course:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation (amphotericin B deoxycholate [0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      [3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily]) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) if the isolate is shown to be susceptible",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      if the isolate is shown to be susceptible; voriconazole dosing is 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for two doses, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every 12 hours. The IV formulation is recommended for at least the initial few days. Oral therapy, using at least 200 mg twice daily can be used following an initial response to the IV formulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It is important to measure serum concentrations of voriconazole approximately one week after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high concentrations that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range between 1 and 5.5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. Once appropriate levels have been achieved, it is not necessary to recheck them unless there is a change in clinical status or concern for drug-drug interactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"       \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with extramacular endogenous chorioretinitis without vitritis, when the organism has been identified as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida spp (eg, C. krusei or fluconazole-resistant C. glabrata), we recommend systemic therapy with",
"      <strong>",
"       either",
"      </strong>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate (0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily);",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses) can be added for C. glabrata, but C. krusei is resistant to this agent",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      if the isolate is shown to be susceptible. It is likely that patients who have only chorioretinitis without vitreous involvement will respond to therapy with other agents, such as echinocandins, but there is little clinical experience using this approach. We do not generally recommend echinocandin therapy. If an echinocandin is considered in cases of chorioretinitis without vitritis (eg, in patients intolerant of other therapeutic options), it should only be used if frequent ophthalmic examinations can be performed and if they demonstrate improvement on therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients who have macular involvement, we suggest an intravitreal injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL) in order to quickly achieve high local antifungal concentrations, in addition to systemic therapy, as noted above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Endogenous endophthalmitis with vitritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with endogenous Candida endophthalmitis with moderate to heavy vitritis, vitrectomy should be performed, but in those with light to moderate vitritis, vitrectomy may not be required. An ophthalmologist should always make the decision as to whether the degree of vitritis is severe enough to warrant vitrectomy and should perform frequent dilated ophthalmic exams to follow the progression of the infection.",
"   </p>",
"   <p>",
"    We recommend the following treatment course for moderate to heavy vitritis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitrectomy",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Intravitreal injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL)",
"      <strong>",
"       and",
"      </strong>",
"     </li>",
"     <li>",
"      Systemic therapy with:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (800 mg [12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) for Candida spp susceptible to fluconazole.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida spp (eg, C. krusei or fluconazole-resistant C. glabrata),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily);",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses) can be added for C. glabrata infection",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      if the isolate is shown to be susceptible (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      intravenously every 12 hours for the first day, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice daily). The IV formulation is recommended for at least the initial few days. Oral therapy, using at least 200 mg twice daily can be used following an initial response to the IV formulation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=see_link&amp;anchor=H19#H19\">",
"       \"Treatment of candidemia and invasive candidiasis in adults\", section on 'C. glabrata and C. krusei'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      It is important to measure serum levels of voriconazole approximately one week after initiating therapy to ensure that adequate concentrations have been achieved to allow success and to avoid high levels that have been associated with adverse events. Although debate remains over the optimal target concentration, available data suggest a therapeutic range between 1",
"      <span class=\"nowrap\">",
"       mcg/mL",
"      </span>",
"      and 5.5",
"      <span class=\"nowrap\">",
"       mcg/mL.",
"      </span>",
"      In patients with concentrations that are too high or too low, the serum concentration should be rechecked four to five days after adjusting the dose. Once appropriate levels have been achieved, it is not necessary to recheck them unless there is a change in clinical status or concern for drug-drug interactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=see_link&amp;anchor=H26#H26\">",
"       \"Pharmacology of azoles\", section on 'Serum drug concentration monitoring'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intravitreal injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"     voriconazole",
"    </a>",
"    may need to be repeated, typically 48 hours or more after the initial injection if there is no clinical improvement.",
"   </p>",
"   <p>",
"    The management of exogenous endophthalmitis caused by Candida species is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727202332\">",
"    <span class=\"h3\">",
"     Duration of systemic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of systemic antifungal therapy for Candida endophthalmitis is a minimum of six weeks, depending upon the improvement of lesions as determined by serial dilated ophthalmic examinations. Many patients require a longer duration of therapy than that noted above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148501932\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to determine exactly the visual outcomes in patients with endogenous Candida endophthalmitis, due at least in part to the fact that many studies include both patients with chorioretinitis alone and patients who also have vitreal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In general, patients who have chorioretinitis alone have better outcomes than those who also have vitritis. It also appears that overall outcomes have improved compared with those reported several decades ago [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39112/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148501899\">",
"     'Voriconazole'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H377352408\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candida species are a common cause of fungal endophthalmitis. This infection arises in two distinct ways:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The exogenous form follows trauma or a surgical procedure on the eye with direct inoculation of the organism into the anterior chamber.",
"     </li>",
"     <li>",
"      The endogenous form follows candidemia with hematogenous seeding of the eye, typically starting with the choroid.",
"      <br/>",
"      <br/>",
"      Regardless of the route of infection, if untreated, both forms progress to endophthalmitis, in which the vitreous (and in some cases the aqueous) is infected. Irreversible vision loss may result. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of endogenous Candida endophthalmitis varies depending on whether only chorioretinitis is present, whether the macula is threatened, and the degree of vitreous extension. Chorioretinitis usually responds to systemic antifungal therapy alone, whereas eyes with marked vitritis usually require systemic antifungal therapy, vitrectomy (surgical removal of the vitreous), and intravitreal injection of an antifungal agent. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H377352637\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165208802\">",
"    <span class=\"h2\">",
"     Endogenous chorioretinitis without vitritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with endogenous chorioretinitis in the absence of vitreal involvement, we recommend systemic antifungal therapy targeted to the susceptibility of the pathogen (",
"    <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"     Grade 1C",
"    </a>",
"    ). The antifungal doses recommended below are intended for patients with normal renal function. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Endogenous endophthalmitis without vitritis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the organism has been identified as Candida albicans or another",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -susceptible species,",
"      <strong>",
"       either",
"      </strong>",
"      of the following antifungal regimens may be used:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      formulation (amphotericin B deoxycholate [0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      [3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily]) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses)",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       Fluconazole",
"      </a>",
"      (400 to 800 mg [6 to 12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When the organism has been identified as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida spp (eg, C. krusei or fluconazole-resistant C. glabrata),",
"      <strong>",
"       either",
"      </strong>",
"      of the following systemic antifungal agents may be used:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       Amphotericin B",
"      </a>",
"      deoxycholate (0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily);",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses) can be added for C. glabrata infection",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      if the isolate is shown to be susceptible (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for the first day, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV twice daily). The IV formulation is recommended for at least the initial few days. Oral therapy, using at least 200 mg twice daily can be used following an initial response to the IV formulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients who have macular involvement, in addition to systemic antifungal therapy, we recommend an intravitreal injection of an antifungal agent to quickly achieve high local concentrations (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water) may be used. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endogenous endophthalmitis without vitritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165208828\">",
"    <span class=\"h2\">",
"     Endogenous endophthalmitis with vitritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with marked vitreous inflammation (vitritis) require a vitrectomy in addition to intravitreal and systemic antifungal therapy. Vitrectomy may also be indicated when vitritis is worsening despite intravitreal and systemic antifungal therapy. An ophthalmologist (usually a retina specialist) should follow the patient closely and determine the degree of vitritis and response to therapy. Minimal vitritis generally does not require vitrectomy, but vitrectomy is usually indicated for moderate to severe vitritis. The antifungal doses recommended below are intended for patients with normal renal function. We use the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend vitrectomy and intravitreal injection of an antifungal agent (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ); appropriate antifungal agents for intravitreal injection include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (5 to 10 mcg in 0.1 mL sterile water) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       voriconazole",
"      </a>",
"      (100 mcg in 0.1 mL sterile water).",
"     </li>",
"     <li>",
"      In addition, we recommend a systemic antifungal agent targeted to the susceptibility of the pathogen (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For Candida spp susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      , fluconazole (800 mg [12",
"      <span class=\"nowrap\">",
"       mg/kg]",
"      </span>",
"      orally daily) should be given.",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"       fluconazole",
"      </a>",
"      -resistant Candida spp (eg, C. krusei or fluconazole-resistant C. glabrata),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"       amphotericin B",
"      </a>",
"      deoxycholate (0.7 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      (3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV daily) should be given;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"       flucytosine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      orally per day in four divided doses) can be added for C. glabrata infection",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/38/17002?source=see_link\">",
"       Voriconazole",
"      </a>",
"      (6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every 12 hours for the first day, then 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV twice daily), if the isolate is shown to be susceptible. The IV formulation is recommended for at least the initial few days. Oral therapy, using at least 200 mg twice daily can be used following an initial response to the IV formulation. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Endogenous endophthalmitis with vitritis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H165208836\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of systemic antifungal therapy for endogenous Candida endophthalmitis is a minimum of six weeks, and often longer, and depends upon the improvement of lesions as determined by serial dilated ophthalmic examinations. (See",
"    <a class=\"local\" href=\"#H727202332\">",
"     'Duration of systemic therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1221871809\">",
"    <span class=\"h2\">",
"     Exogenous endophthalmitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of exogenous Candida endophthalmitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36102?source=see_link\">",
"     \"Treatment of exogenous endophthalmitis due to Candida species\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/1\">",
"      Barza M. Treatment options for candidal endophthalmitis [editoria; comment]. Clin Infect Dis 1998; 27:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/2\">",
"      GREEN WR, BENNETT JE, GOOS RD. OCULAR PENETRATION OF AMPHOTERICIN B: A REPORT OF LABORATORY STUDIES AND A CASE REPORT OF POSTSURGICAL CEPHALOSPORIUM ENDOPHTHALMITIS. Arch Ophthalmol 1965; 73:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/3\">",
"      Savani DV, Perfect JR, Cobo LM, Durack DT. Penetration of new azole compounds into the eye and efficacy in experimental Candida endophthalmitis. Antimicrob Agents Chemother 1987; 31:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/4\">",
"      Scherer WJ, Lee K. Implications of early systemic therapy on the incidence of endogenous fungal endophthalmitis. Ophthalmology 1997; 104:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/5\">",
"      Griffin JR, Pettit TH, Fishman LS, Foos RY. Blood-borne Candida endophthalmitis. A clinical and pathologic study of 21 cases. Arch Ophthalmol 1973; 89:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/6\">",
"      Edwards JE Jr, Foos RY, Montgomerie JZ, Guze LB. Ocular manifestations of Candida septicemia: review of seventy-six cases of hematogenous Candida endophthalmitis. Medicine (Baltimore) 1974; 53:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/7\">",
"      Donahue SP, Greven CM, Zuravleff JJ, et al. Intraocular candidiasis in patients with candidemia. Clinical implications derived from a prospective multicenter study. Ophthalmology 1994; 101:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/8\">",
"      Bisbe J, Miro JM, Latorre X, et al. Disseminated candidiasis in addicts who use brown heroin: report of 83 cases and review. Clin Infect Dis 1992; 15:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/9\">",
"      Goldblum D, Rohrer K, Frueh BE, et al. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002; 46:3719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/10\">",
"      Tod M, Lortholary O, Padoin C, Chaine G. Intravenous penetration of fluconazole during endophthalmitis. Clin Microbiol Infect 1997; 3:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/11\">",
"      Urbak SF, Degn T. Fluconazole in the management of fungal ocular infections. Ophthalmologica 1994; 208:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/12\">",
"      Mart&iacute;nez-V&aacute;zquez C, Fern&aacute;ndez-Ulloa J, Bord&oacute;n J, et al. Candida albicans endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis 1998; 27:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/13\">",
"      del Palacio A, Cu&eacute;tara MS, Ferro M, et al. Fluconazole in the management of endophthalmitis in disseminated candidosis of heroin addicts. Mycoses 1993; 36:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/14\">",
"      Luttrull JK, Wan WL, Kubak BM, et al. Treatment of ocular fungal infections with oral fluconazole. Am J Ophthalmol 1995; 119:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/15\">",
"      Akler ME, Vellend H, McNeely DM, et al. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis 1995; 20:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/16\">",
"      Nomura J, Ruskin J. Failure of therapy with fluconazole for candidal endophthalmitis. Clin Infect Dis 1993; 17:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/17\">",
"      Filler SG, Crislip MA, Mayer CL, Edwards JE Jr. Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits. Antimicrob Agents Chemother 1991; 35:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/18\">",
"      Louie A, Liu W, Miller DA, et al. Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans. Antimicrob Agents Chemother 1999; 43:2831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/19\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/20\">",
"      Breit SM, Hariprasad SM, Mieler WF, et al. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol 2005; 139:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/21\">",
"      Hariprasad SM, Mieler WF, Lin TK, et al. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008; 92:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/22\">",
"      Riddell J 4th, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis 2011; 52:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/23\">",
"      Oude Lashof AM, Rothova A, Sobel JD, et al. Ocular manifestations of candidemia. Clin Infect Dis 2011; 53:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/24\">",
"      Hariprasad SM, Mieler WF, Holz ER, et al. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans. Arch Ophthalmol 2004; 122:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/25\">",
"      Kim JE, Perkins SL, Harris GJ. Voriconazole treatment of fungal scleritis and epibulbar abscess resulting from scleral buckle infection. Arch Ophthalmol 2003; 121:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/26\">",
"      Reis A, Sundmacher R, Tintelnot K, et al. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophthalmol 2000; 84:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/27\">",
"      Garbino J, Ondrusova A, Baglivo E, et al. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis 2002; 34:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/28\">",
"      Riddell Iv J, McNeil SA, Johnson TM, et al. Endogenous Aspergillus endophthalmitis: report of 3 cases and review of the literature. Medicine (Baltimore) 2002; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/29\">",
"      Sarria JC, Bradley JC, Habash R, et al. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis 2005; 40:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/30\">",
"      Gauthier GM, Nork TM, Prince R, Andes D. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 2005; 41:e27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/31\">",
"      Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/32\">",
"      Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/33\">",
"      Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/34\">",
"      Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/35\">",
"      Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/36\">",
"      Tabbara KF, al Jabarti AL. Hospital construction-associated outbreak of ocular aspergillosis after cataract surgery. Ophthalmology 1998; 105:522.",
"     </a>",
"    </li>",
"    <li>",
"     Durand ML. Endophthalmitis. In: Principles and Practice of Infectious Diseases, 7th edition, Mandell GL, Bennett JE, Dolin R.  (Eds), Churchill Livingstone Elsevier, Philadelphia 2010. Vol 1, p.1553.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39112/abstract/38\">",
"      Binder MI, Chua J, Kaiser PK, et al. Endogenous endophthalmitis: an 18-year review of culture-positive cases at a tertiary care center. Medicine (Baltimore) 2003; 82:97.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2446 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-78.134.254.52-42756325B5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39112=[""].join("\n");
var outline_f38_12_39112=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H377352408\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377352637\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278914249\">",
"      Systemic antifungal therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148501878\">",
"      - Choice of agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148501885\">",
"      Amphotericin B and flucytosine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148501892\">",
"      Fluconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148501899\">",
"      Voriconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148501906\">",
"      Posaconazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148501913\">",
"      Echinocandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H278914238\">",
"      Intravitreal antifungal agents and vitrectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Approach to treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Endogenous endophthalmitis without vitritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Endogenous endophthalmitis with vitritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H727202332\">",
"      - Duration of systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148501932\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H377352408\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165208802\">",
"      Endogenous chorioretinitis without vitritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165208828\">",
"      Endogenous endophthalmitis with vitritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H165208836\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1221871809\">",
"      Exogenous endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2446|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/35/42549\" title=\"figure 1\">",
"      Eye anatomy in cross section",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/11/30899\" title=\"figure 2\">",
"      Vitreous aspirate vitrectomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/21/29018?source=related_link\">",
"      Antifungal susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13849?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of fungal endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/5/42071?source=related_link\">",
"      Overview of Candida infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15001?source=related_link\">",
"      Pharmacology of amphotericin B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/42/3753?source=related_link\">",
"      Treatment and prevention of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/13/29914?source=related_link\">",
"      Treatment of candidemia and invasive candidiasis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/16/36102?source=related_link\">",
"      Treatment of exogenous endophthalmitis due to Candida species",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_12_39113="Causes of acute respiratory compromise in children";
var content_f38_12_39113=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Causes of acute respiratory compromise in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     Debra L Weiner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39113/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/12/39113/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H13169081\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress is one of the most common chief complaints for which children seek medical care. It accounts for nearly 10 percent of pediatric emergency department visits and 20 percent of hospitalizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Respiratory compromise in children, particularly neonates and infants, must be promptly recognized and aggressively treated because children may become fatigued",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decompensate quickly. Respiratory arrest is the most common cause of cardiac arrest in children. Factors that exacerbate rapid respiratory compromise in children as compared to adults include smaller airways, increased metabolic demands, decreased respiratory reserves, and inadequate compensatory mechanisms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17367?source=see_link\">",
"     \"Emergency airway management in children: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review causes of acute respiratory compromise in children. A detailed discussion of the approach to children with acute respiratory compromise and approach to children with severe upper airway obstruction is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=see_link\">",
"     \"Emergent evaluation of acute respiratory compromise in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other related topics including the initial assessment and stabilization of children with respiratory and circulatory compromise and airway management techniques, including rapid sequence intubation (RSI), and conditions causing respiratory distress in newborns are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=see_link\">",
"       \"Initial assessment and stabilization of children with respiratory or circulatory compromise\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=see_link\">",
"       \"Basic airway management in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=see_link\">",
"       \"Rapid sequence intubation (RSI) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=see_link\">",
"       \"Overview of neonatal respiratory distress: Disorders of transition\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21768?source=see_link\">",
"       \"Clinical features and diagnosis of meconium aspiration syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12360?source=see_link\">",
"       \"Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169088\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory compromise results when breathing does not match the body&rsquo;s metabolic demand for oxygenation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventilation. Respiratory distress is typically characterized by signs of increased work of breathing, such as tachypnea, use of accessory muscles,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retractions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/2\">",
"     2",
"    </a>",
"    ]. A patient with inadequate respiratory effort may also have signs of increased work of breathing, most commonly tachypnea, but will also have an abnormal pattern of respiration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a respiratory rate that is inappropriately slow for the clinical condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=see_link&amp;anchor=H16#H16\">",
"     \"Emergent evaluation of acute respiratory compromise in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory compromise may develop in children due to multiple etiologies (",
"    <a class=\"graphic graphic_table graphicRef61637 \" href=\"mobipreview.htm?27/39/28285\">",
"     table 1",
"    </a>",
"    ) that result in one of the following final common pathways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypoxemia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link&amp;anchor=H12#H12\">",
"       \"Control of ventilation\", section on 'Hypoxic challenge'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypercarbia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link&amp;anchor=H13#H13\">",
"       \"Control of ventilation\", section on 'Hypercapnic challenge'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Difficulty with the mechanics of respiration, typically from airway obstruction, muscle weakness, or discomfort (as may occur for patients who are splinting due to abdominal pain).",
"     </li>",
"     <li>",
"      Disordered control of ventilation, in which respiration may be depressed (eg, opioid overdose, severe head injury) or stimulated (eg, metabolic acidosis, hyperammonemia, salicylate intoxication)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Respiratory distress in response to hypoxemia or hypercarbia can rapidly progress to life-threatening respiratory failure. Neonates, infants, and young children are at particular risk given their high oxygen consumption and decreased respiratory reserve. Children with inadequate respiratory effort (as can occur with fatigue, muscle weakness or CNS depression) can also quickly develop significant physiologic compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17367?source=see_link\">",
"     \"Emergency airway management in children: Unique pediatric considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, children with respiratory distress secondary to altered stimulation of respiratory centers or pain, who do not have significant cardiopulmonary disease, usually improve with treatment of the primary condition and do not generally progress to respiratory failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169095\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many conditions may cause acute respiratory compromise in children (",
"    <a class=\"graphic graphic_table graphicRef61637 \" href=\"mobipreview.htm?27/39/28285\">",
"     table 1",
"    </a>",
"    ). The underlying etiology, while commonly within the respiratory system, may also be within other systems, most notably cardiovascular, nervous, gastrointestinal, hematologic, or",
"    <span class=\"nowrap\">",
"     metabolic/endocrine,",
"    </span>",
"    and may not be immediately obvious (eg, fever and rales may be due to heart failure as the result of myocarditis rather than pneumonia which is more common).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169102\">",
"    <span class=\"h2\">",
"     Immediately life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any process that causes respiratory distress by compromising ventilation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    oxygenation can be life-threatening. Imminently life-threatening conditions require early recognition and immediate, aggressive intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169109\">",
"    <span class=\"h3\">",
"     Severe upper airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with complete upper airway obstruction have no effective air movement, hence no audible speech, cry, or cough. Causes of complete upper airway obstruction include foreign body aspiration, angioedema from anaphylaxis, laryngospasm caused by hypocalcemia, and epiglottitis (",
"    <a class=\"graphic graphic_table graphicRef62015 \" href=\"mobipreview.htm?2/44/2763\">",
"     table 2",
"    </a>",
"    ). Foreign body aspiration, anaphylaxis, and epiglottitis, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H2#H2\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Causes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=see_link\">",
"     \"Epiglottitis (supraglottitis): Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Noisy inspiration (stridor) is a hallmark of severe partial upper airway obstruction although absence of stridor does not preclude significant partial airway obstruction, especially in a patient with depressed mental status. Common causes of severe partial upper airway obstruction include foreign body aspiration, infection (most commonly croup), and injury (such as airway thermal or chemical burns). Causes of acute upper airway obstruction that are commonly life-threatening are discussed separately (",
"    <a class=\"graphic graphic_table graphicRef62015 \" href=\"mobipreview.htm?2/44/2763\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H2#H2\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Causes'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169123\">",
"    <span class=\"h3\">",
"     Tension pneumothorax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension pneumothorax is an acutely life-threatening emergency that develops when increased intrathoracic volume from air that has leaked into the pleural cavity causes a shift of mediastinal structures toward the opposite side, compressing the contralateral lung and cardiac vessels. It is rapidly fatal without immediate decompression.",
"   </p>",
"   <p>",
"    Hallmarks of tension pneumothorax are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe respiratory distress",
"     </li>",
"     <li>",
"      Ipsilateral hyperexpansion of the chest",
"     </li>",
"     <li>",
"      Decreased or absent breath sounds and hyper-resonance to percussion on the side of the collapsed lung",
"     </li>",
"     <li>",
"      Shift of mediastinal structures, including the trachea, toward the side opposite of the collapsed lung",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the rare patient with bilateral tension pneumothoraces, physical findings may be symmetric. Tension pneumothorax is usually due to penetrating or blunt trauma, including mechanical ventilation and cardiopulmonary resuscitation but it can also occur on occasion as the result of a spontaneous pneumothorax [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/3\">",
"     3",
"    </a>",
"    ]. Although tension usually develops immediately, it may be delayed for up to 24 hours, particularly if the pneumothorax is spontaneous and develops slowly. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=see_link\">",
"     \"Spontaneous pneumothorax in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Needle decompression can be a life-saving, although temporizing measure that any physician should be able to perform. If immediately available, a thoracostomy tube can be placed in children with a tension pneumothorax without first performing needle thoracostomy only if the tube can be placed without delaying decompression; otherwise needle thoracostomy should be performed immediately, followed by chest tube placement as soon as possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H254982395#H254982395\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Tube thoracostomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H254983853#H254983853\">",
"     \"Placement and management of thoracostomy tubes\", section on 'Needle thoracostomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169137\">",
"    <span class=\"h3\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary embolism (PE) can cause life-threatening respiratory distress. It is an uncommon condition in children and is often associated with the use of central venous lines or access devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/4\">",
"     4",
"    </a>",
"    ]. Other risk factors for PE include a hypercoagulable state (such as factor V Leiden mutation, protein S or protein C deficiency), congenital heart disease, trauma, nephrotic syndrome, systemic lupus erythematosus, and complications of some chemotherapeutic regimens (such as L-asparaginase and steroids for acute lymphoblastic leukemia). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18957925\">",
"    <span class=\"h3\">",
"     Cardiac tamponade",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac tamponade occurs when blood, serous fluid, or air under tension (usually in neonates) fills the pericardial sack, resulting in life-threatening compromise of venous return and decreased stroke volume. Cardiac tamponade can present acutely with hypotension. Children may also have signs of respiratory distress or apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The classic signs of pericardial tamponade, referred to as Beck's triad (hypotension, jugular venous distention, and muffled heart sounds), are present in less than one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulsus paradoxus (a drop in the systolic blood pressure of &gt;10 mmHg upon inspiration and, when severe, a weakening or disappearance of the peripheral pulse upon inspiration) is an indication for pericardiocentesis and fluid removal in children with pericardial effusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11158?source=see_link\">",
"     \"Pulsus paradoxus in pericardial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11158?source=see_link&amp;anchor=H2#H2\">",
"     \"Pulsus paradoxus in pericardial disease\", section on 'Measurement of pulsus paradoxus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11158?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulsus paradoxus in pericardial disease\", section on 'Pulsus paradoxus in tamponade'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44119?source=see_link\">",
"     \"Emergency pericardiocentesis\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Acute cardiac tamponade is rare in children and usually accompanies trauma, particularly penetrating cardiac injury. It is rapidly fatal. Pericardial effusions in children are more commonly caused by insidious accumulation of pericardial fluid as a result of infection, inflammation (most commonly collagen vascular disease), malignancy (eg, mediastinal lymphoma), or cardiac surgery (post-pericardiotomy syndrome). However, tamponade may occur in these conditions as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169144\">",
"    <span class=\"h3\">",
"     Other traumatic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to tension pneumothorax and cardiac tamponade, several other traumatic conditions may cause respiratory compromise including flail chest, pulmonary contusion, open pneumothorax, hemothorax, hemorrhagic shock, and central nervous system trauma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Flail chest",
"      </strong>",
"      &ndash; Flail chest occurs when multiple rib fractures result in a loss of stability of the chest wall. The flail segment retracts with inspiration and bulges with exhalation, resulting in inefficient expansion of the thorax, inefficient ventilation, and a significant increase in the energy expenditure for breathing (",
"      <a class=\"graphic graphic_figure graphicRef79746 \" href=\"mobipreview.htm?23/19/23857\">",
"       figure 1",
"      </a>",
"      ). The mechanism of injury usually is direct impact. Flail chest is uncommon in children because the greater deformability of immature bone makes rib fractures less likely than in adults, and when present, is often associated with pulmonary contusion. Even without rib fractures, children may have significant pulmonary injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12807?source=see_link&amp;anchor=H8#H8\">",
"       \"Chest wall injuries in children\", section on 'Flail chest'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pulmonary contusion",
"      </strong>",
"      &ndash; In children, pulmonary contusion occurs when traumatic force is applied to the chest wall and results in parenchymal damage with hemorrhage and edema. The initial presentation of children with pulmonary contusion is often dominated by clinical features associated with extrathoracic injuries. Nevertheless, pulmonary contusion should be suspected in any child with significant blunt force to the thorax, whether or not there are signs of respiratory distress or chest wall injury. Decreased breath sounds, rales, or rhonchi may be noted on physical examination. Chest radiography should be performed for all children with suspected pulmonary contusion. Further imaging with computed tomography (CT) may be useful when the plain films are negative if identification of a pulmonary contusion would affect management (eg, in anesthetic management for patients requiring emergent surgery). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29285?source=see_link&amp;anchor=H4#H4\">",
"       \"Pulmonary contusion in children\", section on 'Clinical features'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29285?source=see_link&amp;anchor=H5#H5\">",
"       \"Pulmonary contusion in children\", section on 'Primary evaluation and management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Open pneumothorax",
"      </strong>",
"      &ndash; Open pneumothorax occurs when ambient air enters the pleural space during inspiration through a traumatic chest wall defect (ie, a \"sucking wound\"). As a result, the mediastinum shifts toward the normal hemithorax and the lung within the injured hemithorax remains collapsed. During expiration, air exits the pleural space through the chest wall defect and the mediastinum swings back toward the injured hemithorax. Expiratory air from the normal lung (ie, &ldquo;pendulum air&rdquo;) fills the collapsed lung. The &ldquo;mediastinal flutter\" may cause respiratory failure. Radiographically, an open pneumothorax is characterized by a visible chest wall defect and by massive expiratory mediastinal shift towards the injured side: this mediastinal behavior is different from tension pneumothorax where the expiratory shift of the mediastinum occurs towards the normal lung, resulting from air-trapping in the affected pleural space. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=see_link&amp;anchor=H2#H2\">",
"       \"Imaging of pneumothorax\", section on 'Types of pneumothorax'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Treatment consists of placing sterile petroleum gauze over the open wound and taping the dressing on three sides to act as a flutter valve that prevents air entry through the wound upon inspiration, but allows air to escape during exhalation. A chest tube should also be placed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=see_link&amp;anchor=H254982395#H254982395\">",
"       \"Placement and management of thoracostomy tubes\", section on 'Tube thoracostomy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hemothorax",
"      </strong>",
"      &ndash; In patients with massive hemothorax, respiratory compromise results from the inability of the lung to expand on the affected side and from hemorrhage shock. Thoracostomy tube placement and fluid resuscitation are key interventions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H11#H11\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Breathing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Smoke inhalation",
"      </strong>",
"      &ndash; Smoke inhalation may cause respiratory compromise due to thermal injury to the upper and lower airways, hypoxic gas inhalation, bronchopulmonary exposure to toxins with direct lung injury,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      systemic toxicity from carbon monoxide and cyanide. Thermal injury to the upper airway is suggested by stridor, respiratory distress, facial burns, oropharyngeal blisters or edema, and carbonaceous sputum and warrants early endotracheal intubation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link&amp;anchor=H2027110#H2027110\">",
"       \"Smoke inhalation\", section on 'Subsequent management'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=see_link&amp;anchor=H2020436#H2020436\">",
"       \"Smoke inhalation\", section on 'Initial management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Submersion injury",
"      </strong>",
"      &ndash; Children with near drowning have varying degrees of hypoxia that correspond to the duration of immersion. Pulmonary insufficiency can develop insidiously or rapidly. Findings include tachypnea, respiratory distress, rales, and wheezing. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26809?source=see_link\">",
"       \"Drowning (submersion injuries)\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Hemorrhagic shock",
"      </strong>",
"      &ndash; Massive hemorrhage can cause respiratory distress from hypoxia and acidosis (as the result of decreased oxygen carrying capacity due to hypovolemic shock). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link&amp;anchor=H12#H12\">",
"       \"Trauma management: Approach to the unstable child\", section on 'Circulation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Central nervous system trauma",
"      </strong>",
"      &ndash; Central nervous system injury involving the brain or spinal cord, may result in life-threatening apnea or respiratory depression. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4250?source=see_link&amp;anchor=H7#H7\">",
"       \"Initial approach to severe traumatic brain injury in children\", section on 'Evaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=see_link&amp;anchor=H8#H8\">",
"       \"Evaluation of cervical spine injuries in children and adolescents\", section on 'Vital signs'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13375299\">",
"    <span class=\"h3\">",
"     Biological or chemical weapons",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several biologic and chemical agents that are potential weapons of terrorism or warfare produce respiratory distress as their most predominant effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39113/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Although exposure to these agents is fortunately rare, prompt recognition is essential in order to contain the exposure and prepare for mass casualties. Children often manifest symptoms prior to adults because of greater exposure per unit body mass, particularly since many agents are heavier than air and are at greatest concentration lower to the ground, and because of less compensatory capacity. The respiratory symptoms are typically nonspecific. Biologic agents include inhalational anthrax, pneumonic plague, pneumonic tularemia, melioidosis, and the toxins staphylococcus enterotoxin B and ricin. Chemical agents such as chlorine, phosgene, and cyanide can also cause respiratory distress. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8521?source=see_link\">",
"     \"Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169151\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169159\">",
"    <span class=\"h3\">",
"     Respiratory tract conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compromise of respiratory function can occur as the result of upper or lower respiratory tract processes. The clinical manifestations of respiratory distress depend, in part, on the location of the disease process. As an example, stridor develops in children with upper airway obstruction, whereas rales are characteristic findings of alveolar disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=see_link&amp;anchor=H23#H23\">",
"     \"Emergent evaluation of acute respiratory compromise in children\", section on 'Physical examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172505\">",
"    <span class=\"h4\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress as the result of an infectious process usually develops gradually, but can be acute in onset if structures of the upper airway are directly involved. Patients are often febrile. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link\">",
"     \"Emergent evaluation of acute upper airway obstruction in children\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Common infectious causes of respiratory distress include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Uvulitis",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Children and adolescents with uvulitis may present with fever, sore throat, difficulty swallowing, pain with swallowing, drooling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      respiratory distress. The clinical features vary depending upon the etiology. Respiratory distress is uncommon in infectious uvulitis unless there is associated epiglottitis. Uvulitis is a clinical diagnosis. The uvula is red and swollen and may be covered by purulent exudates (",
"      <a class=\"graphic graphic_picture graphicRef67939 \" href=\"mobipreview.htm?31/19/32049\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10649?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features and treatment of uvulitis\", section on 'Clinical features'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Peritonsillar abscesses",
"      </strong>",
"      &ndash; Peritonsillar abscesses typically cause local pain, sore throat, trismus, difficulty swallowing, and muffled (\"hot potato\") voice. Patients with peritonsillar abscesses exhibit to tonsillar and peritonsillar swelling and erythema with deviation of the uvula to the unaffected side. It is rare that the swelling is so severe that it obstructs the oral airway enough to cause difficulty breathing. Peritonsillar abscess is most commonly caused by Group A streptococcus, but can be caused by other bacteria and sometimes develops secondary to Epstein-Barr virus (ie, mononucleosis). Peritonsillar abscess is more common in older children and adolescents. The onset of symptoms is typically gradual. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=see_link&amp;anchor=H6#H6\">",
"       \"Peritonsillar cellulitis and abscess\", section on 'Evaluation and diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Retropharyngeal abscesses",
"      </strong>",
"      &ndash; Children with retropharyngeal abscesses may develop stridor and typical signs of respiratory distress if the abscess impedes on the trachea. Retropharyngeal abscess usually develops in infants and toddlers (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63233 \" href=\"mobipreview.htm?23/20/23887\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51505 \" href=\"mobipreview.htm?11/46/12015\">",
"       image 2",
"      </a>",
"      ). Additional findings include drooling, dysphagia, torticollis, meningismus, and change in voice. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=see_link&amp;anchor=H5#H5\">",
"       \"Retropharyngeal infections in children\", section on 'Presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Croup",
"      </strong>",
"      &ndash; Croup (laryngotracheobronchitis) is the most common infectious cause of upper airway obstruction in children between 6 and 36 months of age, but can be seen from early infancy through school age (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64727 \" href=\"mobipreview.htm?41/59/42943\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef52418 \" href=\"mobipreview.htm?2/56/2959\">",
"       image 4",
"      </a>",
"      ). The etiology may be viral (most commonly due to infection with parainfluenza virus) or allergic (spasmodic croup). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features, evaluation, and diagnosis of croup\", section on 'Epidemiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features, evaluation, and diagnosis of croup\", section on 'Etiology'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The onset of symptoms is usually gradual, beginning with nasal congestion, and coryza. Symptoms generally progress over 12 to 48 hours to include fever, usually &lt;39&deg;C although may be higher especially if due to influenza, hoarseness, barking cough, and stridor. Barky cough most commonly begins during the night or with napping. Respiratory distress increases as upper airway obstruction becomes more severe. Rapid progression or signs of lower airway involvement suggests a more serious illness. Symptoms typically persist for three to seven days with resolution of barky cough by day four in most children. Deviations from this expected course should prompt consideration of diagnoses other than laryngotracheitis. Some children with severe or recurrent croup may have underlying airway abnormalities (eg, subglottic hemangioma). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical features, evaluation, and diagnosis of croup\", section on 'Clinical presentation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bacterial tracheitis",
"      </strong>",
"      &ndash; Bacterial tracheitis is an invasive exudative bacterial infection of the soft tissues of the trachea usually caused by Staphylococcus aureus (",
"      <a class=\"graphic graphic_picture graphicRef55364 \" href=\"mobipreview.htm?16/55/17264\">",
"       picture 2",
"      </a>",
"      ). In some instances, bacterial tracheitis may be the result of viral infection or bacterial superinfection in a child with croup (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80331 \" href=\"mobipreview.htm?33/50/34606\">",
"       image 5",
"      </a>",
"      ). The predominant clinical features of bacterial tracheitis are those of airway obstruction: stridor, cough, and respiratory distress accompanied by fever. Children younger than two to three years of age may be at increased risk for severe disease because of their relatively narrow airway diameter. In children with signs of total or near-total airway obstruction, airway control precedes diagnostic evaluation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=see_link&amp;anchor=H11#H11\">",
"       \"Bacterial tracheitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Bronchiolitis",
"      </strong>",
"      &ndash; Bronchiolitis (usually caused by respiratory syncytial virus) typically affects children younger than two years of age. It is characterized by several days of upper airway symptoms, most classically nasal congestion and copious nasal secretions, followed by onset of lower airway symptoms that include wheezing, rales, rhonchi, and cough. Peak severity of illness is usually between days 4 and 6 with resolution of symptoms between days 10 and 14. A detailed review of bronchiolitis can be found separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=see_link\">",
"       \"Bronchiolitis in infants and children: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Pneumonia",
"      </strong>",
"      &ndash; Pneumonia is one of the most common causes of lower airway disease in infants and children. The disease process is more likely to be localized in the setting of bacterial pneumonia, whereas patients with viral and atypical pneumonias, such as Mycoplasma or Chlamydia, tend to have diffuse peribronchial, interstitial processes. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38970?source=see_link&amp;anchor=H3#H3\">",
"       \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Clinical evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172649\">",
"    <span class=\"h4\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchospasm due to reactive airways can cause severe respiratory distress. It may be triggered by infection, exercise, environmental irritants, stress,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gastroesophageal reflux. Respiratory distress from bronchospasm may be exacerbated by alveolar disease (as a result of infection)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atelectasis. Assessment of severity and acute management of children with asthma exacerbations in the outpatient setting are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H2#H2\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Assessment of severity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute asthma exacerbations in children: Outpatient management\", section on 'Overview of treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172656\">",
"    <span class=\"h4\">",
"     Anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis and anaphylactoid reactions (most commonly caused by food or medications) may be severe and life-threatening, particularly when edema involves the retropharynx",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    larynx. In the lower airways, anaphylaxis usually causes bronchospasm (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 3",
"    </a>",
"    ). Onset is most often sudden, and there may be associated signs and symptoms, such as facial swelling, urticaria, vomiting, dizziness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    syncope. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H7#H7\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Symptoms and signs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172670\">",
"    <span class=\"h4\">",
"     Foreign body",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies that partially obstruct the upper airway or those lodged in the lower airways or esophagus, are not usually acutely life-threatening, but often cause respiratory distress. Children with foreign bodies in the upper airway, or with esophageal foreign bodies compressing the airway, are more likely to acutely develop severe symptoms, typically choking, drooling, dysphagia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stridor. In comparison, foreign body in the lower airway, most commonly manifests as unilateral wheeze, but presentation may be delayed days to weeks and manifest as fever, rales, or cough due to infection. Children with significant upper airway obstruction may develop pulmonary edema following relief of the obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=see_link&amp;anchor=H3#H3\">",
"     \"Airway foreign bodies in children\", section on 'Presentation'",
"    </a>",
"    .) Rarely, foreign bodies lodged in the esophagus may compress the airway, causing partial airway obstruction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=see_link&amp;anchor=H2#H2\">",
"     \"Foreign bodies of the esophagus and gastrointestinal tract in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172709\">",
"    <span class=\"h4\">",
"     Airway anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fixed and functional congenital abnormalities of the airway that include vocal cord paralysis, mass, tracheal stenosis, ring, sling, tracheoesophageal fistula and laryngomalacia may all cause respiratory distress that usually manifests in the neonate or infant. Laryngospasm, hypocalcemic tetany, paradoxical vocal cord movement, and vocal cord paralysis are acquired causes of upper airway obstruction and may be seen at any age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172716\">",
"    <span class=\"h4\">",
"     Pulmonary edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noncardiogenic pulmonary edema may occur from upper airway obstruction (such as from foreign body or croup), pulmonary irritants, submersion injury, severe CNS insult and acute salicylate toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25271?source=see_link\">",
"     \"Neurogenic pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=see_link\">",
"     \"Salicylate poisoning in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172761\">",
"    <span class=\"h4\">",
"     Chest wall and thoracic cavity abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease processes involving the chest wall structure (such as asphyxiating thoracic dystrophy, muscular dystrophy, severe pectus excavatum) may severely restrict lung expansion, limiting ventilatory efforts. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link\">",
"     \"Diseases of the chest wall\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mass lesions in the chest or mediastinum may be congenital or acquired and include diaphragmatic hernia, esophageal anomalies, bronchopulmonary sequestration, benign and malignant masses and vascular anomalies. They cause respiratory distress usually by compression of the airway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=see_link&amp;anchor=H15#H15\">",
"     \"Clinical assessment of the child with suspected cancer\", section on 'Mediastinal masses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=see_link&amp;anchor=H5#H5\">",
"     \"Evaluation of mediastinal masses\", section on 'Signs and symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural effusion may be caused by infection, inflammation, ischemia, malignancy, organ failure, drug hypersensitivity, venous or lymphatic obstruction and trauma. Infectious causes are most common in children. The onset and progression of respiratory distress are usually gradual. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9770?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169166\">",
"    <span class=\"h3\">",
"     Cardiovascular conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular causes of respiratory compromise may be congenital or acquired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172909\">",
"    <span class=\"h4\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital cardiac anomalies with right-to-left shunting of deoxygenated blood result in reduced oxygen saturation of blood entering the systemic circulation, causing hypoxia with cyanosis (",
"    <a class=\"graphic graphic_table graphicRef50161 \" href=\"mobipreview.htm?18/6/18540\">",
"     table 4",
"    </a>",
"    ). Signs of respiratory distress other than cyanosis may not be present, however, unless the child is also in heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link\">",
"     \"Cardiac causes of cyanosis in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13172916\">",
"    <span class=\"h4\">",
"     Acute decompensated heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure may develop due to a congenital or acquired cardiac condition. For congenital heart defects, the time of onset of congestive heart failure (CHF) is dependent on the specific heart defect and its severity. As an example, a newborn with an obstructive left-sided heart lesion, such as severe coarctation of the aorta, may develop severe CHF when the ductus arteriosus closes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=see_link&amp;anchor=H22#H22\">",
"     \"Cardiac causes of cyanosis in the newborn\", section on 'Heart failure'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most common acquired conditions that cause CHF in children are myocarditis and supraventricular tachycardia that persists for more than 12 to 24 hours. Other conditions include valvular heart disease, myocardial dysfunction, sepsis, metabolic disturbance, fluid overload, severe anemia, ischemia, and myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=see_link\">",
"     \"Clinical manifestations and diagnosis of myocarditis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link&amp;anchor=H12#H12\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\", section on 'Heart failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9466?source=see_link\">",
"     \"Etiology and diagnosis of heart failure in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Respiratory manifestations of CHF include tachypnea, dyspnea, orthopnea, cough, wheeze, and rales. Other manifestations include poor feeding, tiring with feeds, failure to thrive, pallor, diaphoresis, tachycardia, murmur, gallop, rub, thready pulses, jugular venous distension, cardiomegaly, hepatomegaly,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    edema.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173068\">",
"    <span class=\"h4\">",
"     Pericarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammation of the pericardium from pericarditis may cause chest pain that results in splinting with respiration and if severe, could compromise cardiac output resulting in inadequate oxygenation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical presentation and diagnostic evaluation of acute pericarditis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30842718\">",
"    <span class=\"h4\">",
"     Cardiac arrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tachyarrhythmias and bradyarrhythmias can cause respiratory distress if circulatory function is inadequate to meet tissue demands especially if circulatory compromise results in metabolic acidosis. Supraventricular tachycardia is the most common arrhythmia in children and can cause heart failure with tachypnea as a manifestation. Ventricular tachycardia, atrial fibrillation, atrial flutter, and atrioventricular block are less common and more likely to occur in children with underlying structural heart disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=see_link\">",
"     \"Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=see_link\">",
"     \"Management and evaluation of wide QRS complex tachycardia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30842755\">",
"    <span class=\"h4\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary vasospasm (variant angina) and myocardial infarction are rare causes of respiratory distress and are associated with chest or supraumbilical abdominal pain in children and adolescents. Coronary vasospasm is associated with transient ischemic changes on ECG, normal coronary arteriography, reversible septal akinesia by echocardiography, and cardiac enzyme elevation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link&amp;anchor=H17#H17\">",
"     \"Approach to chest pain in children\", section on 'Cardiac conditions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=see_link\">",
"     \"Variant angina\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Myocardial infarctions occur more frequently in adolescent males and are associated with substance abuse and smoking. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=see_link&amp;anchor=H19#H19\">",
"     \"Approach to chest pain in children\", section on 'Toxic exposure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173115\">",
"    <span class=\"h3\">",
"     Neurologic and muscle diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central nervous system (CNS) disturbances typically cause respiratory compromise as the result of depressed ventilation. Conditions may be congenital (such as CNS malformation, neuromuscular disease, seizures) or acquired (eg, intoxication, CNS infection, seizures, or brain or spinal cord trauma) and may involve the central",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the peripheral nervous system (",
"    <a class=\"graphic graphic_table graphicRef65571 \" href=\"mobipreview.htm?39/19/40254\">",
"     table 5",
"    </a>",
"    ). Children with central causes may have hypo or hyperventilation, decreased gag reflex,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    decreased pharyngeal tone. Associated neurologic findings include focal neurologic deficits, hypo or hypertonia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    altered level of consciousness. Fever, headache,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stiff neck suggest CNS infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of stupor and coma in children\", section on 'Evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute muscle weakness may result in dysfunction of respiratory muscles causing respiratory compromise. Etiologies include conditions that affect the cerebral cortex, spinal cord, anterior horn cell, peripheral nerve, neuromuscular junction, and muscle (",
"    <a class=\"graphic graphic_table graphicRef81649 \" href=\"mobipreview.htm?35/18/36140\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/54/24425?source=see_link\">",
"     \"Etiology and evaluation of the child with muscle weakness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173122\">",
"    <span class=\"h3\">",
"     Gastrointestinal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroesophageal reflux can cause stridor due to irritation of infraglottic structures, or pneumonia due to aspiration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abdominal processes that cause pain (such as appendicitis or intraabdominal injury) or distention (as with a small bowel obstruction) may cause respiratory distress as the result of splinting or interference with excursion of the diaphragm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=see_link&amp;anchor=H6#H6\">",
"     \"Intestinal malrotation\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173129\">",
"    <span class=\"h3\">",
"     Metabolic and endocrine diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachypnea, with or without hyperventilation, may occur as a compensatory mechanism in children with metabolic acidosis from any cause (",
"    <a class=\"graphic graphic_table graphicRef51117 \" href=\"mobipreview.htm?16/52/17229\">",
"     table 7",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the child with metabolic acidosis\", section on 'Clinical evaluation and diagnosis'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Less common metabolic conditions that can cause tachypnea include hyperammonemia (stimulates central hyperventilation), hyperthyroidism (as a result, in part, of increased metabolic rate), and mitochondrial disorders (through interruption of oxygen metabolism). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=see_link&amp;anchor=H6#H6\">",
"     \"Urea cycle disorders: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173144\">",
"    <span class=\"h3\">",
"     Hematologic conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory distress may develop in patients with decreased oxygen delivery to tissues due to acute onset of severe anemia (eg, hemolytic uremic syndrome, autoimmune hemolytic anemia, aplastic crisis) or the presence of a significant amount of abnormal hemoglobin with decreased or absent oxygen-carrying capacity (eg, sickle cell disease, methemoglobinemia, carbon monoxide poisoning). See selected topic reviews.",
"   </p>",
"   <p>",
"    Neonatal polycythemia may cause tachypnea and distress due to compromised oxygen delivery by sludging of blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    acute decompensated heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36968?source=see_link&amp;anchor=H7#H7\">",
"     \"Neonatal polycythemia\", section on 'Cardiorespiratory effects'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13169188\">",
"    <span class=\"h3\">",
"     Acute on chronic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with chronic disease may develop acute respiratory compromise or worsening of a chronic respiratory condition. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children who have chronic causes of upper airway obstruction (such as laryngotracheomalacia, an anatomic abnormality of the airway, or tonsillar hypertrophy) often have worsening obstruction when they develop an acute condition such as an upper respiratory tract infection (",
"      <a class=\"graphic graphic_table graphicRef62718 graphicRef71405 \" href=\"mobipreview.htm?5/6/5230\">",
"       table 8A-B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=see_link\">",
"       \"Assessment of stridor in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=see_link&amp;anchor=H2#H2\">",
"       \"Emergent evaluation of acute upper airway obstruction in children\", section on 'Causes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with chronic pulmonary diseases such as cystic fibrosis or bronchopulmonary dysplasia are at increased risk for bronchopulmonary infections. Patients with asthma are at increased risk for pneumothorax and pneumomediastinum, which is usually asymptomatic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/24/15753?source=see_link&amp;anchor=H13#H13\">",
"       \"Management of bronchopulmonary dysplasia\", section on 'Acute exacerbations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute chest syndrome is a cause of respiratory distress that occurs in children with sickle cell disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=see_link\">",
"       \"The acute chest syndrome in children and adolescents with sickle cell disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with neuromuscular disease may develop upper airway obstruction from poor pharyngeal muscle tone, pneumonia from aspiration, or atelectasis from impaired respiratory effort. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=see_link\">",
"       \"Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13173364\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory compromise may develop in children due to multiple etiologies that result in one of the following final common pathways (",
"      <a class=\"graphic graphic_table graphicRef61637 \" href=\"mobipreview.htm?27/39/28285\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H13169088\">",
"       'Definition'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypoxemia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link&amp;anchor=H12#H12\">",
"       \"Control of ventilation\", section on 'Hypoxic challenge'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hypercarbia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=see_link&amp;anchor=H13#H13\">",
"       \"Control of ventilation\", section on 'Hypercapnic challenge'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Difficulty with the mechanics of respiration, typically from airway obstruction, muscle weakness, or discomfort (as may occur for patients who are splinting due to abdominal pain)",
"     </li>",
"     <li>",
"      Disordered control of ventilation, in which respiration may be depressed (eg, opioid overdose, severe head injury) or stimulated (eg, metabolic acidosis, hyperammonemia, salicylate intoxication)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory distress in response to hypoxemia or hypercarbia can rapidly progress to life-threatening respiratory failure. Neonates, infants, and young children are at particular risk given their high oxygen consumption and decreased respiratory reserve. (See",
"      <a class=\"local\" href=\"#H13169088\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17367?source=see_link\">",
"       \"Emergency airway management in children: Unique pediatric considerations\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Many conditions may cause acute respiratory distress in children (",
"      <a class=\"graphic graphic_table graphicRef61637 \" href=\"mobipreview.htm?27/39/28285\">",
"       table 1",
"      </a>",
"      ). The inciting condition, while commonly within the respiratory system, may also be within other systems, most notably cardiovascular, nervous, gastrointestinal, hematologic, or",
"      <span class=\"nowrap\">",
"       metabolic/endocrine,",
"      </span>",
"      and may not be immediately obvious (eg, fever and rales may be due to heart failure due to myocarditis rather than pneumonia which is more common). (See",
"      <a class=\"local\" href=\"#H13169095\">",
"       'Causes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/1\">",
"      Krauss BS, Harakal T, Fleisher GR. The spectrum and frequency of illness presenting to a pediatric emergency department. Pediatr Emerg Care 1991; 7:67.",
"     </a>",
"    </li>",
"    <li>",
"     Pediatric Advanced Life Support Provider Manual. Ralston M, et al (Eds), American Heart Association, Subcommittee on Pediatric Resuscitation, Dallas, 2006, p.33.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/3\">",
"      Soundappan SV, Holland AJ, Browne G. Sports-related pneumothorax in children. Pediatr Emerg Care 2005; 21:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/4\">",
"      Parasuraman S, Goldhaber SZ. Venous thromboembolism in children. Circulation 2006; 113:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/5\">",
"      Milner D, Losek JD, Schiff J, Sicoli R. Pediatric pericardial tamponade presenting as altered mental status. Pediatr Emerg Care 2003; 19:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/6\">",
"      Cousineau A, Savitsky E. Cardiac tamponade presenting as an apparent life-threatening event. Pediatr Emerg Care 2005; 21:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/7\">",
"      Henretig FM, Cieslak TJ, Kortepeter MG, Fleisher GR. Medical management of the suspected victim of bioterrorism: an algorithmic approach to the undifferentiated patient. Emerg Med Clin North Am 2002; 20:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39113/abstract/8\">",
"      Patt HA, Feigin RD. Diagnosis and management of suspected cases of bioterrorism: a pediatric perspective. Pediatrics 2002; 109:685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16315 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-B3AA2FA6DE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39113=[""].join("\n");
var outline_f38_12_39113=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13173364\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13169081\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13169088\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13169095\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13169102\">",
"      Immediately life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169109\">",
"      - Severe upper airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169123\">",
"      - Tension pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169137\">",
"      - Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18957925\">",
"      - Cardiac tamponade",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169144\">",
"      - Other traumatic conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13375299\">",
"      - Biological or chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13169151\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169159\">",
"      - Respiratory tract conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172505\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172649\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172656\">",
"      Anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172670\">",
"      Foreign body",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172709\">",
"      Airway anomalies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172716\">",
"      Pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172761\">",
"      Chest wall and thoracic cavity abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169166\">",
"      - Cardiovascular conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172909\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13172916\">",
"      Acute decompensated heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13173068\">",
"      Pericarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30842718\">",
"      Cardiac arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H30842755\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13173115\">",
"      - Neurologic and muscle diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13173122\">",
"      - Gastrointestinal conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13173129\">",
"      - Metabolic and endocrine diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13173144\">",
"      - Hematologic conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13169188\">",
"      - Acute on chronic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13173364\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/16315\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16315|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?23/20/23887\" title=\"diagnostic image 1\">",
"      Retropharyngeal abscess plain radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/46/12015\" title=\"diagnostic image 2\">",
"      Retropharyngeal abscess CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/59/42943\" title=\"diagnostic image 3\">",
"      Croup lateral neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/56/2959\" title=\"diagnostic image 4\">",
"      Steeple sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?33/50/34606\" title=\"diagnostic image 5\">",
"      Bacterial tracheitis x-ray",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16315|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?23/19/23857\" title=\"figure 1\">",
"      Flail chest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16315|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/19/32049\" title=\"picture 1\">",
"      Uvulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/55/17264\" title=\"picture 2\">",
"      Bacterial tracheitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/16315|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/39/28285\" title=\"table 1\">",
"      Causes acute respiratory distress in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/44/2763\" title=\"table 2\">",
"      Common lifethreat UAO children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 3\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/6/18540\" title=\"table 4\">",
"      Causes central cyanosis newborn",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/19/40254\" title=\"table 5\">",
"      Causes of coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/18/36140\" title=\"table 6\">",
"      Muscle weakness child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/52/17229\" title=\"table 7\">",
"      Pediatric causes metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/12/2253\" title=\"table 8A\">",
"      Congenital anomalies associated with stridor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/49/38684\" title=\"table 8B\">",
"      Causes of stridor other than congenital anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33034?source=related_link\">",
"      Acute asthma exacerbations in children: Outpatient management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27241?source=related_link\">",
"      Approach to chest pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/11/6330?source=related_link\">",
"      Approach to the child with metabolic acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/61/21464?source=related_link\">",
"      Assessment of stridor in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32536?source=related_link\">",
"      Bacterial tracheitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/22/29030?source=related_link\">",
"      Basic airway management in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/44/16074?source=related_link\">",
"      Bronchiolitis in infants and children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/56/20359?source=related_link\">",
"      Cardiac causes of cyanosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/20/8521?source=related_link\">",
"      Chemical terrorism: Diagnosis and treatment of exposure to chemical weapons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/32/12807?source=related_link\">",
"      Chest wall injuries in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/16/21768?source=related_link\">",
"      Clinical features and diagnosis of meconium aspiration syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10649?source=related_link\">",
"      Clinical features and treatment of uvulitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/32/43529?source=related_link\">",
"      Clinical features, evaluation, and diagnosis of croup",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/41/41625?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34647?source=related_link\">",
"      Clinical manifestations and diagnosis of myocarditis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/47/37625?source=related_link\">",
"      Clinical presentation and diagnostic evaluation of acute pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/11/26809?source=related_link\">",
"      Drowning (submersion injuries)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/61/17367?source=related_link\">",
"      Emergency airway management in children: Unique pediatric considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/5/44119?source=related_link\">",
"      Emergency pericardiocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/61/7130?source=related_link\">",
"      Emergent evaluation of acute respiratory compromise in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/61/10201?source=related_link\">",
"      Emergent evaluation of acute upper airway obstruction in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/34/9770?source=related_link\">",
"      Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/45/4826?source=related_link\">",
"      Epiglottitis (supraglottitis): Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9466?source=related_link\">",
"      Etiology and diagnosis of heart failure in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/54/24425?source=related_link\">",
"      Etiology and evaluation of the child with muscle weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/7/32889?source=related_link\">",
"      Evaluation of cervical spine injuries in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28136?source=related_link\">",
"      Evaluation of stupor and coma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/22/1386?source=related_link\">",
"      Foreign bodies of the esophagus and gastrointestinal tract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/19/22838?source=related_link\">",
"      Imaging of pneumothorax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/51/22327?source=related_link\">",
"      Initial assessment and stabilization of children with respiratory or circulatory compromise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/48/20232?source=related_link\">",
"      Intestinal malrotation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22152?source=related_link\">",
"      Management and evaluation of wide QRS complex tachycardia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36968?source=related_link\">",
"      Neonatal polycythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25271?source=related_link\">",
"      Neurogenic pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31511?source=related_link\">",
"      Overview of neonatal respiratory distress: Disorders of transition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25033?source=related_link\">",
"      Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/4/12360?source=related_link\">",
"      Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/12/1226?source=related_link\">",
"      Placement and management of thoracostomy tubes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/38/29285?source=related_link\">",
"      Pulmonary contusion in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11158?source=related_link\">",
"      Pulsus paradoxus in pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/29/24026?source=related_link\">",
"      Rapid sequence intubation (RSI) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/20/35142?source=related_link\">",
"      Respiratory muscle weakness due to neuromuscular disease: Clinical manifestations and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43992?source=related_link\">",
"      Retropharyngeal infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/41/19098?source=related_link\">",
"      Salicylate poisoning in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/16/22790?source=related_link\">",
"      Smoke inhalation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40793?source=related_link\">",
"      Spontaneous pneumothorax in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/54/31593?source=related_link\">",
"      Supraventricular tachycardia in children: AV reentrant tachycardia (including WPW) and AV nodal reentrant tachycardia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/26/16810?source=related_link\">",
"      The acute chest syndrome in children and adolescents with sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20248?source=related_link\">",
"      Urea cycle disorders: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3706?source=related_link\">",
"      Variant angina",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_12_39114="Chemotherapy for advanced exocrine pancreatic cancer";
var content_f38_12_39114=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chemotherapy for advanced exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/12/39114/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/12/39114/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 45,000 people develop exocrine pancreatic cancer each year in the United States, and because of its aggressive character and the fact that most patients present with relatively advanced disease, most die from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection offers the only chance of cure. However, only 15 to 20 percent of patients have resectable disease at initial diagnosis; the majority have either locally advanced or metastatic cancer. Median survival is 8 to 12 months for patients with locally advanced unresectable disease and only three to six months for those who present with metastases.",
"   </p>",
"   <p>",
"    The use of chemotherapy in the treatment of metastatic pancreatic adenocarcinoma will be reviewed here. Multimodality management for locally advanced disease, specific methods for symptom palliation, and management of patients with metastatic islet cell (endocrine) tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=see_link\">",
"     \"Management of locally advanced and borderline resectable exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT ENDPOINTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional two-dimensional or unidimensional tumor measurements to determine objective response to therapy are often inadequate when evaluating the primary site in the pancreas due to the characteristic desmoplastic reaction and inflammatory response that develops there [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/2\">",
"     2",
"    </a>",
"    ]. Despite this, single agent chemotherapy trials in pancreatic cancer have commonly used objective response as a primary endpoint. This endpoint is likely more accurate for assessment of liver and other metastatic disease sites than it is for assessing the primary tumor.",
"   </p>",
"   <p>",
"    Many trials have permitted patients with both locally advanced and metastatic disease to enroll, perhaps leading to an underestimation of response rates. More recent trials have included quality of life (QOL) endpoints, since so many patients with pancreatic cancer present with pain and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. In addition, increasing emphasis has been placed upon \"clinical benefit\" and survival as more accurate determinants of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical benefit response rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase III study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    to 5-FU suggested that patients who lacked an objective response to treatment often had improvement in symptoms (ie, pain, weight loss) and performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/8\">",
"     8",
"    </a>",
"    ]. The percentage of patients who derived clinical benefit from therapy was almost three-fold higher than the fraction that had an objective antitumor response (11 versus 27 percent). This study led to the approval of single agent gemcitabine for the treatment of metastatic pancreatic cancer and changed the paradigm used to assess efficacy by defining symptom control as a beneficial endpoint for evaluating treatments in this disease. These data are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Gemcitabine'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     CA 19-9 level",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many studies of patients receiving chemotherapy for advanced disease, there has been a correlation between the duration of patient survival and decline in CA 19-9 levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/9-14\">",
"     9-14",
"    </a>",
"    ]. The magnitude of marker reduction that best predicts improved outcomes (any reduction, &gt;50 percent reduction, 89 versus &gt;50 percent reduction) is not clear.",
"   </p>",
"   <p>",
"    However, whether decreases in serum CA19-9 can act as a reliable surrogate for survival in patients receiving chemotherapy for advanced pancreatic cancer has been called into question by others. As an example, in a series of 175 patients who were assessable for tumor marker response during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , an early 50 percent or greater decrease in CA 19-9 levels after the first eight weeks of therapy was not associated with a significant prolongation of survival compared to lesser degrees of CA19-9 response (median 10.1 versus 8.6 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short time frame of CA 19-9 assessment (after eight weeks of therapy) may have contributed to these negative results. Among patients who enter complete remission from chemotherapy, tumor marker normalization is a gradual process, with an estimated half-life of 15 to 33 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 expert panel on tumor markers in gastrointestinal cancer convened by the American Society of Clinical Oncology (ASCO) concluded that the data are insufficient to recommend the use of serum CA 19-9 levels alone for monitoring response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/16\">",
"     16",
"    </a>",
"    ]. The panel recommended that CA 19-9 levels be measured at the start of treatment and then every one to three months during therapy for advanced pancreatic cancer. Suspected disease progression based upon rising CA 19-9 levels should be confirmed radiographically.",
"   </p>",
"   <p>",
"    CA 19-9 requires the presence of the Lewis blood group antigen (a glycosyl transferase) to be expressed. Among individuals with a Lewis-negative phenotype (an estimated 5 to 10 percent of the population), CA 19-9 levels are not a useful tumor marker.",
"   </p>",
"   <p>",
"    The impact of chemotherapy on survival is discussed below. (See",
"    <a class=\"local\" href=\"#H16\">",
"     '5-FU combination therapy versus supportive care'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SINGLE AGENT CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent therapy has been the mainstay of treatment for metastatic pancreatic cancer. However, among active single agents, none has been consistently associated with objective response rates above 10 percent, or median survival durations above 6 to 7 months.",
"   </p>",
"   <p>",
"    The reason for the relative refractoriness of pancreatic cancer to cytotoxic chemotherapy is unclear. According to one hypothesis, inactivating mutations that inhibit p16 protein function, which are present in over 90 percent of pancreatic cancers, release transcriptional inhibition of the retinoblastoma (RB) tumor suppressor gene; this overexpression of RB may then permit tumor cells to evade chemotherapy-induced apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=see_link&amp;anchor=H4#H4\">",
"     \"Molecular pathogenesis of exocrine pancreatic cancer\", section on 'Tumor suppressor genes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fluorouracil",
"    </span>",
"    &nbsp;&mdash;&nbsp;5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU) has been extensively studied since the 1950s, and objective response rates vary widely from 0 to 67 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/18\">",
"     18",
"    </a>",
"    ]. However, contemporary studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (LV)-modulated 5-FU in patients with advanced disease suggest a very low response rate (0 to 9 percent) using infusional as well as bolus administration schedules and a median survival that ranges from 2.5 to 6 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     Capecitabine",
"    </a>",
"    is a rationally designed oral fluoropyrimidine that is reliably absorbed intact through the intestinal wall and then converted to 5-FU in three sequential enzymatic reactions. The final requisite enzyme, thymidine phosphorylase, is present at consistently higher levels in tumor rather than normal tissue, thereby providing the basis for enhanced selectivity and better tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    monotherapy (1250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    orally twice daily for 14 of every 21 days) was shown in a study of 42 patients with chemotherapy-naive advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/23\">",
"     23",
"    </a>",
"    ]. Although only three patients (7 percent) had an objective response, the clinical benefit response rate was 24 percent. Treatment was well tolerated with grade 3 hand-foot syndrome (also called acral erythema or palmar-plantar erythrodysesthesia), nausea, and diarrhea in 17, 10, and 12 percent, respectively. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preliminary data suggest a greater degree of antitumor activity in regimens combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    &nbsp;(see",
"    <a class=\"local\" href=\"#H19\">",
"     'Gemcitabine combinations'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    is a nucleoside analog with structural similarity to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . Initial studies suggested a low objective response rate (6 to 11 percent) in chemotherapy-naive patients administered single agent gemcitabine (800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV weekly for three of every four weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, as discussed above, clinical benefit has been observed in patients who lack an objective response. In a pivotal phase II study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef60330 \" href=\"mobipreview.htm?35/56/36749\">",
"     table 1",
"    </a>",
"    ), \"clinical benefit\" was defined as an improvement in pain, performance status or weight without a deterioration in any other factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/8\">",
"     8",
"    </a>",
"    ]. Although the objective response rate for patients with measurable disease was only 11 percent, a clinical benefit was observed in 27 percent. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical benefit response rate'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon these data, clinical benefit and survival were used as the primary end points in a follow-up trial that included 126 previously untreated patients with locally advanced or metastatic pancreatic cancer who were randomly assigned to 5-FU (600",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (using the same regimen as was tested in the phase II trial) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there were no confirmed objective responses in either group,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was associated with significantly better clinical response (24 versus 5 percent), median overall survival (5.6 versus 4.4 months)one-year survival (18 versus 2 percent), although grade 3 or 4 neutropenia was more frequent (23 versus 5 percent). This study was criticized for its failure to use a prospectively validated QOL instrument and the failure to blind treatment assignment to those assessing \"clinical benefit.\" In fact, a later analysis of patients enrolled in a randomized trial of gemcitabine with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    concluded that response to gemcitabine treatment in advanced pancreatic cancer was not associated with an appreciable improvement in health-related QOL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, on the basis of significant improvements in \"clinical benefit\" and survival,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was approved for first-line therapy of metastatic pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Fixed-dose rate infusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that increasing the dose intensity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    above 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week when administered as a 30-minute infusion improves antitumor activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/28\">",
"     28",
"    </a>",
"    ]. However, longer infusion times appear to have a pharmacokinetic advantage. Intracellular activation of gemcitabine to gemcitabine triphosphate (the active metabolite) by deoxycytidine kinase is saturated at infusion rates of approximately 10",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per minute [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. With the use of this \"fixed-dose rate infusion\" (ie, administration at a fixed rate per minute over a prolonged period of time) the maximum tolerated dose (MTD) is much higher (4800",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    infused over 480 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for this approach was suggested in a randomized phase II study in which 67 patients with advanced disease were assigned to dose-intense",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    at a fixed dose rate (1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 150 minutes) or 2200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over a standard 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/33\">",
"     33",
"    </a>",
"    ]. The fixed dose rate infusion was associated with a significant increase in the level of intracellular gemcitabine triphosphate within peripheral blood mononuclear cells (398 versus 188 mm), and significantly better median (8 versus 5 months) and one-year survival (29 versus 2 percent).",
"   </p>",
"   <p>",
"    Unfortunately, a benefit for the fixed-dose rate infusion regimen could not be confirmed in a United States Intergroup study in which 832 patients with advanced pancreatic cancer were randomly assigned to standard-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 30 minutes weekly for seven of the first eight weeks, then for three of every four weeks) or fixed-dose rate gemcitabine (1500",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 150 minutes weekly for three of every four weeks); a third arm was combined fixed-dose rate gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to standard",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone, there was no significant difference in response rates with the fixed-dose rate regimen (10 versus 5 percent, respectively), and there was only a trend toward improvement in median survival (6.2 versus 4.9 months, hazard ratio 0.83, p = 0.05). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Gemcitabine combinations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It has been suggested that significant variability in intracellular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    triphosphate accumulation between and within individuals might provide some explanation for these negative results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/35\">",
"     35",
"    </a>",
"    ]. Regardless, dose-rate infusion schedules have not been shown to offer a significant survival benefit, and they are associated with increased toxicity. Therefore, their use cannot be recommended over standard methods of gemcitabine administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anthracyclines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthracyclines have limited activity in advanced pancreatic cancer. In a Gastrointestinal Tumor Study Group (GITSG) study, 2 of 15 chemotherapy-naive patients had an objective response, compared to 0 of 10 with previously treated disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/36\">",
"     36",
"    </a>",
"    ]. An EORTC study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    in 41 patients with advanced disease showed an objective response rate of 24 percent, but median survival was only three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Streptozocin and ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     Streptozocin",
"    </a>",
"    has limited activity in pancreatic ductal adenocarcinoma. In a series of early studies, only 3 of 27 patients (11 percent) had an objective response to single agent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/18\">",
"     18",
"    </a>",
"    ]. Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    also has limited activity; in two phase II studies, the objective response rate was only 7 and 10 percent, and median survival was only three months or less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/38,39\">",
"     38,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Taxanes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taxanes are of limited benefit as monotherapy in advanced pancreatic cancer. In one phase II study, in which 33 patients with advanced pancreatic cancer received single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    with granulocyte colony stimulating factor support, the objective response rate was only 6 percent, but a disease-stabilizing effect was suggested because the one-year survival was 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/40\">",
"     40",
"    </a>",
"    ]. In a second report of 40 patients with advanced disease who received docetaxel alone (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks), the objective response rate was 15 percent while stable disease was observed in an additional 38 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/41\">",
"     41",
"    </a>",
"    ]. Others have reported little to no benefit from single agent docetaxel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    was studied in 39 patients with pancreatic cancer; the objective response rate was 8 percent and the median survival five months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/44\">",
"     44",
"    </a>",
"    ]. Combinations of taxanes with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    may be more active. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Gemcitabine plus a taxane'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Camptothecins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Camptothecins such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    have limited activity in advanced pancreatic cancer, with objective response rates of 0 to 29 percent and median survival duration of 4 to 6.5 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/45-47\">",
"     45-47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     COMBINATION CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With few exceptions, multiagent regimens are associated with higher response rates, but no clear survival benefit in patients with advanced pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Older 5-FU-based combination regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite higher objective response rates in some studies, randomized trials do not support a survival benefit for 5-FU-based combination regimens compared to 5-FU alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/26,48-57\">",
"     26,48-57",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial in which 385 patients were randomly assigned to single agent 5-FU, 5-FU plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , or 5-FU, doxorubicin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (FAM), there was no difference in either response rate or median survival among the regimens; the median survival for all patients was 5.5 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/50\">",
"       50",
"      </a>",
"      ] .",
"     </li>",
"     <li>",
"      Similar results were noted in a second trial, in which 187 patients with advanced pancreatic cancer were randomly assigned to single agent 5-FU, or 5-FU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , or 5-FU,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/51\">",
"       51",
"      </a>",
"      ]. Again, neither combination regimen offered a survival advantage over 5-FU alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     5-FU combination therapy versus supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the relatively low objective response rates typically associated with chemotherapy for advanced pancreatic cancer and the paucity of trials that demonstrate a clear survival benefit, it is reasonable to ask if chemotherapy impacts on survival. In this regard, several trials and two meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/58,59\">",
"     58,59",
"    </a>",
"    ] have compared older 5-FU-based combination chemotherapy regimens with supportive care alone. In the Cochrane meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/59\">",
"     59",
"    </a>",
"    ], which included eight prospective randomized trials of chemotherapy versus supportive care alone for advanced pancreatic cancer conducted between 1974 and 2001 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/48,49,52,60-64\">",
"     48,49,52,60-64",
"    </a>",
"    ], chemotherapy significantly improved one-year survival (58 versus 0 percent, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     5-FU plus irinotecan and/or oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer regimens that combine LV-modulated 5-FU with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (agents that are highly active for metastatic colorectal cancer) show promise for advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84834598\">",
"    <span class=\"h3\">",
"     FOLFIRINOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superiority of short-term infusional 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (FOLFIRINOX) over",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    monotherapy was initially suggested in a randomized phase II study conducted in 176 patients with previously untreated metastatic pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/68\">",
"     68",
"    </a>",
"    ]. FOLFIRINOX was associated with a high objective response rate (39 versus 11 percent with gemcitabine alone) and manageable toxicity.",
"   </p>",
"   <p>",
"    The study was expanded to a phase III trial (the ACCORD 11 trial) in which a total of 342 patients with chemotherapy-na&iuml;ve, metastatic pancreatic cancer, a performance status 0 or 1 (",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    ) and a serum bilirubin &lt;1.5 times the upper limit of normal (ULN) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for seven weeks, one week rest, then weekly times three every four weeks) versus FOLFIRINOX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/69\">",
"     69",
"    </a>",
"    ]. The FOLFIRINOX regimen is outlined in the table (",
"    <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"     \"Treatment protocols for pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trial was stopped after enrolling only 250 patients when a preplanned interim analysis demonstrated that the primary trial endpoint (improved overall survival) had been met. The objective response rate was significantly higher with FOLFIRINOX (32 versus 9 percent) as was median PFS (6.4 versus 3.3 months) and overall survival (11.1 versus 6.8 months).",
"   </p>",
"   <p>",
"    Treatment-related toxicity was also significantly worse with FOLFIRINOX, including grade 3 or 4 neutropenia (46 versus 21 percent), febrile neutropenia (5.4 versus 1.2 percent), thrombocytopenia (9.1 versus 3.6 percent), sensory neuropathy (9 versus 0 percent), vomiting (15 versus 8 percent), fatigue (23 versus 18 percent) and diarrhea (13 versus 2 percent). However, despite greater toxicity as compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone, FOLFIRINOX significantly improved global health status compared to gemcitabine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/70\">",
"     70",
"    </a>",
"    ]. In addition, the time to deterioration in quality of life by &ge;20 points was significantly longer for FOLFIRINOX compared to gemcitabine for global health status, physical, role, social and cognitive functioning, and six symptom domains (fatigue,",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    pain, dyspnea, anorexia, and constipation).",
"   </p>",
"   <p>",
"    There was no information on rates of infection, including cholangitis complicating treatment. However, only about one-third of enrolled patients had tumors in the head of the pancreas, and thus, the number of patients who had biliary stents in place was limited compared to other populations in which pancreatic head lesions predominate.",
"   </p>",
"   <p>",
"    The contribution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    to the efficacy of the FOLFIRINOX regimen is unclear. Similar response rates have been reported in a phase II study of 30 patients with locally advanced or metastatic pancreatic cancer who were treated with short-term infusional",
"    <span class=\"nowrap\">",
"     5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (FOLFOX6, (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/66\">",
"     66",
"    </a>",
"    ]. There were eight partial responses (27 percent), but the median progression-free and overall survival durations were only 4 and 7.5 months, respectively.",
"   </p>",
"   <p>",
"    Nevertheless, these data establish FOLFIRINOX as the preferred regimen for patients with metastatic pancreatic cancer who have good performance status, and a normal serum bilirubin level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Gemcitabine combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    has been combined with many other active cytotoxic agents including 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    . The combination of gemcitabine with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Approaches targeting the EGFR'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Gemcitabine plus 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    has been combined with both bolus as well as infusional 5-FU. Although promising results have been suggested in phase II trials, at least three phase III trials comparing gemcitabine plus 5-FU with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    modulation have failed to demonstrate any advantage over gemcitabine alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/71-73\">",
"     71-73",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Gemcitabine plus capecitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early uncontrolled trials suggested a greater degree of efficacy when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    was combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    . [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Benefit for combined therapy could not be confirmed in two subsequent multinational phase III trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial in which 319 patients with locally advanced or metastatic pancreatic cancer were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with or without oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      , median survival was not significantly improved by the addition of capecitabine (8.4 versus 7.3 months) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second European trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      alone versus gemcitabine (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three of every four weeks) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (830",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily for 21 days of every 28 day cycle) in 533 patients with locally advanced or metastatic pancreatic cancer showed a significantly higher response rate (19 versus 12 percent) but no significant overall survival benefit from the addition of capecitabine (median overall survival 7.1 versus 6.2 months; p = 0.08) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/77\">",
"       77",
"      </a>",
"      ]. Combination therapy resulted in more grade 3 or 4 neutropenia (35 versus 22 percent) but not febrile neutropenia, and there was more hand foot syndrome as well, but only 4 percent had grade 3 or 4.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These same investigators performed a meta-analysis of the two phase III trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/76,77\">",
"     76,77",
"    </a>",
"    ] and a third randomized phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/75\">",
"     75",
"    </a>",
"    ]. When all three trials were analyzed together there was a statistically significant survival benefit favoring combined therapy with capecitabine plus gemcitabine (hazard ratio 0.86, 95% CI 0.75 to 0.98). Despite the fact that the schedules and dose intensities of gemcitabine and capecitabine in the three trials were completely different, there appeared to be no intertrial heterogeneity. The authors concluded that the combination of gemcitabine plus capecitabine should be considered a standard first-line option for locally advanced and metastatic pancreatic cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Gemcitabine plus cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preclinical studies, combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    are synergistic. Gemcitabine enhances the formation of cisplatin-DNA adducts, an effect that may be due to suppression of nuclear excision repair (a mechanism of cisplatin resistance) by gemcitabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Moreover, cisplatin may augment the incorporation of gemcitabine triphosphate into DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least three phase III trials have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone to the combination of gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/80-82\">",
"     80-82",
"    </a>",
"    ], none of which suggests a significant survival advantage for this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Gemcitabine plus irinotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     Irinotecan",
"    </a>",
"    monotherapy has minimal clinical activity in patients with advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/45\">",
"     45",
"    </a>",
"    ]. Not surprisingly, combined therapy did not outperform",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone in two phase III trials, only one of which has been reported in final form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Gemcitabine plus a taxane",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase II studies combining",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    have shown encouraging response rates with good tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/85-90\">",
"     85-90",
"    </a>",
"    ]. An exception was one series in which only one partial response was noted in 18 patients receiving gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    days 1 and 8) plus docetaxel (70",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    once every three weeks), and grade 3 fatigue complicated therapy in over one-half of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/91\">",
"     91",
"    </a>",
"    ]. A phase III trial has not yet been completed.",
"   </p>",
"   <p>",
"    Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    in combination with nanoparticle albumin bound (nab)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    was suggested in a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study conducted in 67 patients with previously untreated metastatic pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/92\">",
"     92",
"    </a>",
"    ]. Among the 44 patients treated at the maximally tolerated dose (gemcitabine 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    followed by nab paclitaxel 125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1, 8, and 15 of every 28 day cycle), the response rate was 48 percent, and median survival was 12.2 months. At this dose, grade 3 or 4 toxicities included fatigue in 27 percent, neuropathy in 20 percent, and neutropenia in 49 percent.",
"   </p>",
"   <p>",
"    This combination of nab",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (125",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    each given on days 1, 8, and 15 every 28 days) was directly compared to gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for seven week, the on days 1, 8, and 15 every four weeks) in 861 patients with previously untreated metastatic pancreatic adenocarcinoma in the multinational MPACT trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/93\">",
"     93",
"    </a>",
"    ]. In a preliminary report presented at the 2013 ASCO GI Cancers Symposium, combined therapy was associated with significantly higher objective response rate (23 versus 7 percent), and significantly longer median overall (8.5 versus 6.7 months) and progression-free survival (5.5 versus 3.7 months). Grade 3 or 4 adverse events that were seen more often with combined therapy included neutropenia (38 versus 27 percent), febrile neutropenia (3 versus 1 percent), fatigue (17 versus 7 percent), and neuropathy (17 versus 1 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Gemcitabine plus 5-FU, cisplatin and epirubicin (PEFG)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the most impressive activity in uncontrolled trials has been noted with the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/27/4536?source=see_link\">",
"     epirubicin",
"    </a>",
"    (PEFG) administered every 28 days. In one study of 49 patients with metastatic pancreatic cancer, the objective response rate was 58 percent, clinical benefit was noted in 78 percent, the median TTP was 7.5 months, and survival was 11 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/94\">",
"     94",
"    </a>",
"    ]. Grade 3 to 4 neutropenia complicated one-half of all delivered cycles, but nonhematologic toxicity, particularly gastrointestinal toxicity, was infrequent.",
"   </p>",
"   <p>",
"    The PEFG regimen was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for seven of eight weeks, then three of every four weeks) in 104 patients with advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/95\">",
"     95",
"    </a>",
"    ]. With a median follow-up of 33 months, PEFG was associated with a significantly higher response rate (39 versus 9 percent) and four month PFS (the primary endpoint, 60 versus 28 percent). Although the difference in one-year survival (39 versus 21 percent) did not reach the level of statistical significance, it was significant at two years (12 versus 2 percent), and the hazard ratio for death overall was 0.65 (95% CI 0.43 to 0.99, p = 0.047). Combination therapy was associated with a significantly higher rate of grade 3 or 4 neutropenia (43 versus 14 percent) and thrombocytopenia (30 versus 1 percent); however, only 1 percent of treatment cycles were complicated by febrile neutropenia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Gemcitabine plus oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    is a platinum derivative that is approved in the United States for the treatment of advanced colorectal cancer. The combination of oxaliplatin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    appeared active and well tolerated in uncontrolled series of patients with advanced pancreatic adenocarcinoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of GEMOX (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1 over 100 minutes plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over two hours on day 2, both administered every two weeks) was compared to gemcitabine alone in two different multicenter trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a trial of 326 patients with either locally advanced or metastatic pancreatic cancer (the",
"      <span class=\"nowrap\">",
"       GERCOR/GISCAD",
"      </span>",
"      Intergroup study), GEMOX was associated with significantly higher response rates (27 versus 17 percent) and significantly longer median PFS (5.8 versus 3.7 months) but only a trend towards improved median survival (9 versus 7.1 months, p = 0.13) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, a benefit for GEMOX could not be shown in the previously described United States Intergroup trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      alone (either as a standard 30-minute infusion or a fixed-dose rate infusion) versus the same GEMOX regimen tested in the",
"      <span class=\"nowrap\">",
"       GERCOR/GISCAD",
"      </span>",
"      study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/34\">",
"       34",
"      </a>",
"      ]. Of the 832 patients enrolled with advanced pancreatic cancer, 90 percent had metastatic disease, while the remainder had locally advanced disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Fixed-dose rate infusions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no significant advantages for GEMOX in terms of objective response rate (9 versus 10 and 6 percent for GEMOX, fixed-dose rate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    and standard gemcitabine, respectively), stable disease rate (36 percent overall), progression-free survival, or overall survival (5.7, 6.2, and 4.9 months, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Meta-analyses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two meta-analyses have come to the conclusion that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based combined therapy is associated with a modest but significant survival advantage relative to single agent therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/58,98\">",
"     58,98",
"    </a>",
"    ]. In both analyses (conducted by two different groups), the hazard ratio for death with combined therapy was identical (HR 0.91, 95% CI 0.85 to 0.97).",
"   </p>",
"   <p>",
"    As noted above, a third meta-analysis that focused on three trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , also concluded that there was a statistically significant benefit from the addition of capecitabine to gemcitabine (HR 0.86, 95% CI 0.75 to 0.98) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/77\">",
"     77",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Gemcitabine plus capecitabine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the large number of randomized trials that have been conducted, very few have demonstrated a benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    combination therapy compared to gemcitabine alone; superiority for combined therapy is best documented for nanoparticle bound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (nab-paclitaxel) plus gemcitabine.",
"   </p>",
"   <p>",
"    However, it is difficult to conclude, based upon the available data, that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus nab-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    represents the new reference standard for first-line treatment of advanced pancreatic cancer, given the results of the ACCORD-11 trial documenting the superiority of FOLFIRINOX over gemcitabine alone. (See",
"    <a class=\"local\" href=\"#H84834598\">",
"     'FOLFIRINOX'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    The only way to know the relative efficacy and toxicity of FOLFIRINOX and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus nab-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is a randomized trial, which will be forthcoming. Until then, in our view, gemcitabine plus nab-paclitaxel represents an acceptable option for first-line therapy, but we prefer FOLFIRINOX for patients who are able to tolerate this intensive regimen. Although the limitations of cross-trial comparisons are well known, the control group in both the ACCORD-11 and MPACT trials was identical, and the response rates with gemcitabine alone were similar (11 and 7 percent) as were median survival durations (6.8 and 6.7 months). The median survival with FOLFIRINOX in the ACCORD-11 trial was 11.1 months, while for gemcitabine plus nab-paclitaxel in the MPACT trial, it was 8.5 months. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;New systemic therapies are being designed based upon the biologic properties of pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/99\">",
"     99",
"    </a>",
"    ]. The ras oncogene and the proteins encoded by this gene have been the subject of considerable research over the last 10 years. Ras proteins are membrane-bound GTP-binding proteins that act as molecular switches in mitogenic signal transduction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/100\">",
"     100",
"    </a>",
"    ]. Mutations of the ras gene, present in approximately 90 percent of pancreatic cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/101,102\">",
"     101,102",
"    </a>",
"    ], lead to constitutive activation of these proteins. Several therapeutic strategies targeting ras mutations are under study, including vaccines and antisense molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/103,104\">",
"     103,104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ras proteins require a post-translational addition of a 15-carbon farnesyl group in order to become attached to the cellular membrane. If the addition of this farnesyl group is blocked, such as with peptidomimetic analogs, the protein cannot attach to the cell membrane and it remains inactive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/105\">",
"     105",
"    </a>",
"    ]. In preclinical studies, benzodiazepine peptidomimetics can restore a normal growth pattern to ras-transformed cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/106\">",
"     106",
"    </a>",
"    ]. Unfortunately, preliminary reports of completed phase II and III studies of farnesyltransferase inhibitors have been disappointing in patients with pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/107-109\">",
"     107-109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Approaches targeting the EGFR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancers often express receptors for epidermal growth factor (EGF) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/110\">",
"     110",
"    </a>",
"    ]. Ongoing studies are incorporating small molecule tyrosine kinase inhibitors of the EGF receptor (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ) as well as monoclonal antibodies directed against this molecule (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A phase III trial from the National Cancer Institute of Canada (NCIC) directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly) with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (100 mg daily) in 569 patients with locally advanced or metastatic pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/111\">",
"     111",
"    </a>",
"    ]. Combined therapy was associated with few objective responses, but overall survival was significantly better compared to gemcitabine alone (hazard ratio 0.81, p = 0.038, median 6.2 versus 5.9 months, one-year survival 23 versus 17 percent, respectively).",
"   </p>",
"   <p>",
"    Although the gain in survival was statistically significant, it is unclear whether the modest, two-week improvement in survival is clinically meaningful. Furthermore the cost per life-year gained is significantly higher than is usually accepted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=see_link\">",
"     \"A short primer on cost-effectiveness analysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nevertheless,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    is approved for use in the United States in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    for the treatment of locally advanced, unresectable, or metastatic pancreatic cancer.",
"   </p>",
"   <p>",
"    Others have attempted to improve upon these results by the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting the vascular endothelial growth factor (VEGF), to the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"      gemcitabine",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"      erlotinib",
"     </a>",
"    </span>",
"    backbone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Approaches targeting angiogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Promising results from a phase II study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , a monoclonal antibody directed against the EGFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/115\">",
"     115",
"    </a>",
"    ], led to a multi-institutional phase III trial, which randomly assigned 745 patients with advanced pancreatic cancer to gemcitabine alone or with cetuximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/116\">",
"     116",
"    </a>",
"    ]. The addition of cetuximab did not significantly improve objective response rate (12 versus 14 percent), progression-free survival (3.4 versus 3 months), overall survival (median 6.3 versus 5.9 months). &nbsp;",
"   </p>",
"   <p>",
"    A randomized phase II study also failed to demonstrate benefit for the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Approaches targeting angiogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancers also frequently overexpress vascular endothelial growth factor (VEGF) and its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/118\">",
"     118",
"    </a>",
"    ]. Although phase II data were promising [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/119\">",
"     119",
"    </a>",
"    ], a phase III trial conducted by the Cancer and Leukemia Group B concluded that there was no benefit for the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    versus gemcitabine alone in 602 patients with advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    resulted in a modest two-week improvement in survival over gemcitabine alone in a phase III trial. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Approaches targeting the EGFR'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Whether additional benefit could be gained by adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    to this doublet was the subject of a phase III trial in which 607 patients with previously untreated metastatic pancreatic cancer were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and either bevacizumab (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other week) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/114\">",
"     114",
"    </a>",
"    ]. The addition of bevacizumab marginally but significantly improved PFS (median 4.6 versus 3.6 months) but not overall survival (median 7.1 versus 6 months, p = 0.21). Toxicity was prominent in both groups.",
"   </p>",
"   <p>",
"    In view of the marginal benefit, toxicity and expense of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , this approach cannot be recommended.",
"   </p>",
"   <p>",
"    Others have failed to demonstrate a benefit for adding",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/13/43222?source=see_link\">",
"     axitinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    (orally active inhibitors of several tyrosine kinases, including VEGF receptors) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/121-123\">",
"     121-123",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     HORMONE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that normal and malignant pancreatic tissues contain estrogen and somatostatin receptors provided the rationale for hormone manipulation in advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Tamoxifen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    as a single agent (usually 10 mg orally twice daily) has minimal activity, with objective response rates less than 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/124-127\">",
"     124-127",
"    </a>",
"    ]. At least three randomized placebo-controlled trials of tamoxifen versus placebo in advanced pancreatic cancer have failed to demonstrate any survival advantage for tamoxifen-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/128-130\">",
"     128-130",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Octreotide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have failed to demonstrate a survival benefit from either standard dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    or combined octreotide plus 5-FU when compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/131-133\">",
"     131-133",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SECOND-LINE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84834721\">",
"    <span class=\"h2\">",
"     Gemcitabine failures",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few randomized trials of second-line therapy for patients who have failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -containing chemotherapy, and there is no widely accepted standard of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/134-148\">",
"     134-148",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Treatment versus supportive care",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit for second-line treatment versus supportive care alone was suggested in a randomized trial in which 46 patients failing first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    were randomly assigned to best supportive care with or without OFF chemotherapy as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/149\">",
"     149",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       Oxaliplatin",
"      </a>",
"      85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 8 and 22",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       Leucovorin",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 30 minutes followed by 5-FU 2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours, with both drugs given on days 1, 8, 15, and 22",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Courses of chemotherapy were repeated every six weeks",
"   </p>",
"   <p>",
"    The trial was stopped prematurely because of insufficient accrual. However, the treated group had a significantly longer median survival from the start of treatment (4.8 versus 2.3 months) and longer median survival from the start of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (9 versus 7.9 months, p=0.031). Additional results with second-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"     /5-FU/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Choice of regimen",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h4\">",
"     Oxaliplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Besides the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    regimen described above, others have shown benefit for oxaliplatin in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/137,142\">",
"     137,142",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/143\">",
"     143",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/138,141\">",
"     138,141",
"    </a>",
"    ] in patients who have failed single agent gemcitabine. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As discussed above, regimens combining",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus 5-FU and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      or oxaliplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      are active in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -refractory disease, and appear to be superior to best supportive care alone, or a fluoropyrimidine alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/102-115,117-119,121,124-135,137-141,144,148,150-156\">",
"       102-115,117-119,121,124-135,137-141,144,148,150-156",
"      </a>",
"      ], as illustrated by the following observations:",
"      <br/>",
"      <br/>",
"      The superiority of oxaliplatin (85",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 8 and 22) plus short-term infusional 5-FU (2000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours and leucovorin 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 30 minutes, both given on days 1, 8, 15, and 22) compared to best supportive care alone was shown in a randomized phase III CONKO-003 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/149\">",
"       149",
"      </a>",
"      ]. Each cycle was 42 days in length. The trial was stopped prematurely after the enrollment of only 46 patients because of low recruitment (best supportive care was not accepted by patients). Despite no confirmed responses better than stable disease, OFF was associated with a significantly longer median overall survival (4.8 versus 2.3 months). Patients receiving oxaliplatin had significantly more neurotoxicity (48 versus 10 percent), but it was mostly grade 1 or 2; otherwise, the regimen was well tolerated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The protocol was modified to include the same schedule of 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    <span class=\"nowrap\">",
"     (FU/LV)",
"    </span>",
"    alone in the control arm rather than BSC. In a preliminary report of this randomized trial in which 168 patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -refractory metastatic pancreatic cancer were randomized , the majority of patients (86 to 89 percent) had metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/144\">",
"     144",
"    </a>",
"    ]. &nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    group had significantly better progression-free survival (median 13 versus 9 weeks) and significantly better median overall survival (the primary endpoint, median 26 versus 13 weeks). There was no significant difference in the rates of grade 3 or 4 hematologic toxicities, although as expected, neurologic side effects were more prominent with OFF.",
"    <br/>",
"    <br/>",
"    Combinations of oxaliplatin with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    are also active. In a phase II trial, 41 patients who failed one prior chemotherapy regimen received oxaliplatin (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks, decreased to 110",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for patients older than the age of 65 and those with a performance status of 2 [(",
"    <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"     table 2",
"    </a>",
"    )]) plus capecitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 of every 21 days, decreased to 750",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for patients older than 65 and those with performance status 2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/143\">",
"     143",
"    </a>",
"    ]. There was one partial response but 22 percent clinical benefit rate; median progression-free survival was 10 weeks. The six- and 12-month survival rates were 44 and 21 percent, respectively.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no prospective trials of FOLFORINOX (",
"      <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"       table 3",
"      </a>",
"      ) in patients treated with first-line",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      . In a retrospective analysis of 27 patients treated with second-line FOLFIRINOX at a single institution over a six-year period, the objective response rate was 19 percent, 12 others had stable disease (44 percent), and the median time to tumor progression was 5.4 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/157\">",
"       157",
"      </a>",
"      ]. Grade 3 or 4 neutropenia developed in 56 percent of patients, but there was only one case of febrile neutropenia. (See",
"      <a class=\"local\" href=\"#H84834598\">",
"       'FOLFIRINOX'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combinations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      are also active. In a preliminary report of 30 patients receiving second-line GEMOX, seven had a partial response, while 52 percent had clinical benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/137\">",
"       137",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 30 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      , three had a partial response (two of whom subsequently underwent resection) and six had clinical benefit; 23 percent were still alive at one year [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h4\">",
"     Other regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;S1, an orally active fluoropyrimidine, is modestly active in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -refractory disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/158\">",
"     158",
"    </a>",
"    ]. It is not available in the US.",
"   </p>",
"   <p>",
"    Modest utility for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 days of every 21 day cycle) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    (150 mg once daily) was suggested in a phase II trial of 32 patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -refractory advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/147\">",
"     147",
"    </a>",
"    ]. Although only three patients (10 percent) achieved a radiologic response, five others had a &ge;50 percent decrease in CA 19-9 level, and median survival was 6.5 months. Grade 3 or 4 toxicities included diarrhea (17 per",
"    <sup>",
"     c",
"    </sup>",
"    ent), rash (13 percent), hand-foot syndrome (13 percent) and stomatitis (10 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     Raltitrexed",
"    </a>",
"    (Tomudex), a folate analog, is a pure thymidylate synthase inhibitor that is available in Canada and elsewhere, but not in the US. Activity for raltitrexed in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    was shown in a randomized phase II trial that compared 21 day cycles of raltitrexed (3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) to 21 day cycles of irinotecan (200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 1) plus raltitrexed (3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    day 2) in 38 patients who failed",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/134\">",
"     134",
"    </a>",
"    ]. Combined therapy was superior in terms of objective response rate (16 versus 0 percent), clinical benefit rate (29 versus 8 percent), PFS (4 versus 2.5 months), and overall survival (6.5 versus 4.3 months).",
"   </p>",
"   <p>",
"    Comparable results were also seen in a single arm trial of 21 day cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/1/21525?source=see_link\">",
"     raltitrexed",
"    </a>",
"    (3",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1) after failure of first-line",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/145\">",
"     145",
"    </a>",
"    ]. Ten of 41 patients (24 percent) had a partial response, and the median survival was 5.2 months.",
"   </p>",
"   <p>",
"    Others have shown modest activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    in combination with short-term infusional 5-FU and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. In two phase II studies totaling 90 patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -refractory advanced pancreatic adenocarcinoma, the partial response rate was 8 and 14 percent, respectively, with disease control rates (objective response plus stable disease) of approximately 35 percent.",
"   </p>",
"   <p>",
"    A regimen containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (G-FLIP) was evaluated in a retrospective study of 34 consecutively-treated patients with chemorefractory metastatic pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/136\">",
"     136",
"    </a>",
"    ]. The objective response rate was high (partial response 24 percent, stable disease in an additional 21 percent) and median survival was 10.3 months. &nbsp;However, hematologic toxicity rates were prominent with grade 3 or 4 neutropenia in 38 percent and thrombocytopenia in 53 percent; nonhematologic toxicity was relatively uncommon. Although these results seem promising, this regimen has not been tested in a prospective trial involving patients with gemcitabine refractory disease. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    has modest activity as a single agent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Second-line weekly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      was studied in 30 patients who failed",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/161\">",
"       161",
"      </a>",
"      ]. The objective response rate was 10 percent, and the overall disease control rate was 47 percent (14 of 30 patients); median survival from the start of paclitaxel was 6.7 months. &nbsp;",
"     </li>",
"     <li>",
"      Nanoparticle albumin-bound",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (Nab-paclitaxel, Abraxane) is also modestly active as a second-line agent. In a phase II trial in which 19 patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -refractory advanced pancreatic cancer received single agent Nab-paclitaxel (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 8, and 15 of each 28-day cycle), one had a partial response, and six had stable disease as the best response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/162\">",
"       162",
"      </a>",
"      ]. The estimated median overall survival was 7.3 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84834736\">",
"    <span class=\"h2\">",
"     Patients failing FOLFIRINOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on second-line chemotherapy in patients failing first-line FOLFIRINOX. (See",
"    <a class=\"local\" href=\"#H84834598\">",
"     'FOLFIRINOX'",
"    </a>",
"    above.) Potential options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone or a single agent taxane.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are refractory to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    monotherapy, a limited amount of data suggest that second-line therapy may affect survival, and it is reasonable to consider further chemotherapy in patients who maintain a good performance status. No regimen has emerged as preferred in this setting. Appropriate choices include a fluoropyrimidine alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    monotherapy. In this setting, guidelines from the National Comprehensive Cancer Network (NCCN) suggest a fluorinated pyrimidine plus oxaliplatin regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/12/39114/abstract/163\">",
"     163",
"    </a>",
"    ]. Whenever possible, patients should be encouraged to enroll on clinical trials testing new strategies.",
"   </p>",
"   <p>",
"    There are no data on second-line therapy after failure of FOLFIRINOX.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    monotherapy is a reasonable option.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=see_link\">",
"       \"Patient information: Pancreatic cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic chemotherapy provides benefit to patients with advanced pancreatic cancer, improving disease-related symptoms and survival when compared to best supportive care alone. (See",
"    <a class=\"local\" href=\"#H16\">",
"     '5-FU combination therapy versus supportive care'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84834843\">",
"    <span class=\"h2\">",
"     First-line therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest FOLFIRINOX (",
"      <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"       table 3",
"      </a>",
"      ) rather than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      or a gemcitabine-based doublet for patients with metastatic pancreatic cancer who have a good ECOG performance status (0 or 1 (",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"mobipreview.htm?9/15/9467\">",
"       table 2",
"      </a>",
"      )) and a serum total bilirubin level that is &lt;1.5 times the upper limit of normal (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H84834598\">",
"       'FOLFIRINOX'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"       \"Treatment protocols for pancreatic cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For patients who are willing to sacrifice some survival benefit for a less toxic regimen, gemcitabine plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      or gemcitabine plus nanoparticle albumin bound (nab)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      represent acceptable alternatives to FOLFIRINOX. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Gemcitabine plus a taxane'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Gemcitabine plus capecitabine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a performance status other than 0 to 1, we suggest monotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gemcitabine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with serum bilirubin &gt;1.5 X ULN despite placement of a stent, we prefer FOLFOX over a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -containing regimen as gemcitabine is hepatically metabolized. (See",
"      <a class=\"local\" href=\"#H17\">",
"       '5-FU plus irinotecan and/or oxaliplatin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      is administered, we suggest not using dose-rate infusion schedules over standard methods of gemcitabine administration (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). They do not offer a significant survival benefit, and they are associated with increased toxicity. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gemcitabine'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H84834850\">",
"    <span class=\"h2\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who retain a good performance status after failing initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    therapy, we suggest second-line therapy rather than best supportive care (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). The optimal regimen is unknown, but an",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"      oxaliplatin",
"     </a>",
"     /fluoropyrimidine",
"    </span>",
"    combination such as FOLFOX (",
"    <a class=\"graphic graphic_table graphicRef50132 \" href=\"mobipreview.htm?16/53/17246\">",
"     table 4",
"    </a>",
"    ) appears to be better than a fluoropyrimidine alone. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Second-line therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"     \"Treatment protocols for pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal management strategy for patients who fail initial FOLFIRINOX is undefined. For patients who retain a good performance status, a reasonable option is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    monotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"     \"Treatment protocols for pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/2\">",
"      Freeny PC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Radiol Clin North Am 1989; 27:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/3\">",
"      Joffe RT, Rubinow DR, Denicoff KD, et al. Depression and carcinoma of the pancreas. Gen Hosp Psychiatry 1986; 8:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/4\">",
"      Holland JC, Korzun AH, Tross S, et al. Comparative psychological disturbance in patients with pancreatic and gastric cancer. Am J Psychiatry 1986; 143:982.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/5\">",
"      Kelsen DP, Portenoy RK, Thaler HT, et al. Pain and depression in patients with newly diagnosed pancreas cancer. J Clin Oncol 1995; 13:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/6\">",
"      Alter CL. Palliative and supportive care of patients with pancreatic cancer. Semin Oncol 1996; 23:229.",
"     </a>",
"    </li>",
"    <li>",
"     Tempero M. Chemotherapy of Pancreatic Cancer, Humana Press, Totowa, NJ 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/8\">",
"      Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/9\">",
"      Halm U, Schumann T, Schiefke I, et al. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/10\">",
"      Ko AH, Hwang J, Venook AP, et al. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Cancer 2005; 93:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/11\">",
"      Heinemann V, Schermuly MM, Stieber P, et al. CA19-9: a pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999; 19:2433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/12\">",
"      Ziske C, Schlie C, Gorschl&uuml;ter M, et al. Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/13\">",
"      Bauer TM, El-Rayes BF, Li X, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer 2013; 119:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/14\">",
"      Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115:2630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/15\">",
"      Hess V, Glimelius B, Grawe P, et al. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol 2008; 9:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/16\">",
"      Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24:5313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/17\">",
"      Plath T, Peters M, Detjen K, et al. Overexpression of pRB in human pancreatic carcinoma cells: function in chemotherapy-induced apoptosis. J Natl Cancer Inst 2002; 94:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/18\">",
"      Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/19\">",
"      Crown J, Casper ES, Botet J, et al. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9:1682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/20\">",
"      DeCaprio JA, Mayer RJ, Gonin R, Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9:2128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/21\">",
"      Van Rijswijk RE, Jeziorski K, Wagener DJ, et al. Weekly high-dose 5-fluorouracil and folinic acid in metastatic pancreatic carcinoma: a phase II study of the EORTC GastroIntestinal Tract Cancer Cooperative Group. Eur J Cancer 2004; 40:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/22\">",
"      Sch&uuml;ller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 2000; 45:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/23\">",
"      Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol 2002; 20:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/24\">",
"      Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/25\">",
"      Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/26\">",
"      Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/27\">",
"      Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 2012; 43:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/28\">",
"      Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol 1997; 15:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/29\">",
"      Grunewald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res 1990; 50:6823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/30\">",
"      Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/31\">",
"      Grunewald R, Kantarjian H, Du M, et al. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol 1992; 10:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/32\">",
"      Touroutoglou N, Gravel D, Raber MN, et al. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 1998; 9:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/33\">",
"      Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003; 21:3402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/34\">",
"      Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2009; 27:3778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/35\">",
"      Grimison P, Galettis P, Manners S, et al. Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation. J Clin Oncol 2007; 25:5704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/36\">",
"      Schein PS, Lavin PT, Moertel CG, et al. Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report. Cancer 1978; 42:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/37\">",
"      Wils J, Bleiberg H, Blijham G, et al. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985; 21:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/38\">",
"      Ajani JA, Abbruzzese JL, Goudeau P, et al. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988; 6:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/39\">",
"      Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Cancer 1989; 64:2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/40\">",
"      Androulakis N, Kourousis C, Dimopoulos MA, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/41\">",
"      Rougier P, Adenis A, Ducreux M, et al. A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur J Cancer 2000; 36:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/42\">",
"      Lenzi R, Yalcin S, Evans DB, Abbruzzese JL. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest 2002; 20:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/43\">",
"      Okada S, Sakata Y, Matsuno S, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in Japan. Br J Cancer 1999; 80:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/44\">",
"      Whitehead RP, Jacobson J, Brown TD, et al. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/45\">",
"      Wagener DJ, Verdonk HE, Dirix LY, et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann Oncol 1995; 6:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/46\">",
"      O'Reilly S, Donehower RC, Rowinsky EK, et al. A phase II trial of topotecan in patients with previously untreated pancreatic cancer. Anticancer Drugs 1996; 7:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/47\">",
"      Stevenson JP, Scher RM, Kosierowski R, et al. Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas. Eur J Cancer 1998; 34:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/48\">",
"      Mallinson CN, Rake MO, Cocking JB, et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/49\">",
"      Frey C, Twomey P, Keehn R, et al. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer 1981; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/50\">",
"      Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985; 253:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/51\">",
"      Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/52\">",
"      Palmer KR, Kerr M, Knowles G, et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/53\">",
"      Di Costanzo F, Tagliaventi M, Carlini P, et al. High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Am J Clin Oncol 1996; 19:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/54\">",
"      Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/55\">",
"      Bukowski RM, Balcerzak SP, O'Bryan RM, et al. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest Oncology Group study. Cancer 1983; 52:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/56\">",
"      Horton J, Gelber RD, Engstrom P, et al. Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat Rep 1981; 65:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/57\">",
"      Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. J Clin Oncol 1986; 4:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/58\">",
"      Sultana A, Smith CT, Cunningham D, et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007; 25:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/59\">",
"      Yip D, Karapetis C, Strickland A, et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; :CD002093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/60\">",
"      Andr&eacute;n-Sandberg A, Holmberg JT, Ihse I. Treatment of unresectable pancreatic carcinoma with 5-fluorouracil, vincristine, and CCNU. Scand J Gastroenterol 1983; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/61\">",
"      Glimelius B, Hoffman K, Sj&ouml;d&eacute;n PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/62\">",
"      Huguier M, Barrier A, Valinas R, et al. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer. Hepatogastroenterology 2001; 48:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/63\">",
"      Takada T, Nimura Y, Katoh H, et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998; 45:2020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/64\">",
"      Andersen JR, Friis-M&ouml;ller A, Hancke S, et al. A controlled trial of combination chemotherapy with 5-FU and BCNU in pancreatic cancer. Scand J Gastroenterol 1981; 16:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/65\">",
"      Conroy T, Paillot B, Fran&ccedil;ois E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study. J Clin Oncol 2005; 23:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/66\">",
"      Ghosn M, Farhat F, Kattan J, et al. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol 2007; 30:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/67\">",
"      Ta&iuml;eb J, Lecomte T, Aparicio T, et al. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 2007; 18:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/68\">",
"      Ychou M, Desseigne F, Guimbaud R, et al. Randomized phase II trial comparing folfirinox (5FU/leucovorin [LV], irinotecan [I] and oxaliplatin [O]) vs gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA). First results of the ACCORD 11 trial (abstract 4516). J Clin Oncol 2007; 25:210s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/69\">",
"      Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/70\">",
"      Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F, et al. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol 2013; 31:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/71\">",
"      Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002; 20:3270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/72\">",
"      Riess H, Helm A, Niedergethmann I, et al. A randomised, multicenter, phase III trial of gemcitabine, 5-fluorouracil, folinic acid versus gemcitabine alone in patients with advanced pancreatic cancer (abstract). J Clin Oncol 2005; 23:310s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/73\">",
"      Di Costanzo F, Carlini P, Doni L, et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer 2005; 93:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/74\">",
"      Hess V, Salzberg M, Borner M, et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial. J Clin Oncol 2003; 21:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/75\">",
"      Scheithauer W, Sch&uuml;ll B, Ulrich-Pur H, et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Ann Oncol 2003; 14:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/76\">",
"      Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 2007; 25:2212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/77\">",
"      Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27:5513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/78\">",
"      Yang LY, Li L, Jiang H, et al. Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair. Clin Cancer Res 2000; 6:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/79\">",
"      van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999; 80:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/80\">",
"      Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24:3946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/81\">",
"      Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010; 28:1645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/82\">",
"      Wang X, Ni Q, Jin M, et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua Zhong Liu Za Zhi 2002; 24:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/83\">",
"      Rocha Lima, CM, Rotche, R, Jeffery, M, et al. A randomized phase 3 study comparing efficacy and safety of gemcitabine and irinotecan to gemcitabine alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy (abstract). Proc Am Soc Clin Oncol 2003; 22:251a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/84\">",
"      Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer 2006; 95:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/85\">",
"      Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study. Oncology 2003; 65:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/86\">",
"      Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/87\">",
"      Jacobs AD, Otero H, Picozzi VJ Jr, Aboulafia DM. Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma. Cancer Invest 2004; 22:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/88\">",
"      Shepard RC, Levy D, Stuart K, et al. Pancreatic cancer: biweekly gemcitabine/docetaxel chemotherapy (abstract). Proc Am Soc Clin Oncol 2001; 20:154a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/89\">",
"      Ryan DP, Kulke MH, Fuchs CS, et al. A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer 2002; 94:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/90\">",
"      Lutz MP, Van Cutsem E, Wagener T, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol 2005; 23:9250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/91\">",
"      Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol 1999; 10:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/92\">",
"      Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548.",
"     </a>",
"    </li>",
"    <li>",
"     Von Hoff DD, Ervin TJ, Arena FP, et al. Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patietns with metastatic adenocarcinoma of the pancreas (MPACT). Abstract. Data presented at the 2013 ASCO Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=133&amp;abstractID=106143&amp;et_cid=30928363&amp;et_rid=463567184&amp;linkid=http%3A%2F%2Fwww.asco.org%2FASCOv2%2FMeetings%2FAbstracts%3F%26amp%3Bvmview%3Dabst_detail_view%26amp%3BconfID%3D133%26amp%3BabstractID%3D106143 (Accessed on February 07, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/94\">",
"      Reni M, Passoni P, Panucci MG, et al. Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. J Clin Oncol 2001; 19:2679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/95\">",
"      Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol 2005; 6:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/96\">",
"      Louvet C, Andr&eacute; T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002; 20:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/97\">",
"      Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/98\">",
"      Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/99\">",
"      Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/100\">",
"      Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem 1993; 62:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/101\">",
"      Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/102\">",
"      Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/103\">",
"      Alberts SR, Schroeder M, Erlichman C, et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial. J Clin Oncol 2004; 22:4944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/104\">",
"      Chang DZ, Abou-Alfa GK, O'Reilly EM, et al. Vaccination of pancreatic cancer patients against mutated ras (abstract). Proc Am Soc Clin Oncol 2003; 22:285a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/105\">",
"      Gibbs JB, Oliff A, Kohl NE. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994; 77:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/106\">",
"      James GL, Goldstein JL, Brown MS, et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 1993; 260:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/107\">",
"      Cohen SI, Ho L, Ranganathan S, et al. Phase II and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic cancer (abstract). Proc Am Soc Clin Oncol 2002; 21:137a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/108\">",
"      MacDonald JS, Chansky K, Whitehead R, et al. A phase II study of farnesylk transferase inhibitor R115777 in pancreatic cancer. A Southwest Oncology Group study (abstract). Proc Am Soc Clin Oncol 2002; 21:138a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/109\">",
"      Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/110\">",
"      Bruns CJ, Solorzano CC, Harbison MT, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 2000; 60:2926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/111\">",
"      Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/112\">",
"      Grubbs SS, Grusenmeyer PA, Petrelli NJ, Gralla RJ. Is it cost effective to add erlotinib to gemcitabine in advanced pancreatic cancer? J Clin Oncol 2006; 24:313s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/113\">",
"      Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25:4506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/114\">",
"      Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009; 27:2231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/115\">",
"      Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004; 22:2610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/116\">",
"      Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 2010; 28:3605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/117\">",
"      Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncol 2008; 9:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/118\">",
"      Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer 2000; 85:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/119\">",
"      Kindler HL, Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005; 23:8033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/120\">",
"      Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010; 28:3617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/121\">",
"      Spano JP, Chodkiewicz C, Maurel J, et al. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008; 371:2101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/122\">",
"      Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011; 12:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/123\">",
"      Gon&ccedil;alves A, Gilabert M, Fran&ccedil;ois E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol 2012; 23:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/124\">",
"      Theve NO, Pousette A, Carlstr&ouml;m K. Adenocarcinoma of the pancreas--a hormone sensitive tumor? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/125\">",
"      T&oslash;nnesen K, Kamp-Jensen M. Antiestrogen therapy in pancreatic carcinoma: a preliminary report. Eur J Surg Oncol 1986; 12:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/126\">",
"      Wong A, Chan A, Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treat Rep 1987; 71:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/127\">",
"      Crowson MC, Dorrell A, Rolfe EB, Fielding JW. A phase II study to evaluate tamoxifen in pancreatic adenocarcinoma. Eur J Surg Oncol 1986; 12:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/128\">",
"      Taylor OM, Benson EA, McMahon MJ. Clinical trial of tamoxifen in patients with irresectable pancreatic adenocarcinoma. The Yorkshire Gastrointestinal Tumour Group. Br J Surg 1993; 80:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/129\">",
"      Keating JJ, Johnson PJ, Cochrane AM, et al. A prospective randomised controlled trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989; 60:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/130\">",
"      Bakkevold KE, Pettersen A, Arnesj&oslash; B, Espehaug B. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and the papilla of Vater. Br J Surg 1990; 77:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/131\">",
"      Roy A, Jacobs A, Bukowski R, et al. Phase 3 trial of SMS 201-995 pa LAR (SMS PA LAR) and continuous infusion 5FU in unresectable stage II, III, and IV pancreatic cancer (abstract). Proc Am Soc Clin Oncol 1998; 17:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/132\">",
"      Pederzoli P, Maurer U, Vollmer K, et al. Phase 3 trial of SMS 201-995 pa LAR (SMS pa LAR) versus placebo in unresectable stage II, III, and IV pancreatic cancer (abstract). Proc Am Soc Clin Oncol 1998; 17:257a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/133\">",
"      Huguier M, Samama G, Testart J, et al. Treatment of adenocarcinoma of the pancreas with somatostatin and gonadoliberin (luteinizing hormone-releasing hormone). The French Associations for Surgical Research. Am J Surg 1992; 164:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/134\">",
"      Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/135\">",
"      Klapdor R, Fenner C. Irinotecan(Campto R): efficacy as third/forth line therapy in advanced pancreatic cancer. Anticancer Res 2000; 20:5209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/136\">",
"      Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/137\">",
"      Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/138\">",
"      Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/139\">",
"      Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone insecond-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) (abstract). J Clin Oncol 2005; 23:315s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/140\">",
"      Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs 2005; 23:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/141\">",
"      Yoo C, Hwang JY, Kim JE, et al. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. Br J Cancer 2009; 101:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/142\">",
"      Fortune BE, Li X, Kosuri KV, et al. Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study. Oncology 2009; 76:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/143\">",
"      Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer 2008; 113:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/144\">",
"      Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine-refractory pancreatic cancer. Final results of the CONKO 003 study (abstract). J Clin Oncol 2008; 26:125s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/145\">",
"      Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/146\">",
"      Oettle H, Arnold D, Esser M, et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/147\">",
"      Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol 2007; 25:4787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/148\">",
"      Pelzer U, Stieler J, Roll L, et al. Second-line therapy in refractory pancreatic cancer. results of a phase II study. Onkologie 2009; 32:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/149\">",
"      Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer 2011; 47:1676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/150\">",
"      Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine plus cetumimab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study (abstract). J Clin Oncol 2007; 25:199s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/151\">",
"      Kindler H, Niedzwiecki D, Hollis D, et al. A double-blind placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo inpatinets with advanced pancreatic cancer: A preliminary analysis of Cancer and Leukemia Group B (CALGB) (abstract). J Clin Oncol 2007; 25:199s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/152\">",
"      Rosenberg L, Barkun AN, Denis MH, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 1995; 75:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/153\">",
"      Sulkowski U, B&uuml;chler M, Pederzoli P, et al. A phase II study of high-dose octreotide in patients with unresectable pancreatic carcinoma. Eur J Cancer 1999; 35:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/154\">",
"      Fazeny B, Baur M, Prohaska M, et al. Octreotide combined with goserelin in the therapy of advanced pancreatic cancer--results of a pilot study and review of the literature. J Cancer Res Clin Oncol 1997; 123:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/155\">",
"      Swarovsky B, Wolf M, Havemann K, Arnold R. Tamoxifen or cyproterone acetate in combination with buserelin are ineffective in patients with pancreatic adenocarcinoma. Oncology 1993; 50:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/156\">",
"      Berk V, Ozdemir N, Ozkan M, et al. XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogastroenterology 2012; 59:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/157\">",
"      Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. Oncology 2011; 80:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/158\">",
"      Sudo K, Yamaguchi T, Nakamura K, et al. Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer. Cancer Chemother Pharmacol 2011; 67:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/159\">",
"      Gebbia V, Maiello E, Giuliani F, et al. Irinotecan plus bolus/infusional 5-Fluorouracil and leucovorin in patients with pretreated advanced pancreatic carcinoma: a multicenter experience of the Gruppo Oncologico Italia Meridionale. Am J Clin Oncol 2010; 33:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/160\">",
"      Zaniboni A, Aitini E, Barni S, et al. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol 2012; 69:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/161\">",
"      Maeda S, Motoi F, Onogawa T, et al. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol 2011; 16:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/12/39114/abstract/162\">",
"      Hosein PJ, de Lima Lopes G Jr, Pastorini VH, et al. A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer. Am J Clin Oncol 2013; 36:151.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2475 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-82D89F4E57-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39114=[""].join("\n");
var outline_f38_12_39114=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT ENDPOINTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical benefit response rate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CA 19-9 level",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SINGLE AGENT CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fluorouracil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Capecitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Fixed-dose rate infusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anthracyclines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Streptozocin and ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Taxanes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Camptothecins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      COMBINATION CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Older 5-FU-based combination regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - 5-FU combination therapy versus supportive care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      5-FU plus irinotecan and/or oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H84834598\">",
"      - FOLFIRINOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Gemcitabine combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Gemcitabine plus 5-FU",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Gemcitabine plus capecitabine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Gemcitabine plus cisplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Gemcitabine plus irinotecan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Gemcitabine plus a taxane",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Gemcitabine plus 5-FU, cisplatin and epirubicin (PEFG)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Gemcitabine plus oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Meta-analyses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      MOLECULARLY TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Approaches targeting the EGFR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Approaches targeting angiogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      HORMONE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Tamoxifen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Octreotide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SECOND-LINE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84834721\">",
"      Gemcitabine failures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Treatment versus supportive care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Choice of regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Oxaliplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Other regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84834736\">",
"      Patients failing FOLFIRINOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84834843\">",
"      First-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H84834850\">",
"      Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2475\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2475|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/56/36749\" title=\"table 1\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/15/9467\" title=\"table 2\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/3/44094\" title=\"table 3\">",
"      FOLFIRINOX for metastatic pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/53/17246\" title=\"table 4\">",
"      Modified FOLFOX6",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/30/26087?source=related_link\">",
"      A short primer on cost-effectiveness analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/37/33370?source=related_link\">",
"      Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/12/13513?source=related_link\">",
"      Molecular pathogenesis of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=related_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=related_link\">",
"      Treatment protocols for pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_12_39115="Echo views cardiac structures";
var content_f38_12_39115=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51250&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used views to evaluate specific cardiac structures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Structure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Views",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left atrium",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical 4-chamber, apical 2-chamber, apical 5-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricle",
"       </td>",
"       <td>",
"        PLA, PSA (mid/apical), apical 4-chamber, apical 2-chamber, apical 5-chamber, apical long axis,",
"subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right atrium",
"       </td>",
"       <td>",
"        Parasternal RV inflow, PSA (base), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short",
"axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Right ventricle",
"       </td>",
"       <td>",
"        PLA, PSA (mid/apical), apical 4-chamber, apical 5-chamber, subcostal 4-chamber, subcostal short axis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascending aorta",
"       </td>",
"       <td>",
"        PLA, PSA (base), apical long axis, apical 5-chamber, right parasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transverse",
"aorta",
"       </td>",
"       <td>",
"        Suprasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Descending",
"aorta",
"       </td>",
"       <td>",
"        PLA, PSA, subcostal, suprasternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interatrial septum",
"       </td>",
"       <td>",
"        PSA (base), apical 4-chamber, subcostal 4-chamber",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coronary",
"sinus",
"       </td>",
"       <td>",
"        PLA, RV inflow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pericardial",
"effusion",
"       </td>",
"       <td>",
"        PLA, PSA, apical 4-chamber, subcostal 4-chamber",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PLA: parasternal long axis; PSA: parasternal short axis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39115=[""].join("\n");
var outline_f38_12_39115=null;
var title_f38_12_39116="MIPI";
var content_f38_12_39116=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86535&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mantle cell lymphoma international prognostic index (MIPI)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        ECOG performance status",
"       </td>",
"       <td class=\"subtitle1\">",
"        LDH:ULN ratio",
"       </td>",
"       <td class=\"subtitle1\">",
"        WBC (10",
"        <sup>",
"         9",
"        </sup>",
"        /L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"       <td class=\"centered\">",
"        &lt;50",
"       </td>",
"       <td class=\"centered\">",
"        0 to 1",
"       </td>",
"       <td class=\"centered\">",
"        &lt;0.67",
"       </td>",
"       <td class=\"centered\">",
"        &lt;6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        1",
"       </td>",
"       <td class=\"centered\">",
"        50 to 59",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        0.67 to 0.99",
"       </td>",
"       <td class=\"centered\">",
"        6.7 to 9.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        60 to 69",
"       </td>",
"       <td class=\"centered\">",
"        2 to 4",
"       </td>",
"       <td class=\"centered\">",
"        1.00 to 1.49",
"       </td>",
"       <td class=\"centered\">",
"        10.0 to 14.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        &ge;70",
"       </td>",
"       <td class=\"centered\">",
"        &nbsp;",
"       </td>",
"       <td class=\"centered\">",
"        &ge;1.50",
"       </td>",
"       <td class=\"centered\">",
"        &ge;15.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        One to three points is given for each of the above characteristics present in the patient with MCL, for a total score ranging from zero to 12. When applied to a study of long term survival in 455 patients with MCL diagnosed between 1996 and 2004, the following three risk groups and their corresponding median and five-year survivals were as follows:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk group",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median survival",
"       </td>",
"       <td class=\"subtitle1\">",
"        Five-year OS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        0 to 3 points",
"       </td>",
"       <td class=\"centered\">",
"        Low risk",
"       </td>",
"       <td class=\"centered\">",
"        Not reached",
"       </td>",
"       <td class=\"centered\">",
"        60 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        4 to 5 points",
"       </td>",
"       <td class=\"centered\">",
"        Intermediate risk",
"       </td>",
"       <td class=\"centered\">",
"        58 months",
"       </td>",
"       <td class=\"centered\">",
"        35 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        6 to 12 points",
"       </td>",
"       <td class=\"centered\">",
"        High risk",
"       </td>",
"       <td class=\"centered\">",
"        37 months",
"       </td>",
"       <td class=\"centered\">",
"        20 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECOG: Eastern Cooperative Oncology Group; LDH: lactate dehydrogenase; ULN: upper limit of normal; WBC: white blood cells; MCL: mantle cell lymphoma; OS: overall survival.",
"    </div>",
"    <div class=\"reference\">",
"     This research was originally published in Blood. Modified from: Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558. Copyright &copy; 2008 American Society of Hematology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39116=[""].join("\n");
var outline_f38_12_39116=null;
var title_f38_12_39117="TNM stage oral cavity";
var content_f38_12_39117=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tumor node metastases (TNM) staging system for cancer of the lip and oral cavity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Primary tumor (T)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       TX",
"      </td>",
"      <td colspan=\"3\">",
"       Primary tumor cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T0",
"      </td>",
"      <td colspan=\"3\">",
"       No evidence of primary tumor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tis",
"      </td>",
"      <td colspan=\"3\">",
"       Carcinoma in situ",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor 2 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 2 cm but not more than 4 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td colspan=\"3\">",
"       Tumor more than 4 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"3\">",
"       T4a",
"      </td>",
"      <td colspan=\"3\">",
"       Moderately advanced local disease*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       <strong>",
"        Lip:",
"       </strong>",
"       Tumor invades through cortical bone, inferior alveolar nerve, floor of mouth, or skin of face, that is, chin or nose",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       <strong>",
"        Oral cavity:",
"       </strong>",
"       Tumor invades adjacent structures only (eg, through cortical bone [mandible or maxilla] into deep [extrinsic] muscle of tongue [genioglossus, hyoglossus, palatoglossus, and styloglossus], maxillary sinus, skin of face)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       T4b",
"      </td>",
"      <td colspan=\"3\">",
"       Very advanced local disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"3\">",
"       Tumor invades masticator space, pterygoid plates, or skull base and/or encases internal carotid artery",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Regional lymph nodes (N)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       NX",
"      </td>",
"      <td colspan=\"3\">",
"       Regional lymph nodes cannot be assessed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N0",
"      </td>",
"      <td colspan=\"3\">",
"       No regional lymph node metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N1",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       N2",
"      </td>",
"      <td class=\"sublist_other_start\" colspan=\"3\">",
"       Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2a",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in single ipsilateral lymph node more than 3 cm but not more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2b",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       N2c",
"      </td>",
"      <td class=\"sublist_other\" colspan=\"3\">",
"       Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       N3",
"      </td>",
"      <td colspan=\"3\">",
"       Metastasis in a lymph node more than 6 cm in greatest dimension",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Distant metastasis (M)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M0",
"      </td>",
"      <td colspan=\"3\">",
"       No distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       M1",
"      </td>",
"      <td colspan=\"3\">",
"       Distant metastasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"4\">",
"       Anatomic stage/prognostic groups",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage 0",
"      </td>",
"      <td>",
"       Tis",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage I",
"      </td>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage II",
"      </td>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"4\">",
"       Stage III",
"      </td>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Stage IVA",
"      </td>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N0",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N1",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T1",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T2",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T3",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4a",
"      </td>",
"      <td>",
"       N2",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"2\">",
"       Stage IVB",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       N3",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       T4b",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M0",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stage IVC",
"      </td>",
"      <td>",
"       Any T",
"      </td>",
"      <td>",
"       Any N",
"      </td>",
"      <td>",
"       M1",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Note: cTNM is the clinical classification, pTNM is the pathologic classification.",
"    <div class=\"footnotes\">",
"     * Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify a tumor as T4.",
"    </div>",
"    <div class=\"reference\">",
"     Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39117=[""].join("\n");
var outline_f38_12_39117=null;
var title_f38_12_39118="IRA patency and mortality";
var content_f38_12_39118=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Patent IRA decreases mortality after thrombolysis for acute MI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Early and long-term mortality according to infarct-related coronary artery patency following thrombolysis in five different trials. Mortality at both time periods was lower in the patients with a patent infarct-related artery (IRA).",
"    <div class=\"footnotes\">",
"     WWICSK: Western Washington Intracoronary Streptokinase Trial; TAMI: Thrombolysis and Angioplasty in Myocardial Infarction; TIMI: Thrombolysis in Myocardial Infarction; TEAM: Thrombolysis with Eminase in Myocardial Infarction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39118=[""].join("\n");
var outline_f38_12_39118=null;
var title_f38_12_39119="T tube related bile leak";
var content_f38_12_39119=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    T tube-related leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP reveals a leak emanating from the T-tube site (arrow). A stent has been placed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_12_39119=[""].join("\n");
var outline_f38_12_39119=null;
